QUARTERLY REPORT
Q1 2024 — Form 10-Q
Q1 2024PDF · 140 pages2.1 MB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 001-33708
Philip Morris International Inc.
(Exact name of registrant as specified in its charter)
Virginia 13-3435103
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)
677 Washington Blvd, Suite 1100 Stamford Connecticut 06901
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (203) 905-2410
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PM New York Stock Exchange
2.875% Notes due 2024 PM24 New York Stock Exchange
2.875% Notes due 2024 PM24C New York Stock Exchange
0.625% Notes due 2024 PM24B New York Stock Exchange
3.250% Notes due 2024 PM24A New York Stock Exchange
2.750% Notes due 2025 PM25 New York Stock Exchange
3.375% Notes due 2025 PM25A New York Stock Exchange
2.750% Notes due 2026 PM26A New York Stock Exchange
2.875% Notes due 2026 PM26 New York Stock Exchange
0.125% Notes due 2026 PM26B New York Stock Exchange
3.125% Notes due 2027 PM27 New York Stock Exchange
3.125% Notes due 2028 PM28 New York Stock Exchange
2.875% Notes due 2029 PM29 New York Stock Exchange
3.375% Notes due 2029 PM29A New York Stock Exchange
0.800% Notes due 2031 PM31 New York Stock Exchange
3.125% Notes due 2033 PM33 New York Stock Exchange
2.000% Notes due 2036 PM36 New York Stock Exchange
Title of each class Trading Symbol(s) Name of each exchange on which registered
1.875% Notes due 2037 PM37A New York Stock Exchange
6.375% Notes due 2038 PM38 New York Stock Exchange
1.450% Notes due 2039 PM39 New York Stock Exchange
4.375% Notes due 2041 PM41 New York Stock Exchange
4.500% Notes due 2042 PM42 New York Stock Exchange
3.875% Notes due 2042 PM42A New York Stock Exchange
4.125% Notes due 2043 PM43 New York Stock Exchange
4.875% Notes due 2043 PM43A New York Stock Exchange
4.250% Notes due 2044 PM44 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ☑ No ☐
-- 1 of 140 --
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or
an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth
company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
At April 19, 2024, there were 1,554,556,966 shares outstanding of the registrant’s common stock, no par value per share.
1
-- 2 of 140 --
Table of Contents
PHILIP MORRIS INTERNATIONAL INC.
TABLE OF CONTENTS
Page No.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Statements of Earnings for the
Three Months Ended March 31, 2024 and 2023 3
Condensed Consolidated Statements of Comprehensive Earnings for the
Three Months Ended March 31, 2024 and 2023 4
Condensed Consolidated Balance Sheets at
March 31, 2024 and December 31, 2023 5 – 6
Condensed Consolidated Statements of Cash Flows for the
Three Months Ended March 31, 2024 and 2023 7 – 8
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the
Three Months Ended March 31, 2024 and 2023 9
Notes to Condensed Consolidated Financial Statements 10 – 43
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 44 – 94
Item 4. Controls and Procedures 95
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 96
Item 1A. Risk Factors 96
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 97
Item 5. Other Information 98
Item 6. Exhibits 99
Signature 100
In this report, “PMI,” “we,” “us” and “our” refer to Philip Morris International Inc. and its subsidiaries.
Trademarks and service marks in this report are the registered property of, or licensed by, the subsidiaries of Philip Morris International Inc. and are
italicized.
2
-- 3 of 140 --
Table of Contents
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(in millions of dollars, except per share data)
(Unaudited)
For the Three Months Ended March
31,
2024 2023
Net revenues (Notes 7 & 12) $ 8,793 $ 8,019
Cost of sales 3,195 3,038
Gross profit 5,598 4,981
Marketing, administration and research costs (Note 15) 2,553 2,250
Operating income 3,045 2,731
Interest expense, net 299 230
Pension and other employee benefit costs (Note 3) 15 22
Earnings before income taxes 2,731 2,479
Provision for income taxes 676 428
Equity investments and securities (income)/loss, net (191) (51)
Net earnings 2,246 2,102
Net earnings attributable to noncontrolling interests 98 107
Net earnings attributable to PMI $ 2,148 $ 1,995
Per share data (Note 6):
Basic earnings per share $ 1.38 $ 1.28
Diluted earnings per share $ 1.38 $ 1.28
Includes net revenues from related parties of $860 million and $873 million for the three months ended March 31, 2024 and 2023, respectively
Net of excise taxes of $11,839 million and $11,299 million for the three months ended March 31, 2024 and 2023, respectively
See notes to condensed consolidated financial statements.
1 & 2
(1)
(2)
3
-- 4 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Earnings
(in millions of dollars)
(Unaudited)
For the Three Months Ended March 31,
2024 2023
Net earnings $ 2,246 $ 2,102
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $(102) in 2024 and $52 in 2023 488 (255)
(Gains)/losses transferred to earnings, net of income taxes of $0 in 2024 and 2023 (Notes 11
&15) 42 —
Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes of $0 in 2024 and $(1) in 2023 — 2
Amortization of net losses, prior service costs and net transition costs, net of income taxes of $(9)
in 2024 and $(7) in 2023 34 25
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $(39) in 2024 and $(16) in 2023 178 59
(Gains) losses transferred to earnings, net of income taxes of $16 in 2024 and $6 in 2023 (46) (29)
Total other comprehensive earnings (losses) 696 (198)
Total comprehensive earnings 2,942 1,904
Less comprehensive earnings (losses) attributable to:
Noncontrolling interests 44 (36)
Comprehensive earnings attributable to PMI $ 2,898 $ 1,940
See notes to condensed consolidated financial statements.
4
-- 5 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in millions of dollars)
(Unaudited)
March 31,
2024 December 31,
2023
ASSETS
Cash and cash equivalents $ 3,968 $ 3,060
Trade receivables (less allowances of $72 in 2024 and $79 in 2023) 4,188 3,461
Other receivables (less allowances of $32 in 2024 and $35 in 2023) 864 930
Inventories:
Leaf tobacco 1,959 1,942
Other raw materials 2,162 2,293
Finished product 5,849 6,539
9,970 10,774
Other current assets 1,884 1,530
Total current assets 20,874 19,755
Property, plant and equipment, at cost 16,545 17,080
Less: accumulated depreciation 9,344 9,564
7,201 7,516
Goodwill (Note 4) 16,458 16,779
Other intangible assets, net (Note 4) 9,448 9,864
Equity investments (Note 12) 4,918 4,929
Deferred income taxes 950 814
Other assets (less allowances of $24 in 2024 and $25 in 2023) (Note 18) 5,466 5,647
TOTAL ASSETS $ 65,315 $ 65,304
Includes trade receivables from related parties of $702 million and $710 million as of March 31, 2024, and December 31, 2023, respectively. For further details, see Note
12. Related Parties - Equity Investments and Other.
See notes to condensed consolidated financial statements.
Continued
(1)
(1)
5
-- 6 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Balance Sheets (Continued)
(in millions of dollars, except share data)
(Unaudited)
March 31,
2024
December 31,
2023
LIABILITIES
Short-term borrowings (Note 10) $ 279 $ 1,968
Current portion of long-term debt (Note 10) 5,425 4,698
Accounts payable 3,648 4,143
Accrued liabilities:
Marketing and selling 823 862
Taxes, except income taxes 5,799 7,514
Employment costs 925 1,262
Dividends payable 2,038 2,041
Other 2,409 2,737
Income taxes 822 1,158
Total current liabilities 22,168 26,383
Long-term debt (Note 10) 44,683 41,243
Deferred income taxes 2,664 2,335
Employment costs 2,824 3,046
Income taxes and other liabilities 1,539 1,743
Total liabilities 73,878 74,750
Contingencies (Note 8)
STOCKHOLDERS’ (DEFICIT) EQUITY
Common stock, no par value
(2,109,316,331 shares issued in 2024 and 2023) — —
Additional paid-in capital 2,205 2,285
Earnings reinvested in the business 34,208 34,090
Accumulated other comprehensive losses (Note 11) (11,065) (11,815)
25,348 24,560
Less: cost of repurchased stock
(554,763,523 and 556,891,800 shares in 2024 and 2023, respectively) 35,657 35,785
Total PMI stockholders’ deficit (10,309) (11,225)
Noncontrolling interests 1,746 1,779
Total stockholders’ deficit (8,563) (9,446)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $ 65,315 $ 65,304
See notes to condensed consolidated financial statements.
6
-- 7 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in millions of dollars)
(Unaudited)
For the Three Months Ended March
31,
2024 2023
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings $ 2,246 $ 2,102
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization expense 367 299
Impairment of other intangibles (Note 4) 27 —
Deferred income tax (benefit) provision 76 (96)
Asset impairment and exit costs, net of cash paid (Note 15) 148 102
Cash effects of changes, net of the effects from acquired companies:
Receivables, net (890) 245
Inventories 527 (783)
Accounts payable (181) (145)
Accrued liabilities and other current assets (1,797) (2,705)
Income taxes (79) (88)
Pension plan contributions (Note 3) (34) (45)
Other (169) 159
Net cash provided by (used in) operating activities 241 (955)
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures (417) (279)
Equity investments (20) (8)
Collateral posted/settlements for derivatives, (paid)/returned (Note 5) 310 (164)
Other (66) (140)
Net cash provided by (used in) investing activities (193) (591)
Includes amounts from related parties of $(45) million and $(76) million for March 31, 2024 and 2023, respectively
See notes to condensed consolidated financial statements.
Continued
(1)
(1)
7
-- 8 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(in millions of dollars)
(Unaudited)
For the Three Months Ended March
31,
2024 2023
CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
Short-term borrowing activity by original maturity:
Net issuances (repayments) - maturities of 90 days or less $ (1,475) $ 3,361
Issuances - maturities longer than 90 days 100 358
Repayments - maturities longer than 90 days (284) (138)
Repayments under credit facilities related to Swedish Match AB acquisition — (4,430)
Long-term debt proceeds 4,659 5,203
Long-term debt repaid — (682)
Dividends paid (2,037) (1,987)
Collateral received/settlements for derivatives, received/(returned) 260 (2)
Payments to acquire Swedish Match AB noncontrolling interests — (883)
Noncontrolling interests activity and Other (Note 18) (88) 64
Net cash provided by (used in) financing activities 1,135 864
Effect of exchange rate changes on cash, cash equivalents and restricted cash (230) (89)
Cash, cash equivalents and restricted cash :
Increase (Decrease) 953 (771)
Balance at beginning of period 3,146 3,217
Balance at end of period $ 4,099 $ 2,446
The amounts for cash, cash equivalents and restricted cash shown above include restricted cash of $131 million and $18 million as of March 31, 2024 and 2023,
respectively, and $86 million and $10 million as of December 31, 2023 and 2022, respectively, which were included in other current assets in the condensed consolidated
balance sheets.
See notes to condensed consolidated financial statements.
(1)
(1)
8
-- 9 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
For the Three Months Ended March 31, 2024 and 2023
(in millions of dollars, except per share amounts)
(Unaudited)
PMI Stockholders’ (Deficit) Equity
Common
Stock
Additional
Paid-in
Capital
Earnings
Reinvested in
the
Business
Accumulated
Other
Comprehensive Losses
Cost of
Repurchased
Stock Noncontrolling
Interests Total
Balances, January 1, 2023 $ — $ 2,230 $ 34,289 $ (9,559) $ (35,917) $ 2,646 $ (6,311)
Net earnings 1,995 107 2,102
Other comprehensive earnings
(losses), net of income taxes (234) 36 (198)
Issuance of stock awards (63) 116 53
Dividends declared ($1.27 per
share) (1,981) (1,981)
Dividends paid to noncontrolling
interests (93) (93)
Sale (purchase) of subsidiary
shares to/(from) noncontrolling
interests (Note 18) 21 179 (825) (625)
Balances, March 31, 2023 $ — $ 2,188 $ 34,303 $ (9,614) $ (35,801) $ 1,871 $ (7,053)
Balances, January 1, 2024 $ — $ 2,285 $ 34,090 $ (11,815) $ (35,785) $ 1,779 $ (9,446)
Net earnings 2,148 98 2,246
Other comprehensive earnings
(losses), net of income taxes 750 (54) 696
Issuance of stock awards (80) 128 48
Dividends declared ($1.30 per
share) (2,030) (2,030)
Dividends paid to noncontrolling
interests (76) (76)
Sale (purchase) of subsidiary
shares to/(from) noncontrolling
interests — — (1) (1)
Balances, March 31, 2024 $ — $ 2,205 $ 34,208 $ (11,065) $ (35,657) $ 1,746 $ (8,563)
See notes to condensed consolidated financial statements.
9
-- 10 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 1. Background and Basis of Presentation:
Background
Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United
States of America), whose subsidiaries and affiliates and their licensees are primarily engaged in the manufacture and sale of cigarettes and smoke-free
products. Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries.
Smoke-Free Business ("SFB”) is the term PMI uses to refer to all of its smoke-free products. SFB also includes wellness and healthcare products, as well as
consumer accessories, such as lighters and matches.
Smoke-free products (also referred to herein as "SFPs") is the term PMI uses to refer to all of its products that provide nicotine without combusting
tobacco, such as heat-not-burn, e-vapor, and oral smokeless, and that therefore generate far lower levels of harmful chemicals. As such, these products have
the potential to present less risk of harm versus continued smoking.
"Platform 1" is the term PMI uses to refer to PMI’s smoke-free products that use a precisely controlled heating device into which a specially designed and
proprietary tobacco unit is inserted and heated to generate an aerosol.
Basis of Presentation
The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been
prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a
consistent basis. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S.GAAP
have been omitted. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been
reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not
necessarily indicative of results that may be expected for the entire year.
Following the combination and the progress in 2023 toward the integration of the Swedish Match business into PMI's existing regional structure, PMI
updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments. The
four existing geographical segments are as follows: Europe Region; South and Southeast Asia, Commonwealth of Independent States, Middle East and
Africa Region ("SSEA, CIS & MEA"); East Asia, Australia, and PMI Duty Free Region ("EA, AU & PMI DF"); and Americas Region. The Wellness and
Healthcare ("W&H") segment remained unchanged.
Certain prior years' amounts have been reclassified to conform with the current year's presentation as a result of the new segment structure discussed above.
See Note 4. Goodwill and Other Intangible Assets, net, Note 7. Segment Reporting and Note 15. Asset Impairment and Exit Costs for further details. These
reclassifications did not impact PMI’s consolidated financial position, results of operations or cash flows in any of the periods presented.
These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report
on Form 10-K for the year ended December 31, 2023.
Note 2. Stock Plans:
In May 2022, PMI’s shareholders approved the Philip Morris International Inc. 2022 Performance Incentive Plan (the “2022 Plan”). Under the 2022 Plan,
PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity
awards. Up to 25 million shares of PMI’s common stock may be issued under the 2022 Plan. At March 31, 2024, shares available for grant under the 2022
Plan were 19,114,716.
In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the “2017
Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of PMI
or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of stock
entitled to vote in the election of
10
-- 11 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-Employee Directors Plan. At March 31,
2024, shares available for grant under the plan were 876,226.
Restricted share unit (RSU) awards
During the three months ended March 31, 2024 and 2023, shares granted to eligible employees, the weighted-average grant date fair value per share and the
recorded compensation expense related to RSU awards were as follows:
Number of
Shares
Granted
Weighted-Average Grant
Date Fair Value Per RSU
Award Granted
Compensation Expense
Related to RSU Awards
(in millions)
2024 1,975,480 $ 89.04 $ 47
2023 1,732,910 $ 102.01 $ 50
As of March 31, 2024, PMI had $274 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the
original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58.
During the three months ended March 31, 2024, 1,546,406 RSU awards vested. The grant date fair value of all the vested awards was approximately $128
million. The total fair value of RSU awards that vested during the three months ended March 31, 2024 was approximately $139 million.
Performance share unit (PSU) awards
During the three months ended March 31, 2024 and 2023, PMI granted PSU awards to certain executives. The PSU awards require the achievement of
certain performance metrics, which are predetermined at the time of grant, typically over a three-year performance cycle.
The performance metrics for such PSU's granted during the three months ended March 31, 2023 consisted of PMI's Total Shareholder Return ("TSR")
relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share
growth rate (30% weight), and a Sustainability Index, which consists of two drivers:
• Product Sustainability (20% weight) measuring progress primarily on PMI's efforts to maximize the benefits of smoke-free products, purposefully
phase out cigarettes, and reduce post-consumer waste; and
• Operational Sustainability (10% weight) measuring progress on PMI's efforts to tackle climate change, preserve nature, improve the quality of life
of people in its supply chain, and foster an empowered, and inclusive workplace.
The performance metrics, targets and relative weights for the PSU’s granted during the three months ended March 31, 2024 were the same as the PSU’s
granted during the three months ended March 31, 2023, with the exception of adjustments made to certain components of the Sustainability Index intended
to address PMI's developing sustainability strategy and reporting.
The PSU performance metrics may be adjusted if appropriate to reflect the impact of unusual or infrequently occurring events, including, to the extent
significant, corporate transactions, accounting or tax law changes, asset write-downs, litigation or claim adjustments, foreign exchange gains and losses,
unbudgeted capital expenditures and other such events.
The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the
end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum
percentage of 200. Each such vested PSU entitles the participant to one share of common stock. An aggregate weighted PSU performance factor of 100 will
result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the
accumulated dividends paid on common stock during the performance cycle for the number of shares earned.
11
-- 12 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
During the three months ended March 31, 2024 and 2023, shares granted to eligible employees, the grant date fair value per share and the recorded
compensation expense related to PSU awards were as follows:
Number of Shares
Granted
Weighted-
Average PSU Grant Date
Fair Value Subject to Other
Performance Factors
Weighted-
Average PSU Grant Date
Fair Value Subject to TSR
Performance Factors Compensation Expense
Related to PSU Awards
(in millions) (Per Share) (Per Share)
2024 543,560 $ 89.01 $ 85.72 $ 31
2023 482,360 $ 102.02 $ 133.54 $ 27
The grant date fair value of the PSU awards subject to the other performance factors was determined by using the market price of PMI’s stock on the date
of the grant. The grant date fair value of the PSU market-based awards subject to the TSR performance factor was determined by using the Monte Carlo
simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance factor:
2024 2023
Average risk-free interest rate 4.2 % 4.1 %
Average expected volatility 19.9 % 24.3 %
Based on the U.S. Treasury yield curve.
Determined using the observed historical volatility.
As of March 31, 2024, PMI had $62 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the
performance cycle of the awards, or upon death, disability or reaching the age of 58.
During the three months ended March 31, 2024, 909,262 PSU awards vested. The grant date fair value of all the vested awards was approximately $86
million. The total fair value of PSU awards that vested during the three months ended March 31, 2024 was approximately $82 million.
Note 3. Benefit Plans:
Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed
by local statutory requirements. In addition, PMI provides health care and other benefits to certain U.S. retired employees and certain non-U.S. retired
employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans.
Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following:
For the Three Months Ended March
31,
(in millions) 2024 2023
Net pension costs (income) $ (19) $ (12)
Net postemployment costs 31 30
Net postretirement costs 3 4
Total pension and other employee benefit costs $ 15 $ 22
(a)
(b)
(a)
(b)
12
-- 13 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Pension Plans
Components of Net Periodic Benefit Cost
Net periodic pension cost consisted of the following:
Pension
For the Three Months Ended March
31,
(in millions) 2024 2023
Service cost $ 55 $ 43
Interest cost 59 66
Expected return on plan assets (101) (90)
Amortization:
Net loss 23 12
Net periodic pension cost $ 36 $ 31
Primarily non-U.S. based defined benefit retirement plans.
Employer Contributions
PMI makes, and plans to make, contributions, to the extent that they are tax deductible and meet specific funding requirements of its funded pension plans.
Employer contributions of $34 million were made to the pension plans during the three months ended March 31, 2024. Currently, PMI anticipates making
additional contributions during the remainder of 2024 of approximately $88 million to its pension plans, based on current tax and benefit laws. However,
this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed
long-term rate of return on pension assets, or changes in interest and currency rates.
Note 4. Goodwill and Other Intangible Assets, net:
Goodwill
The movements in goodwill were as follows:
(in millions) Europe
SSEA, CIS &
MEA
EA, AU & PMI
DF Americas
Wellness &
Healthcare Total
Balances at December 31, 2023 $ 4,173 $ 2,877 $ 492 $ 8,847 $ 390 $ 16,779
Changes due to:
Currency (247) (61) (12) 6 (7) (321)
Balances, March 31, 2024 $ 3,926 $ 2,816 $ 480 $ 8,853 $ 383 $ 16,458
As discussed in Note 1. Background and Basis of Presentation, PMI updated in January 2024 its segment reporting by including the former Swedish Match
segment results into its geographical segments. As a result, the December 31, 2023 goodwill balance in the table above included the reclassification of the
former Swedish Match segment to the Europe and Americas segments.
At March 31, 2024, goodwill primarily reflects PMI’s acquisitions of Swedish Match AB, Fertin Pharma A/S and Vectura Group plc., as well as
acquisitions in Greece, Indonesia, Mexico, the Philippines and Serbia.
(1)
(1)
13
-- 14 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Intangible Assets
Details of other intangible assets were as follows:
March 31, 2024 December 31, 2023
(in millions)
Weighted-Average
Remaining Useful
Life Gross Carrying
Amount Accumulated
Amortization Net
Gross Carrying
Amount Accumulated
Amortization Net
Non-amortizable intangible assets $ 4,392 $ 4,392 $ 4,543 $ 4,543
Amortizable intangible assets:
Trademarks 16 years 2,185 $ 794 1,391 2,267 $ 784 1,483
Developed technology, including
patents 7 years 747 330 417 774 329 445
Customer relationships and other 11 years 3,753 505 3,248 3,843 450 3,393
Total other intangible assets $ 11,077 $ 1,629 $ 9,448 $ 11,427 $ 1,563 $ 9,864
Non-amortizable intangible assets substantially consist of the ZYN trademarks and other trademarks related to acquisitions in Indonesia and Mexico. The
decrease since December 31, 2023 was mainly due to currency movements of $119 million and a pre-tax impairment charge of $27 million primarily for an
in-process research and development project in the Wellness and Healthcare segment. The pre-tax impairment charge during the three months ended March
31, 2024 was recorded in marketing, administration and research costs on PMI's condensed consolidated statements of earnings.
The decrease in the gross carrying amount of amortizable intangible assets from December 31, 2023, was primarily due to currency movements of
$204 million.
The change in the accumulated amortization from December 31, 2023, was mainly due to the 2024 amortization of $120 million, partially offset by
currency movements of $54 million. The amortization of intangibles for the three months ended March 31, 2024 was recorded in cost of sales ($16 million)
and in marketing, administration and research costs ($104 million) on PMI's condensed consolidated statements of earnings.
Amortization expense for each of the next five years is estimated to be approximately $479 million or less, assuming no additional transactions occur that
require the amortization of intangible assets. Additionally, the estimated future amortization expense could significantly increase following the
reacquisition of IQOS commercialization rights in the U.S. from Altria Group, Inc., (see Note 18, Acquisitions) the accounting for which will depend on the
facts and circumstances effective May 1, 2024, when PMI will hold the full rights.
Note 5. Financial Instruments:
Overview
PMI operates globally with manufacturing and sales facilities in various locations around the world and is exposed to risks such as changes in foreign
currency exchange rates and interest rates. As a result, PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency
swaps and foreign currency options, (collectively referred to as "foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes
in foreign currency exchange and interest rates related to net investments in foreign operations, third-party and intercompany actual and forecasted
transactions. The primary currencies to which PMI is exposed include the Euro, Egyptian pound, Indonesian rupiah, Japanese yen, Mexican peso,
Philippine peso, Russian ruble and Swiss franc.
14
-- 15 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Additionally, certain materials that PMI uses in the manufacturing of its products are exposed to market price risks. PMI uses commodity derivative
contracts (“commodity contracts") to manage its exposure to the market price volatility of certain commodity components of these materials.
These foreign exchange contracts, interest rate contracts and commodity contracts are collectively referred to as "derivative contracts". PMI is not a party to
leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial
instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these
contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the condensed consolidated
balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Changes in collateral posted are included in cash
flows from investing activities and changes in collateral received are included in cash flows from financing activities. Financial instruments qualifying for
hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and
throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-
management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of
forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be
probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be
recognized in earnings.
The gross notional amounts for outstanding derivatives at the end of each period were as follows:
(in millions) At March 31, 2024 At December 31, 2023
Derivative contracts designated as hedging instruments:
Foreign exchange contracts $ 22,910 $ 21,987
Interest rate contracts 1,000 3,600
Commodity contracts 17 20
Derivative contracts not designated as hedging instruments:
Foreign exchange contracts 16,185 17,658
Total $ 40,112 $ 43,265
15
-- 16 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of March 31, 2024 and December 31, 2023, were as
follows:
Derivative Assets Derivative Liabilities
Fair Value Fair Value
At At At At
(in millions)
Balance Sheet
Classification March 31, 2024
December 31,
2023 Balance Sheet
Classification March 31, 2024
December 31,
2023
Derivative contracts
designated as hedging
instruments:
Foreign exchange contracts
Other current
assets $ 488 $ 345
Other accrued
liabilities $ 79 $ 249
Other assets 264 153
Income taxes and
other liabilities 236 449
Interest rate contracts Other current
assets — 1
Other accrued
liabilities 42 78
Other assets — —
Income taxes and
other liabilities 29 18
Commodity contracts Other current
assets — —
Other accrued
liabilities 8 5
Other assets — —
Income taxes and
other liabilities 2 1
Derivative contracts not
designated as hedging
instruments:
Foreign exchange contracts Other current
assets 236 85
Other accrued
liabilities 72 425
Other assets 1 —
Income taxes and
other liabilities 61 143
Total gross amount
derivatives contracts
presented in the condensed
consolidated balance sheets $ 989 $ 584 $ 529 $ 1,368
Gross amounts not offset in
the condensed consolidated
balance sheets
Financial instruments (377) (374) (377) (374)
Cash collateral
received/pledged (380) (109) (102) (551)
Net amount $ 232 $ 101 $ 50 $ 443
PMI assesses the fair value of its derivative contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair
value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign
exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is
determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity
dates. The fair value of PMI’s commodity contracts is determined by using the prevailing market spot and futures prices and the respective maturity dates
of the instruments. PMI’s derivative contracts have been classified within Level 2 at March 31, 2024 and December 31, 2023.
16
-- 17 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For the three months ended March 31, 2024 and 2023, PMI's derivative contracts impacted the condensed consolidated statements of earnings and
comprehensive earnings as follows:
(pre-tax, in millions) For the Three Months Ended March 31,
Amount of Gain/(Loss)
Recognized in Other
Comprehensive
Earnings/(Losses) on
Derivatives
Statement of Earnings
Classification of
Gain/(Loss)
on Derivatives
Amount of Gain/(Loss)
Reclassified from Other
Comprehensive
Earnings/(Losses) into
Earnings Amount of Gain/(Loss)
Recognized in Earnings
2024 2023 2024 2023 2024 2023
Derivative contracts designated
as hedging instruments:
Cash flow hedges:
Foreign exchange contracts $ 166 $ 10 Net revenues $ 29 $ 12
Cost of sales — —
Marketing, administration
and research costs 24 16
Interest expense, net (3) (3)
Interest rate contracts 54 65 Interest expense, net 12 10
Commodity contracts (3) — Cost of sales — —
Fair value hedges:
Interest rate contracts Interest expense, net $ (11) $ 3
Net investment hedges :
Foreign exchange contracts 453 (258) Interest expense, net 72 63
Derivative contracts not
designated as hedging
instruments:
Foreign exchange contracts Interest expense, net 44 90
Marketing, administration
and research costs 512 (16)
Total $ 670 $ (183) $ 62 $ 35 $ 617 $ 140
The gains (losses) from these contracts are offset by the changes in the fair value of the hedged item
Amount of gains (losses) on hedges of net investments principally related to changes in foreign currency exchange and interest rates between the Euro and U.S. dollar
Represent the gains for amounts excluded from the effectiveness testing
The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are partially offset by the (losses) and gains generated by the underlying
intercompany and third-party loans being hedged
Cash Flow Hedges
PMI has entered into derivative contracts to hedge the foreign currency exchange, interest rate and commodity price risks related to certain forecasted
transactions. Gains and losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses
until the underlying hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of March 31, 2024, PMI has hedged
forecasted transactions with derivative contracts expiring at various dates through May 2028. Premiums paid for, and settlements of, the derivative
contracts designated as cash flow hedges are included primarily in cash flows from operating activities on PMI’s condensed consolidated statements of cash
flows.
(a)
(b)
(c)
(d)
(a)
(b)
(c)
(d)
17
-- 18 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Fair Value Hedges
PMI has entered into fixed-to-floating interest rate contracts, designated as fair value hedges to minimize exposure to changes in the fair value of fixed rate
U.S. dollar-denominated debt that results from fluctuations in benchmark interest rates. For derivative contracts that are designated and qualify as fair value
hedges, the gain or loss on the derivative, as well as the offsetting gain or loss on the hedged items attributable to the hedged risk, is recognized in current
earnings. The carrying amount of the debt hedged, which includes the cumulative adjustment for fair value gains/losses, as of March 31, 2024 was $926
million, and is recorded in long-term debt in the condensed consolidated balance sheets. The cumulative amount of fair value gains/(losses) included in the
carrying amount of the debt hedged was $71 million as of March 31, 2024.
Hedges of Net Investments in Foreign Operations
PMI designates derivative contracts and certain foreign currency denominated debt and other financial instruments as net investment hedges, primarily of
its Euro net assets. For the three months ended March 31, 2024 and 2023, the amount of pre-tax gain/(loss) related to the non-derivative financial
instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $5 million and $1
million, respectively. Settlements of the derivative contracts designated as net investment hedges are included in cash flows from investing activities on
PMI’s condensed consolidated statements of cash flows.
Other Derivatives
PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain
subsidiaries and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses)
relating to these contracts are reported in PMI’s condensed consolidated statements of earnings. Settlements of other derivative contracts are included
primarily in cash flows from investing activities on PMI's condensed consolidated statements of cash flows.
Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses
Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses
to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive
losses, net of income taxes, as follows:
(in millions)
For the Three Months Ended March
31,
2024 2023
Gain/(loss) as of January 1, $ 241 $ 266
Derivative (gains)/losses transferred to earnings (46) (29)
Change in fair value 178 59
Gain/(loss) as of March 31, $ 373 $ 296
At March 31, 2024, PMI expects $157 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the
condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings
impact of the respective hedged transactions.
Contingent Features
PMI’s derivative instruments do not contain contingent features.
Credit Exposure and Credit Risk
PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the
fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of
credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as
counterparties.
18
-- 19 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Other Investments
A certain PMI investment, which is comprised primarily of money market funds, has been classified within Level 1 and had a fair value of $117 million at
March 31, 2024. For the three months ended March 31, 2024, the unrealized pre-tax gains (losses) on these investments were immaterial.
Note 6. Earnings Per Share:
Basic and diluted earnings per share (“EPS”) were calculated using the following:
(in millions)
For the Three Months Ended March
31,
2024 2023
Net earnings attributable to PMI $ 2,148 $ 1,995
Less distributed and undistributed earnings attributable to share-based payment awards 6 6
Net earnings for basic and diluted EPS $ 2,142 $ 1,989
Weighted-average shares for basic EPS 1,553 1,552
Plus contingently issuable performance stock units (PSUs) 2 1
Weighted-average shares for diluted EPS 1,555 1,553
Including rounding adjustment
Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are
included in PMI’s earnings per share calculation pursuant to the two-class method.
For the 2024 and 2023 computations, there were no antidilutive stock awards.
Note 7. Segment Reporting:
PMI’s subsidiaries and affiliates are primarily engaged in the manufacture and sale of cigarettes and smoke-free products, including heat-not-burn, e-vapor
and oral nicotine products. Excluding the Wellness and Healthcare segment, PMI's segments are generally organized by geographic region and managed by
segment managers who are responsible for the operating and financial results of the regions inclusive of combustible tobacco and smoke-free product
categories sold in the region. As discussed in Note 1. Background and Basis of Presentation, PMI updated in January 2024 its segment reporting by
including the former Swedish Match segment results into the four existing geographical segments. The four existing geographical segments are as follows:
Europe Region; South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Region ("SSEA, CIS & MEA"); East Asia,
Australia, and PMI Duty Free Region ("EA, AU & PMI DF"); and Americas Region. The Wellness and Healthcare segment remained unchanged.
PMI’s chief operating decision maker evaluates geographical segment performance and allocates resources based on regional operating income, which
includes results from all product categories sold in each region, excluding Wellness and Healthcare products. Business operations in the Wellness and
Healthcare segment are evaluated separately.
PMI disaggregates its net revenues from contracts with customers by product category for each of PMI's four geographical segments. For the Wellness and
Healthcare business, Vectura Fertin Pharma, net revenues from contracts with customers are included in the Wellness and Healthcare segment. PMI
believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.
(1)
(1)
19
-- 20 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Segment data were as follows:
(in millions)
For the Three Months Ended March
31,
2024 2023
Net revenues:
Europe $ 3,365 $ 3,068
SSEA, CIS & MEA 2,658 2,477
EA, AU & PMI DF 1,684 1,520
Americas 996 868
Wellness and Healthcare 90 86
Net revenues $ 8,793 $ 8,019
Operating income (loss):
Europe $ 1,456 $ 1,215
SSEA, CIS & MEA 772 734
EA, AU & PMI DF 763 637
Americas 99 183
Wellness and Healthcare (45) (38)
Operating income $ 3,045 $ 2,731
PMI's net revenues by product category were as follows:
(in millions)
For the Three Months Ended March
31,
2024 2023
Net revenues:
Combustible tobacco:
Europe $ 1,931 $ 1,815
SSEA, CIS & MEA 2,346 2,154
EA, AU & PMI DF 597 689
Americas 534 566
Total combustible tobacco 5,407 5,223
Smoke-free:
Smoke-free excluding Wellness and Healthcare:
Europe 1,434 1,253
SSEA, CIS & MEA 312 323
EA, AU & PMI DF 1,087 831
Americas 462 302
Total Smoke-free excluding Wellness and Healthcare 3,296 2,710
Wellness and Healthcare 90 86
Total Smoke-free 3,386 2,796
Total PMI net revenues $ 8,793 $ 8,019
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.
20
-- 21 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Items affecting the comparability of results from operations were as follows:
• Asset impairment and exit costs – See Note 15. Asset Impairment and Exit Costs for a breakdown of these costs by segment for the three months
ended March 31, 2024 and 2023.
• Termination of distribution arrangement in the Middle East – In the first quarter of 2023, PMI recorded a pre-tax charge of $80 million following
the termination of a distribution arrangement in the Middle East. This pre-tax charge was recorded as a reduction of net revenues in the condensed
consolidated statements of earnings, and was included in the SSEA, CIS & MEA segment results for the three months ended March 31, 2023.
• Swedish Match AB acquisition accounting related items – In the first quarter of 2023, PMI recorded $18 million pre-tax purchase accounting
adjustments related to the sale of acquired inventories stepped up to fair value included in the Americas segment.
Net revenues related to combustible tobacco refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and
other tobacco products that are combusted. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and
cigarillos, and do not include smoke-free products.
Net revenues related to smoke-free, excluding wellness and healthcare, refer to the operating revenues generated from the sale of these products, including
shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes, if applicable. These net revenue amounts consist
of the sale of PMI's products that are not combustible tobacco products, such as heat-not-burn, e-vapor, and oral products, as well as consumer accessories.
Net revenues related to wellness and healthcare consist of operating revenues generated from the sale of products primarily associated with inhaled
therapeutics, and oral and intra-oral delivery systems that are included in the operating results of PMI's Wellness and Healthcare business, Vectura Fertin
Pharma.
Note 8. Contingencies:
Tobacco and/or Nicotine-Related Litigation
Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various
jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend,
as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between
Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco
product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify
PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for
PMI.
It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending
tobacco or nicotine-related litigation could encourage the commencement of additional litigation.
Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Canada and Nigeria, range into the billions of U.S. dollars.
The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary
relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. While, as discussed below, we have to date been largely successful in
defending tobacco-related litigation, litigation is subject to uncertainty. Additionally, as reported further below, beginning in March 2024, litigation related
to oral nicotine products was filed against us and our subsidiary before certain courts in the United States.
We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is
probable and the amount of the loss can be reasonably estimated. At the present time, except as
21
-- 22 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
stated otherwise in this Note 8. Contingencies, it is reasonably possible that an unfavorable outcome in a case may occur. Legal defense costs are expensed
as incurred.
It is possible that our consolidated financial statements, including our results of operations, cash flows or financial position could be materially affected in a
particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to
uncertainty, we and each of our subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we
have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be,
vigorously defended. However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do
so.
After assessing the information available to it, except as stated otherwise in this Note 8. Contingencies, (i) management has not concluded that it is
probable that a loss has been incurred in any of the pending combustible tobacco product-related cases; (ii) management is unable to estimate the possible
loss or range of loss for any of the pending combustible tobacco product-related cases; and (iii) accordingly, no estimated loss has been accrued in the
consolidated financial statements for unfavorable outcomes in these cases, if any.
CCAA Proceedings and Stay of Combustible Tobacco Product-Related Cases Pending in Canada
As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson &
Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior
Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a
Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA
order made by the Ontario Superior Court on March 22, 2019 authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course
after the CCAA filing, including obligations to employees, vendors, and suppliers. RBH's financial results have been deconsolidated from our consolidated
financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30,
2024 of all combustible tobacco product-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees
(PM USA and Altria), namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These
proceedings are presented below under the caption “Stayed Litigation — Canada.” Ernst & Young Inc. has been appointed as monitor of RBH in the
CCAA proceedings. In accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation,
it is anticipated that the court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled
that RBH and the other defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s
decision in the Létourneau and the Blais cases so long as the comprehensive stay of all combustible tobacco product-related litigation in Canada remains in
effect and that the time period to file the application would be extended by the stay period. While RBH believes that the findings of liability and damages in
both Létourneau and the Blais cases were incorrect, the CCAA proceedings will provide a forum for RBH to seek resolution through a plan of arrangement
or compromise of all combustible tobacco product-related litigation pending in Canada. It is not possible to predict the resolution of the underlying legal
proceedings or the length of the CCAA process.
Stayed Litigation — Canada
Smoking and Health Litigation — Canada
In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Canada Ltd., Rothmans,
Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in November 1998, RBH and other Canadian cigarette
manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants (the "Blais Class Action"). The plaintiffs, an anti-smoking
organization and an individual smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain
smoking-related diseases. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other
Canadian manufacturers liable and found that the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $11.3
billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our
subsidiary (approximately CAD 3.1 billion (approximately $2.3 billion) including pre-judgment interest). In addition, the trial court awarded CAD 90,000
(approximately $66,000) in punitive damages, allocating CAD 30,000 (approximately $22,000) to RBH. The trial court estimated the disease class at
99,957 members. RBH appealed to the Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD
226 million (approximately $165 million) to cover both the Létourneau and Blais cases, which RBH has
22
-- 23 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco Canada Ltd. to furnish security totaling CAD 758 million
(approximately $552 million) in installments through June 2017. JTI Macdonald Corp. was not required to furnish security in accordance with plaintiffs’
motion. The Court of Appeal ordered that the security is payable upon a final judgment of the Court of Appeal affirming the trial court’s judgment or upon
further order of the Court of Appeal.
On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages
award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion (approximately $9.8 billion), including interest due to
the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH
(approximately CAD 2.7 billion (approximately $2.0 billion), including pre-judgment interest). The Court of Appeal upheld the trial court’s findings that
defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to
warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further
held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the
judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais
case, approximately CAD 1.1 billion (approximately $801 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD
257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax,
as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents
probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment.
In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp.,
Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-
Macdonald Corp.) are defendants (the "Létourneau Class Action"). The plaintiff, an individual smoker, sought compensatory and punitive damages for
each member of the class who is deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The
trial court found RBH and two other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $95 million) in punitive
damages, allocating CAD 46 million (approximately $34 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but
declined to award compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court
found that a claims process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On
March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages
awarded allocating CAD 57 million (approximately $42 million), including interest to RBH. See the Blais description above for further detail concerning
the security order pertaining to both Létourneau and Blais cases and the impact of the decision on PMI’s financial statements.
RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on
several grounds including, the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of
smoking; (ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be
liable to all class members given the individual differences among class members.
In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada, filed
June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease
resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers,
their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by
tobacco products.
In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada, filed
July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on
behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD,
emphysema, heart disease, or cancer, as well as restitution of profits.
23
-- 24 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia,
Canada, filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an
individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and
punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits,
and reimbursement of government health care costs allegedly caused by tobacco products.
In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed
June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking
compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of
profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have
not been properly served with the complaint.
In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed
June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive
damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by
smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the
claim was filed.
In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada, filed
June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased
smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is
seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered
from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the
defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim.
In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed
June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker,
alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on
behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD,
heart disease, or cancer, as well as restitution of profits.
Health Care Cost Recovery Litigation — Canada
In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al.,
Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the
industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province
authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting
from a “tobacco related wrong.”
In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's
Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and
other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the
province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette
manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of
Justice, Toronto, Canada, filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants.
The claim was filed by the government of the province of Ontario
24
-- 25 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
based on legislation enacted in the province. This legislation is similar to the laws introduced in British Columbia and New Brunswick that authorize the
government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco
related wrong.”
In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of
Newfoundland and Labrador, St. Johns, Canada, filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the
industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province
that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action
against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec,
Canada, filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the
government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces.
The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will
incur, as a result of a “tobacco related wrong.”
In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench
Alberta, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was
filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian
provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred,
and will incur, as a result of a “tobacco related wrong.”
In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges,
Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada, filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other
members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province
that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette
manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench,
Judicial Centre of Saskatchewan, Canada, filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are
defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws
enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the
health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson &
Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada, filed September 10, 2012, we, RBH, our indemnitees (PM USA
and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on
legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file
a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges
Inc., et al., Supreme Court of Nova Scotia, Canada, filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the
industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar
to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to
recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.”
Combustible tobacco products litigation
Since 1995, 622 combustible tobacco product-related cases, including Smoking and Health, Label-Related, Health Care Cost Recovery, and Public Civil
Actions, have been filed against a PMI entity, 547 of those cases have been terminated in our favor,
25
-- 26 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
and the balance of 75 remains pending. Of those pending cases, four were initially decided in favor of plaintiffs and remain on appeal, or are subject to an
appeal. These four cases include the Blais Class Action and the Létourneau Class Action, described above under the caption "Smoking and Health
Litigation — Canada," and two individual cases where final resolution in the amount of the verdict would not have a material adverse effect on our
consolidated financial statements, including our results of operations, cash flows, or financial position.
Pending claims related to combustible tobacco products generally fall within the following categories:
Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported
class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross
negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade
practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and
injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause,
assumption of the risk, contributory negligence, and statute of limitations.
As of March 31, 2024, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows:
• 44 cases brought by individual plaintiffs in Argentina (29), Canada (2), Chile (12), and Turkey (1), compared with 46 such cases on March 31,
2023; and
• 9 cases brought on behalf of classes of individual plaintiffs, compared with 9 such cases on March 31, 2023.
The class actions pending in Canada are described above under the caption “Smoking and Health Litigation — Canada.”
Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost
expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including
unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special
duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under
statutes governing competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other
damages, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim,
adequate remedy at law, “unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of
cigarettes), and statute of limitations.
As of March 31, 2024, there were 17 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Brazil (1), Canada (10), Korea
(1) and Nigeria (5), compared with 17 such cases on March 31, 2023.
The health care cost recovery actions pending in Canada are described above under the caption “Health Care Cost Recovery Litigation — Canada.”
In the health care cost recovery case in Brazil, The Attorney General of Brazil v. Souza Cruz Ltda., et al., Federal Trial Court, Porto Alegre, Rio Grande do
Sul, Brazil, filed May 21, 2019, we, our subsidiaries, and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases in certain prior years, payment of anticipated costs of treating future alleged smoking-related diseases, and moral
damages. Defendants filed answers to the complaint in May 2020.
In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court
of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction.
Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High
Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of
treating alleged smoking-related diseases for the past 20 years,
26
-- 27 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages.
We are in the process of challenging the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants
relating to service objections.
In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High
Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the
cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next
20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural
steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served.
In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al.,
High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants. Plaintiffs seek reimbursement for the
cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next
20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not
have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served.
In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court
of Ogun State, Abeokuta, Nigeria, filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost
of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20
years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our objections to the court's jurisdiction. We have
appealed. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections.
In the health care cost recovery case in Korea, the National Health Insurance Service v. KT&G, et. al., filed April 14, 2014, our subsidiary and other
Korean manufacturers are defendants. Plaintiff alleges, among other things, that defendants concealed the health hazards of smoking, marketed to youth,
added ingredients to make their products more harmful and addictive, and misled consumers into believing that Lights cigarettes are safer than regular
cigarettes. The National Health Insurance Service seeks to recover damages allegedly incurred in treating 3,484 patients with small cell lung cancer,
squamous cell lung cancer, and squamous cell laryngeal cancer from 2003 to 2012. The trial court dismissed the case in its entirety on November 20, 2020.
The Appellate court granted the Plaintiff a de novo appeal in 2021 and determined that the appellate proceedings will take place in stages: wrongful
conduct/product defect allegations first, then causation and finally issues such as standing/direct action.
Label-Related Cases: These cases, brought only by individual plaintiffs, allege that the use of the descriptor “Lights” or other alleged misrepresentations or
omissions of labeling information constitute fraudulent and misleading conduct. Plaintiffs' allegations of liability in these cases are based on various
theories of recovery including misrepresentation, deception, and breach of consumer protection laws. Plaintiffs seek various forms of relief including
restitution, injunctive relief, and compensatory and other damages. Defenses raised include lack of causation, lack of reliance, assumption of the risk, and
statute of limitations.
As of March 31, 2024, there were 4 label-related cases brought by individual plaintiffs in Italy (1) and Chile (3) pending against our subsidiaries, compared
with 6 such cases on March 31, 2023.
Public Civil Actions: Claims have been filed either by an individual, or a public or private entity, seeking to protect collective or individual rights, such as
the right to health, the right to information or the right to safety. Plaintiffs' allegations of liability in these cases are based on various theories of recovery
including product defect, concealment, and misrepresentation. Plaintiffs in these cases seek various forms of relief including injunctive relief such as
banning cigarettes, descriptors, smoking in certain places and advertising, as well as implementing communication campaigns and reimbursement of
medical expenses incurred by public or private institutions.
As of March 31, 2024, there was 1 public civil action pending against our subsidiary in Venezuela (1), compared with 1 such case on March 31, 2023.
In a public civil action in Venezuela, Federation of Consumers and Users Associations (“FEVACU”), et al. v. National Assembly of Venezuela and the
Venezuelan Ministry of Health, Constitutional Chamber of the Venezuelan Supreme Court, filed
27
-- 28 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
April 29, 2008, we were not named as a defendant, but the plaintiffs published a notice pursuant to court order, notifying all interested parties to appear in
the case. In January 2009, our subsidiary appeared in the case in response to this notice. The plaintiffs purport to represent the right to health of the citizens
of Venezuela and claim that the government failed to protect adequately its citizens' right to health. The claim asks the court to order the government to
enact stricter regulations on the manufacture and sale of tobacco products. In addition, the plaintiffs ask the court to order companies involved in the
tobacco industry to allocate a percentage of their “sales or benefits” to establish a fund to pay for the health care costs of treating smoking-related diseases.
In October 2008, the court ruled that plaintiffs have standing to file the claim and that the claim meets the threshold admissibility requirements. In
December 2012, the court admitted our subsidiary and a subsidiary of British American Tobacco plc as interested third parties. In February 2013, our
subsidiary answered the complaint. On February 27, 2024, the Attorney General of Venezuela filed, on behalf of defendants, a motion to dismiss the case
for lack of prosecution.
U.S. Government Matter: The U.S. government contacted Altria and PM USA in connection with an agreement between PMI and Altria to end their
commercial relationship with respect to Platform 1 in the U.S. as of April 30, 2024 (“Altria Agreement"). Altria and PM USA are parties to a 2006 order in
the United States District Court for the District of Columbia holding that they violated the Racketeer Influenced and Corrupt Organizations Act (“2006
Order”). PMI was not a defendant in that proceeding. The 2006 Order imposed injunctive relief on defendants including, but not limited to, enjoining false,
misleading, or deceptive statements concerning cigarettes; prohibiting express or implied health statements for any cigarette brand; and requiring
defendants to make certain corrective statements at point-of sale and on websites. The 2006 Order also imposed restrictions on defendants from selling or
transferring their cigarette brands, brand names, cigarette product formulas or cigarette businesses without the transferee submitting to the jurisdiction of
the court and subjecting itself to the 2006 Order as of the date of sale or transfer. The U.S. government informed Altria that it believed the transaction
contemplated by the Altria Agreement falls within the scope of this provision and that, before it can be effectuated, PMI must submit to the 2006 Order. To
date, the U.S. government has not pursued the matter with or sought any relief from the court, and we believe that there are strong arguments as to why the
provision cited by the U.S. government is inapplicable to the Altria Agreement.
Smoke-Free Products-Related Litigation
Claims have been filed against PMI and a subsidiary related to ZYN nicotine pouches. These cases were filed either on behalf of an individual plaintiff, or
on behalf of a purported class of individuals. Plaintiffs assert a variety of common law and statutory claims, and seek various forms of relief, including
monetary and equitable relief.
In the first case, a putative class action, Wolters v. Swedish Match North America LLC, et al., filed March 1, 2024, before United States District Court for
the Southern District of California, plaintiff alleged, among other things, addiction to nicotine and dental harm resulting from the use of ZYN nicotine
pouches. The named defendants were PMI and Swedish Match North America LLC. Plaintiff purported to represent classes comprised of (i) all persons
who purchased ZYN products in the United States, (ii) all residents of California who purchased ZYN products, and (iii) all residents of California who, at
the time of their use of ZYN products, were under the age of 18, and who procured and used ZYN products. He alleged, among other things, that defendants
defectively designed ZYN products and sold them in an unreasonably unsafe and dangerous condition, marketed ZYN products to minors, and
misrepresented or failed to warn consumers about information related to ZYN products, including information about health risks associated with these
products. Plaintiff asserted strict liability design defect and failure to warn claims, as well as negligence and fraud claims and sought compensatory and
punitive damages, attorney’s fees and costs, interest, and medical monitoring. On April 9, 2024, plaintiff voluntarily dismissed this lawsuit without
prejudice.
In the second case, a putative class action, Kelly v. Philip Morris International Inc., et al., filed March 19, 2024, before United States District Court for the
Southern District of Florida, plaintiff alleges, among other things, addiction to nicotine resulting from the use of ZYN nicotine pouches. The named
defendants are PMI and Swedish Match North America LLC. Plaintiff purports to represent classes comprised of (i) all persons who purchased ZYN
products in the United States, (ii) all residents of Florida who purchased ZYN products, and (iii) all residents of Florida who, at the time of their use of ZYN
products, were under the age of 21, and who procured and used ZYN products. He alleges, among other things, that defendants defectively designed ZYN
products and sold them in an unreasonably unsafe and dangerous condition, marketed ZYN products to minors, and misrepresented or failed to warn
consumers about information related to ZYN products, including information about health risks associated with these products. Plaintiff asserts strict
liability design defect and failure to warn claims, as well as negligence and fraud claims and is seeking compensatory and punitive damages, attorney’s fees
and costs, interest, and medical monitoring. At this time, no estimated loss has been accrued in the consolidated financial statements for this proceeding and
we cannot determine the likelihood of loss, or reasonably estimate a range of loss, if any, from this proceeding.
28
-- 29 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In the third case, a putative class action, Doe v. Philip Morris International Inc., et al., filed March 29, 2024, before United States District Court for the
Eastern District of California, plaintiff alleges, among other things, addiction to nicotine resulting from the use of ZYN nicotine pouches. The named
defendants are PMI and Swedish Match North America LLC. Plaintiff purports to represent classes comprised of (i) all persons who used ZYN products in
the United States, (ii) all persons who used ZYN products in the United States while under the age of 18, (iii) all residents of California who used ZYN
products, and (iv) all residents of California who used ZYN products while under the age of 18. Plaintiff alleges, among other things, that defendants made
misrepresentations about ZYN products in their advertising and marketing, marketed ZYN products to minors, and misrepresented or failed to disclose to
consumers information about ZYN products, including information about health risks associated with these products. Plaintiff asserts fraud, unjust
enrichment, breach of implied warranty, and breach of consumer protection, unfair competition and advertising statutes claims and is seeking compensatory
and punitive damages, disgorgement of profits, attorney’s fees and expenses, interest and other applicable injunctive relief. At this time, no estimated loss
has been accrued in the consolidated financial statements for this proceeding and we cannot determine the likelihood of loss, or reasonably estimate a range
of loss, if any, from this proceeding.
In the fourth case, an individual complaint, Palmer v. Philip Morris International Inc., et al., filed April 3, 2024, before United States District Court for the
Southern District of Florida, plaintiff alleges, among other things, addiction to nicotine resulting from the use of ZYN nicotine pouches. The named
defendants are PMI and Swedish Match North America LLC. He alleges, among other things, that defendants defectively designed ZYN products and sold
them in an unreasonably unsafe and dangerous condition, marketed ZYN products to minors, and misrepresented or failed to warn consumers about
information related to ZYN products, including information about health risks associated with these products. Plaintiff asserts strict liability design defect
and failure to warn claims, as well as negligence and fraud claims, and is seeking compensatory and punitive damages, attorney’s fees and costs, interest,
and medical monitoring. At this time, no estimated loss has been accrued in the consolidated financial statements for this proceeding and we cannot
determine the likelihood of loss, or reasonably estimate a range of loss, if any, from this proceeding.
Other Litigation
The Department of Special Investigations of the government of Thailand ("DSI") conducted an investigation into alleged underpayment by our subsidiary,
Philip Morris (Thailand) Limited ("PM Thailand"), of customs duties and excise taxes relating to imports from the Philippines covering the period 2003-
2007. On January 18, 2016, the Public Prosecutor filed charges against our subsidiary and seven former and current employees in the Bangkok Criminal
Court alleging that PM Thailand and the individual defendants jointly and with the intention to defraud the Thai government, under-declared import prices
of cigarettes to avoid full payment of taxes and duties in connection with import entries of cigarettes from the Philippines during the period of July 2003 to
June 2006. The government sought a fine of approximately THB 80.8 billion (approximately $2.2 billion). In May 2017, Thailand enacted a new customs
act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand
believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law and that
the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and other Thai governmental agencies. Trial
in the case began in November 2017 and concluded in September 2019. In November 2019, the trial court found our subsidiary guilty of under-declaration
of the prices and imposed a fine of approximately THB 1.2 billion (approximately $32.4 million). The trial court dismissed all charges against the
individual defendants. In December 2019, as required by the Thai law, our subsidiary paid the fine. This payment is included in other assets on the
condensed consolidated balance sheets and negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash
flows in the period of payment. Both our subsidiary and the Public Prosecutor filed an appeal of the trial court's decision. The appellate court issued its
decision on the appeals on June 1, 2022. The appellate court affirmed the findings of under-declaration of import prices of cigarettes but reduced the fine to
approximately THB 122 million (approximately $3.3 million) finding the trial court erred in its calculation of the under-declaration and fine. The appellate
court affirmed the acquittals of the individual defendants. Our subsidiary has appealed the decision to the Supreme Court of Thailand. The Public
Prosecutor has also filed an appeal challenging the dismissal of charges against the individual defendants and the amount of the fine imposed. Thailand is
required to refund any payment made by our subsidiary in excess of any fine asserted by the courts.
The DSI also conducted an investigation into alleged underpayment by PM Thailand of customs duties and excise taxes relating to imports from Indonesia
covering the period 2000-2003. On January 26, 2017, the Public Prosecutor filed charges against PM Thailand and its former Thai employee in the
Bangkok Criminal Court alleging that PM Thailand and its former employee jointly and with the intention to defraud the Thai government under-declared
import prices of cigarettes to avoid full payment of taxes and duties in connection with import entries during the period from January 2002 to July 2003.
The government is seeking a fine of approximately THB 19.8 billion (approximately $535 million). In May 2017, Thailand enacted a new customs
29
-- 30 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
act. The new act, which took effect in November 2017, substantially limits the amount of fines that Thailand could seek in these proceedings. PM Thailand
believes that its declared import prices are in compliance with the Customs Valuation Agreement of the World Trade Organization and Thai law, and that
the allegations of the Public Prosecutor are inconsistent with several decisions already taken by Thai Customs and a Thai court. Trial in the case began in
November 2018 and concluded in December 2019. In March 2020, the trial court found our subsidiary guilty of under-declaration of the prices and
imposed a fine of approximately THB 130 million (approximately $3.5 million). The trial court dismissed all charges against the individual defendant. In
April 2020, as required by Thai law, our subsidiary paid the fine. This payment is included in other assets on the condensed consolidated balance sheets and
negatively impacted net cash provided by operating activities in the condensed consolidated statements of cash flows in the period of payment. Our
subsidiary filed an appeal of the trial court's decision. In addition, the Public Prosecutor filed an appeal of the trial court's decision challenging the dismissal
of charges against the individual defendant and the amount of the fine imposed. The appellate court issued its decision on the appeals on January 31, 2023.
The appellate court affirmed the findings of under-declaration of import prices of cigarettes but reduced the fine imposed by the trial court. The appellate
court directed the Public Prosecutor to coordinate with customs officials to calculate such reduced fine in accordance with the appellate court’s decision.
The appellate court affirmed the acquittal of the individual defendant. Our subsidiary has appealed the decision to the Supreme Court of Thailand. The
Public Prosecutor has filed an appeal to the Supreme Court of Thailand challenging the dismissal of charges against the individual defendant and the
amount of the fine. Thailand is required to refund any payment made by our subsidiary in excess of any fine assessed by the courts.
On February 1, 2024, Philip Morris Products S.A. ("PMPSA") entered into a settlement agreement (the “Settlement Agreement”) with Nicoventures
Trading Limited (“NTV”), an affiliate of British American Tobacco p.l.c. (“BAT”). Under the Settlement Agreement, PMPSA, NTV and their respective
affiliates (the “Parties”) have agreed, among other things, to: (i) dismiss with prejudice, subject to certain limited exceptions, and without admission of
liability certain pending legal proceedings (the “Proceedings”) between them and concerning certain of their respective products; (ii) request rescission of
the limited exclusion order and the cease-and-desist order issued by the International Trade Commission (“ITC”) on September 29, 2021, and (iii) fully and
finally discharge without admission of liability any injunctions granted to the Parties in the Proceedings.
In April 2020, affiliates of BAT commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Altria Client Services LLC, et al., in
the federal court in the Eastern District of Virginia, where PMI's subsidiary, PMPSA, as well as Altria Group, Inc.'s subsidiaries, were defendants. Plaintiffs
sought damages and injunctive relief against the commercialization of the Platform 1 blade products in the United States. In April 2020, BAT affiliates
filed a complaint against PMI, PMPSA, Altria Group, Inc., and its subsidiaries before the ITC. Plaintiffs sought an order to prevent the importation of
Platform 1 products into the United States. The ITC evidentiary hearing closed on February 1, 2021. On May 14, 2021, the administrative law judge issued
an Initial and Recommended Determination ("ID/RD") finding that the Platform 1 blade products infringe two of the three patents asserted by Plaintiffs,
recommending that the ITC issue a Limited Exclusion order against infringing products, and recommending against a cease-and-desist, as well as
recommending against a bond pending Presidential review of the ITC's Final Determination ("FD"). Defendants and Plaintiffs filed separate Petitions for
Review with the ITC of the ID/RD on May 28, 2021; on July 27, 2021, the ITC granted each of the petitions in part, deciding to review certain issues in the
ID/RD. Plaintiffs and Defendants also submitted brief statements of the public interest factors in issue to the ITC on June 15, 2021. On September 29,
2021, the ITC issued its FD finding a violation of section 337 of the U.S. Tariff Act and issued (a) a limited exclusion order against PMPSA, prohibiting,
inter alia, the importation of Platform 1 product and infringing components; and (b) a cease-and-desist order against Altria Client Services, LLC and its
affiliate prohibiting, inter alia, sales of imported Platform 1 products. The ITC predicated the orders on its finding that Platform 1 blade products infringe
two patents owned by a BAT affiliate. The ITC also found that Platform 1 blade products do not infringe a third patent owned by a BAT affiliate. The ITC
further held that there were insufficient concerns over public interest to prevent the issuance of remedial orders. Following the Presidential Review period,
the orders became effective and Defendants filed a petition for review of the FD with the U.S. Court of Appeals for the Federal Circuit. Defendants also
filed motions in the ITC and Federal Circuit for a stay of the orders pending disposition of the appeal; the ITC denied the motion on January 20, 2022 and
the Federal Circuit denied the motion on January 25, 2022. The Federal Circuit heard oral argument on defendants' appeal of the FD on October 3, 2022
and, on March 31, 2023, the Federal Circuit affirmed the FD. The Eastern District of Virginia proceeding and related Federal Circuit appeals were
dismissed pursuant to the Settlement Agreement. Also pursuant to the Settlement Agreement, the parties filed a joint motion to rescind the limited
exclusion order and the cease-and-desist order issued by the ITC on September 29, 2021, which was granted on March 11, 2024.
30
-- 31 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In the Eastern District of Virginia case, the defendants also counterclaimed that BAT infringed their patents relating to certain e-vapor products, seeking
damages for, and injunctive relief against, the commercialization of these products by BAT. The trial of Defendant PMPSA’s counterclaims took place from
June 8-14, 2022 and, on June 15, 2022, the jury returned a verdict for PMPSA awarding approximately $10.8 million in damages for infringement up to
December 31, 2021 of two PMPSA patents by BAT’s affiliate and two of BAT’s e-vapor products; the jury also found BAT’s affiliate did not infringe one
of the two PMPSA patents and that the BAT affiliates had failed to prove one of the two PMPSA patents was invalid. PMPSA filed a motion for an
injunction or, in the alternative, an ongoing royalty on August 12, 2022. On March 30, 2023, the court denied PMPSA's motion for an injunction and
granted PMPSA an ongoing royalty against two of BAT's U.S. e-vapor products. On May 1, 2023, the court entered partial final judgment under Rule 54(b)
on PMPSA's claim against BAT's affiliate. That same day, BAT's affiliate filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit. On
May 10, 2023, PMPSA filed a notice of cross-appeal. As noted above, these appeals were dismissed pursuant to the Settlement Agreement. Upon petition
of PMPSA, the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office has instituted review of certain claims
pertaining to four of the six patents asserted by BAT affiliates in both proceedings. On January 11, 2022, PTAB issued its final decision on one of the two
patents underlying the ITC's FD, invalidating all challenged claims of BAT's patent. On March 30, 2022, PTAB issued its final decision on the second of
the two patents underlying the ITC's FD, finding the challenged claims patentable. The parties filed appeals of these PTAB results to the U.S. Court of
Appeals for the Federal Circuit. Oral argument was held on July 13, 2023. On July 17, 2023, the Federal Circuit issued a decision summarily affirming
PTAB’s decision to invalidate all challenged claims in one of the two patents underlying the ITC’s FD. The Federal Circuit issued the mandate notifying
the USPTO to record the invalidity of the challenged claims on August 23, 2023. On September 14, 2023, the Federal Circuit issued a decision affirming
the PTAB's decision finding certain claims in the second of the two patents underlying the ITC’s FD patentable. PMPSA’s counterclaim in the Eastern
District of Virginia challenging the validity of the remaining claims in the second of the two patents underlying the ITC’s FD was stayed pending resolution
of a related PTAB appeal. As noted above, the Eastern District of Virginia proceeding was dismissed pursuant to the Settlement Agreement. On July 21,
2022, PMPSA filed a Request for Rehearing of PTAB's November 2020 decision not to institute review of certain claims in the second of the two patents
underlying the ITC's FD; PTAB denied the Request on October 13, 2022.
In April 2020, BAT’s affiliate commenced patent infringement proceedings, Nicoventures Trading Limited v. PM GmbH, et al., against PMI’s German
subsidiary, Philip Morris GmbH, and PMPSA, in the Regional Court in Munich, Germany. Plaintiffs sought damages and injunctive relief against the
commercialization of the Platform 1 blade products in Germany. In June 2021, the court stayed the proceeding in respect of one of the two patents asserted
by BAT’s Affiliate. Following the December 2022 confirmation of the revocation of the other BAT patent by the European Patent Office Board of Appeal,
BAT withdrew its initial claim based on that patent; the stayed action based on the second patent was stayed pending final resolution of the revocation
action. The remaining case was dismissed pursuant to the Settlement Agreement.
In September 2020, BAT’s affiliates commenced patent infringement and unfair competition proceedings, RAI Strategic Holdings, Inc., et al. v. Philip
Morris Products S.A., et al., against PMPSA and PMI’s Italian subsidiaries, Philip Morris Manufacturing & Technology Bologna S.p.A. and Philip Morris
Italia S.r.l., in the Court of Milan, Italy. Plaintiffs sought damages, as well as injunctive relief against the manufacture in Italy of the Platform 1 blade
heated tobacco units allegedly infringing the asserted patents and the commercialization of the Platform 1 blade products in Italy. As part of this
proceeding, in October 2020, BAT’s affiliates filed a request based on one of the two asserted patents seeking preliminary injunctive relief against the
manufacture and commercialization of the Platform 1 blade products in Italy. In July 2022, the court dismissed plaintiffs’ request for preliminary injunction
in its entirety and plaintiffs did not appeal this ruling. The case was dismissed pursuant to the Settlement Agreement.
In October 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Japan, Limited, et al.,
against PMI’s Japanese subsidiary, Philip Morris Japan Limited, and a third-party distributor in the Tokyo District Court. Plaintiffs sought damages and
injunctive relief against the commercialization of the Platform 1 blade products in Japan. On December 23, 2022, the Court dismissed BAT’s claims with
respect to one of the two patents that it asserted, finding no infringement; BAT filed an appeal of this dismissal. On September 21, 2023, the IP High Court
issued its judgment dismissing BAT's appeal regarding the first patent. BAT appealed this decision to the Supreme Court on November 2, 2023. On
November 29, 2023, the Tokyo District Court issued a first instance decision favorable to PMI, finding no infringement of the second patent BAT asserted
and dismissing BAT's claim. BAT appealed this decision to the IP High Court on January 12, 2024. These cases were dismissed pursuant to the Settlement
Agreement.
In November 2020, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Romania SRL, et al.,
against PMI’s Romanian subsidiaries, Philip Morris Romania S.R.L. and Philip Morris Trading
31
-- 32 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
S.R.L., and a third-party distributor in the Court of Law of Bucharest, Civil Registry. Plaintiffs sought damages and preliminary and permanent injunctive
relief against the manufacture and commercialization of the Platform 1 blade products in Romania. In February 2021, the court dismissed plaintiffs’ request
for a preliminary injunction. In April 2021, the appellate court denied plaintiffs' appeal, confirming the dismissal of plaintiffs' request for preliminary
injunction. Plaintiffs' proceeding requesting damages and a permanent injunction remained pending before the Court of Law of Bucharest, Civil Registry.
In an October 14, 2021 hearing, the court stayed the proceeding. This case was dismissed pursuant to the Settlement Agreement. On February 2, 2024, the
parties filed a request that the Court revoke the stayed status of the file. Simultaneously, BAT filed a request to renounce claims in full. As per applicable
procedural rules, the Court took notice of the requests and closed the file in a hearing held on April 18, 2024.
In March 2021, BAT’s affiliates commenced patent infringement proceedings, RAI Strategic Holdings, Inc., et al. v. Philip Morris Korea, Co., Ltd., against
PM Korea in the Seoul Central District Court. Plaintiffs sought damages and injunctive relief against the commercialization of the Platform 1 blade heated
tobacco units in South Korea. On May 30, 2022, the Korean Patent Office issued a decision that all of the challenged claims in the patent asserted by
Plaintiffs are invalid; Plaintiffs filed an appeal of this decision. Following BAT’s unsuccessful correction action at the Korean Patent Office, the court held
the first hearing in the appeal of the infringement proceeding on September 12, 2023. A hearing was held by the IP High Court on December 21, 2023, for
BAT's appeal of the decisions in the invalidation proceeding and claim correction proceeding. On February 7, 2024, the IP High Court issued a decision
dismissing BAT's appeal for both the invalidation action and the claim correction action. BAT elected not to appeal either the invalidation or claim
correction decisions, so the IP High Court's decision is now final. The infringement proceeding was dismissed pursuant to the Settlement Agreement.
On December 21, 2023, we were informed that Future Technology K.K. (“FTKK”) filed an application with Tokyo Customs against Sojitz Corporation
(“Sojitz”), Philip Morris Japan Limited’s (“PMJL”) importer and distributor, due to alleged infringement of JP7299432. FTKK is seeking an order stopping
the importation of TEREA consumables. At this time, FTKK is not seeking any monetary damages or costs. PMJL has entered an appearance in the
proceeding as an interested party and filed its response to FTKK's application on January 31, 2024. The Customs hearing is currently scheduled for May
28, 2024. We believe that this lawsuit is without merit and will defend it vigorously. On January 26, 2024, PMJL filed a declaratory judgment action in
Tokyo District Court seeking a declaration that JP7299432 is invalid and/or infringed. The declaratory judgment action is ongoing.
Other patent challenges are pending in various jurisdictions.
We are also involved in additional litigation arising in the ordinary course of our business. While the outcomes of these proceedings are uncertain,
management does not expect that the ultimate outcomes of other litigation, including any reasonably possible losses in excess of current accruals, will have
a material adverse effect on our consolidated results of operations, cash flows or financial position.
Note 9. Income Taxes:
Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a
separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets.
PMI’s effective tax rates for the three months ended March 31, 2024 and 2023 were 24.8% and 17.3%, respectively. The effective tax rate for the three
months ended March 31, 2024, was unfavorably impacted by a deferred tax charge for unrealized foreign currency gains on intercompany loans related to
the Swedish Match acquisition financing reflected in the condensed consolidated statements of earnings ($111 million), while the underlying pre-tax
foreign currency movements fully offset in the condensed consolidated statements of earnings and were reflected as currency translation adjustments in its
condensed consolidated statements of stockholders' (deficit) equity and an increase in deferred tax liabilities related to the fair value adjustment of equity
securities held by PMI ($43 million), partially offset by a U.S. tax benefit for a worthless stock deduction under section 165(g) of the Internal Revenue
Code related to PMI's investment in C.A. Tabacalera Nacional, a wholly owned foreign corporation incorporated in Venezuela ($47 million). For further
details on PMI's ceased operations in Venezuela, see Note 15. Asset Impairment and Exit Costs.
Changes in the tax laws of foreign jurisdictions could arise as a result of the Base Erosion and Profit Shifting project undertaken by the Organisation for
Economic Co-operation and Development (“OECD”), which recommended changes to numerous long-
32
-- 33 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
standing tax principles. As of March 31, 2024, many countries have enacted the OECD’s framework on a global minimum tax (referred to as “Pillar Two”),
effective for taxable years beginning after December 31, 2023. PMI has determined that Pillar Two should not have a material impact on its 2024
consolidated financial statements.
The effective tax rate for the three months ended March 31, 2023, was favorably impacted by a deferred tax benefit for unrealized foreign currency losses
on intercompany loans related to the Swedish Match acquisition financing reflected in the condensed consolidated statements of earnings ($79 million),
while the underlying pre-tax foreign currency movements fully offset in the condensed consolidated statements of earnings and were reflected as currency
translation adjustments in its condensed consolidated statements of stockholders' (deficit) equity.
PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of
limitations remains open for the years 2019 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from 3 to 5 years
after the filing of a return.
Subsidiaries of PMI in Indonesia, principally PT Hanjaya Mandala Sampoerna Tbk ("HMS"), have recorded income tax receivables in the amount of
3.9 trillion Indonesian rupiah (approximately $245 million) relating to corporate income tax assessments paid to avoid potential penalties, primarily for
domestic and other intercompany transactions for the years 2015 to 2020. Objection letters have been filed with the Tax Office and these assessments are
being challenged at various levels in court. These income tax receivables are included in other assets in PMI’s condensed consolidated balance sheets at
March 31, 2024 and December 31, 2023.
It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits
along with related interest and penalties. An estimate of any possible change cannot be made at this time.
Note 10. Indebtedness:
Short-term Borrowings:
At March 31, 2024 and December 31, 2023, PMI’s short-term borrowings and related average interest rates consisted of the following:
March 31, 2024 December 31, 2023
(in millions)
Amount
Outstanding Average Rate
Amount
Outstanding Average Rate
Commercial paper $ 149 5.7 % $ 1,685 5.6 %
Bank loans 130 10.7 283 8.9
$ 279 $ 1,968
Given the mix of PMI's legal entities and their respective local economic environments, the average interest rate for bank loans above can vary significantly
from day to day and country to country.
The fair values of PMI’s short-term borrowings, based on current market interest rates, approximate carrying value.
33
-- 34 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Long-term Debt:
At March 31, 2024 and December 31, 2023, PMI’s long-term debt consisted of the following:
(in millions) March 31, 2024 December 31, 2023
U.S. dollar notes, 0.875% to 6.375% (average interest rate 4.529%), due through 2044 $ 34,932 $ 30,272
Foreign currency obligations:
Euro notes, 0.125% to 3.125% (average interest rate 1.877%), due through 2039 8,277 8,526
Swiss franc note, 1.625%, due 2024 276 299
Euro credit facility borrowings related to Swedish Match AB acquisition, (average
interest rate 4.454%), due through 2027 5,934 6,121
Swedish krona notes, 1.395% to 2.710% (average interest rate 2.016%), due through 2029 221 236
Other (average interest rate 6.146%), due through 2031 468 487
Carrying value of long-term debt 50,108 45,941
Less current portion of long-term debt 5,425 4,698
$ 44,683 $ 41,243
Includes long-term bank loans at subsidiaries, as well as $45 million and $53 million in finance leases at March 31, 2024 and December 31, 2023, respectively.
The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates
currently available to PMI for issuances of debt with similar terms and remaining maturities. At March 31, 2024, the fair value of PMI's outstanding long-
term debt, excluding the aforementioned finance leases, was as follows:
(in millions) March 31, 2024
Level 1 $ 42,335
Level 2 6,477
For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant
Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2023.
Credit Facilities related to the Financing of the Swedish Match Acquisition
In connection with PMI's all-cash recommended public offer to the shareholders of Swedish Match, on May 11, 2022, PMI entered into a credit agreement
relating to a 364-day senior unsecured bridge facility. The facility provided for borrowings up to an aggregate principal amount of $17 billion, expiring 364
days after the occurrence of certain events unless extended. On June 23, 2022, PMI entered into a €5.5 billion (approximately $5.8 billion at the date of
signing) senior unsecured term loan credit agreement consisting of a €3.0 billion (approximately $3.2 billion at the date of signing) tranche expiring three
years after the occurrence of certain events and a €2.5 billion (approximately $2.6 billion at the date of signing) tranche expiring on June 23, 2027. In
connection with the term loan facility, the aggregate principal amount of commitments under the 364-day senior unsecured bridge facility was reduced
from $17 billion to $11 billion. On November 11, 2022, PMI acquired a controlling interest of 85.87% of the total issued shares in Swedish Match and
acquired 94.81% of its outstanding shares as of December 31, 2022. In accordance with the Swedish Companies Act, PMI subsequently exercised its right
to compulsorily redeem the remaining shares for which acceptances were not received and obtained legal title to 100% of the shares in Swedish Match on
February 17, 2023.
PMI borrowed $8.4 billion under the bridge facility by delivering notices of borrowing for advances of $7.9 billion and $0.5 billion on November 7, 2022
and November 10, 2022, respectively. On November 21, 2022 and February 17, 2023, PMI repaid $4.0 billion and $4.4 billion, respectively, under the
bridge facility. Effective February 20, 2023, the remaining outstanding
(a)
(a)
34
-- 35 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
commitments under the bridge facility were fully canceled and the bridge facility agreement was terminated in accordance with its terms.
On November 7, 2022, PMI also delivered notices of borrowing for advances totaling €5.5 billion under the term loan facility, of which €3.0 billion will
become due on November 9, 2025 and €2.5 billion will become due on June 23, 2027 unless prepaid pursuant to the terms of the credit agreement. As of
March 31, 2024 and December 31, 2023, the €5.5 billion (approximately $6 billion) term loan facility was fully drawn and remained outstanding.
The proceeds under the bridge facility and the term loan facility were used, directly or indirectly, to finance the acquisition, including, the payment of
related fees and expenses.
Debt Issuances
PMI's debt issuances in the first three months of 2024 were as follows:
(in millions)
Type Face Value Interest Rate Issuance Maturity
U.S. dollar notes (a) $750 4.750% February 2024 February 2027
U.S. dollar notes (a) $1,000 4.875% February 2024 February 2029
U.S. dollar notes (a) $1,250 5.125% February 2024 February 2031
U.S. dollar notes (a) $1,750 5.250% February 2024 February 2034
(a) Interest is payable semi-annually, commencing in August 2024
The net proceeds from the sale of the securities listed in the table above have been or will be used for general corporate purposes, including working capital
requirements, repayment of commercial paper and to refinance certain of our outstanding notes due in 2024.
Revolving Credit Facilities:
At March 31, 2024, PMI's total committed revolving credit facilities were as follows:
(in billions)
Type
Committed
Revolving Credit
Facilities
364-day revolving credit, expiring January 28, 2025 $ 1.7
Multi-year revolving credit, expiring February 10, 2026 2.0
Multi-year revolving credit, expiring September 29, 2026 2.5
Total facilities $ 6.2
On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for
an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion.
Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails
to achieve, certain specified targets.
On September 20, 2022, PMI entered into an agreement, effective September 29, 2022, to amend and extend the term of its $2.5 billion multi-year revolving credit
facility, for an additional year covering the period September 30, 2026 to September 29, 2027, in the amount of $2.3 billion. On September 20, 2023, PMI entered into an
agreement, effective September 29, 2023, to amend and further extend the term to September 29, 2028.
At March 31, 2024, there were no borrowings under these committed revolving credit facilities, and the entire committed amounts were available for
borrowing.
(1)
(2) (3)
(1)
(2)
(3)
35
-- 36 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In addition to the committed revolving credit facilities discussed above, PMI maintains certain short-term credit arrangements, including uncommitted
credit lines, to primarily meet working capital needs. These credit arrangements amounted to approximately $2.1 billion at March 31, 2024, and
approximately $2.7 billion at December 31, 2023. Borrowings under these arrangements and other bank loans amounted to $130 million at March 31,
2024, and $283 million at December 31, 2023.
Note 11. Accumulated Other Comprehensive Losses:
PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following:
(Losses) Earnings At At At
(in millions) March 31, 2024 December 31, 2023 March 31, 2023
Currency translation adjustments $ (8,883) $ (9,467) $ (8,120)
Pension and other benefits (2,555) (2,589) (1,790)
Derivatives accounted for as hedges 373 241 296
Total accumulated other comprehensive losses $ (11,065) $ (11,815) $ (9,614)
Reclassifications from Other Comprehensive Earnings
The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period
activity and reclassifications to the income statement, are shown on the condensed consolidated statements of comprehensive earnings for the three months
ended March 31, 2024 and 2023. For additional information, see Note 3. Benefit Plans for disclosures related to PMI's pension and other benefits, Note 5.
Financial Instruments for disclosures related to derivative financial instruments, Note 15. Asset Impairment and Exit Costs for disclosures related to the
reclassification of accumulated foreign currency translation losses from other comprehensive losses and Note 18. Acquisitions (Transactions With
Noncontrolling Interests) for disclosures related to currency translation adjustments
Note 12. Related Parties - Equity Investments and Other:
Equity Method Investments:
At March 31, 2024 and December 31, 2023, PMI had total equity method investments of $1,227 million and $1,309 million, respectively. Equity method
investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or
losses, dividends, capital contributions, changes in ownership interests and movements in currency translation adjustments. The carrying value of our
equity method investments at March 31, 2024 and December 31, 2023, exceeded our share of the investees' book value by $853 million and $907 million,
respectively. The difference between the investment carrying value and the amount of underlying equity in net assets is mainly attributable to equity
method goodwill, convertible debt instruments, and definite-lived intangible assets and other assets. The difference related to the definite-lived intangibles
and other assets at March 31, 2024 and December 31, 2023 of $22 million and $31 million, respectively, is amortized on a straight-line basis and is
included in Equity investments and securities (income)/loss, net on the condensed consolidated statements of earnings. At March 31, 2024, PMI received
no year-to-date dividends from equity method investees. At December 31, 2023, PMI received year-to-date dividends from equity method investees of $57
million.
PMI holds a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia (SSEA, CIS &
MEA segment), which as of March 31, 2024 had a carrying value of $389 million. While as of March 31, 2024, there have been no impairment indicators
based on the business’ performance, there are still risks related to this investment as the fair value of these assets is difficult to predict due to the volatility
in foreign currency and commodity markets, supply chain, and current economic, political and social conditions. Additionally, there was approximately
$570 million of cumulative foreign currency translation losses associated with Megapolis Distribution BV reflected in accumulated other comprehensive
losses in the condensed consolidated statement of stockholders’ equity as of March 31, 2024.
PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest
in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise
Management et Développement des Actifs et des Ressources
36
-- 37 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Holding ("MADAR Holding"), which manufactures and distributes under license some of PMI’s brands (SSEA, CIS & MEA segment).
In April 2023, PMI increased its equity ownership and acquired 66.73% of Egyptian Investment Holding (“EIH”), a United Arab Emirates based company
and as a result, acquired an approximate economic interest of 25% in United Tobacco Company ("UTC"). UTC is an entity incorporated in Egypt, which is
38% owned by EIH and manufactures products under license for Philip Morris Misr LCC (“PMM”), an entity incorporated in Egypt which is consolidated
in PMI’s financial statements in the SSEA, CIS & MEA segment.
The initial investments in Megapolis Distribution BV, EITA and UTC have been recorded at cost and are included in equity investments on the
consolidated balance sheets. Transactions between these equity method investees and PMI subsidiaries are considered to be related-party transactions and
are included in the tables below.
Equity securities:
On March 22, 2019, PMI’s wholly owned subsidiary in Canada, Rothmans, Benson & Hedges Inc. (“RBH”) obtained an initial order from the Ontario
Superior Court of Justice granting it protection under the Companies’ Creditors Arrangement Act ("CCAA"), which is a Canadian federal law that permits
a Canadian business to restructure its affairs while carrying on its business in the ordinary course with minimal disruption to its customers, suppliers and
employees. The administration of the CCAA process, principally relating to the powers provided to the court under the CCAA and the oversight provided
by the court appointed monitor, removes certain elements of control of the business from both PMI and RBH. As a result, PMI determined that it no longer
had a controlling financial interest over RBH as defined in ASC 810 (Consolidation), and deconsolidated RBH as of the date of the CCAA filing. For
further details, see Note 8. Contingencies.
Since the deconsolidation of RBH on March 22, 2019, PMI has accounted for its continuing investment in RBH in accordance with ASC 321 (Investments-
Equity Securities) as an equity security, without readily determinable fair value, and recorded its continuing investment in RBH at fair value of $3,280
million at the date of deconsolidation, within equity investments. Developments in the CCAA process, including resolution through a plan of arrangement
or compromise of some or all tobacco-related litigation pending in Canada may have a material adverse impact on the fair value of PMI’s continuing
investment in RBH and may result in impairment charges. Transactions between PMI and RBH are considered to be related-party transactions from the
date of deconsolidation and are included in the tables below.
The fair value of PMI’s other equity securities, which have been classified within Level 1, was $544 million at March 31, 2024. Unrealized pre-tax gain
(loss) of $169 million ($126 million net of tax) on these equity securities was recorded in equity investments and securities (income)/loss, net on the
condensed consolidated statements of earnings for the three months ended March 31, 2024.
Other related parties:
United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC
("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the SSEA, CIS & MEA segment. PMM sells, under
license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI.
Godfrey Phillips India Ltd ("GPI") is one of the non-controlling interest holders in IPM India, which is a 56.3% owned PMI consolidated subsidiary in the
SSEA, CIS & MEA segment. GPI also acts as contract manufacturer and distributor for IPM India.
37
-- 38 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Financial activity with the above related parties:
PMI’s net revenues and expenses with the above related parties were as follows:
For the Three Months Ended March
31,
(in millions) 2024 2023
Net revenues:
Megapolis Group $ 520 $ 588
Other 340 285
Net revenues $ 860 $ 873
Expenses:
Other $ 40 $ 50
Expenses $ 40 $ 50
Net revenues exclude excise taxes and VAT billed to customers.
PMI’s balance sheet activity with the above related parties was as follows:
(in millions) At March 31, 2024 At December 31, 2023
Receivables:
Megapolis Group $ 467 $ 474
Other 235 236
Receivables $ 702 $ 710
Payables:
Other $ 26 $ 18
Payables $ 26 $ 18
The activities with the above related parties are in the ordinary course of business, and are primarily for distribution, service fees, contract manufacturing
and license agreements. PMI eliminated its respective share of all significant intercompany transactions with the equity method investees.
Note 13. Sale of Accounts Receivable:
To mitigate risk and enhance cash and liquidity management, PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow
PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed
from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing
arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial
institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing
liability were not material as of March 31, 2024 and March 31, 2023. Under the non-servicing arrangements, PMI does not provide any administrative
support or servicing after the trade receivables have been sold to the unaffiliated financial institutions.
Cumulative trade receivables sold, including excise taxes, for the three months ended March 31, 2024 and 2023, were $2.7 billion and $2.9 billion,
respectively. PMI’s operating cash flows were positively impacted by the amount of the trade receivables sold and derecognized from the condensed
consolidated balance sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding
under these arrangements as of March 31, 2024 and March 31, 2023, were $701 million, and $970 million, respectively. The net proceeds received are
included in cash provided by operating activities in the condensed consolidated statements of cash flows. The difference
(a)
(a)
38
-- 39 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of trade receivables within
marketing, administration and research costs in the condensed consolidated statements of earnings. For the three months ended March 31, 2024 and 2023,
the loss on sale of trade receivables was $12 million and $10 million, respectively.
Note 14. Product Warranty:
PMI's heat-not-burn devices and e-vapor products are subject to standard product warranties generally for a period of 12 months from the date of purchase
or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is
recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in
future estimates. Factors that affect product warranties may vary across markets but typically include device version mix, product failure rates, logistics and
service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At March 31, 2024 and December 31,
2023, these amounts were as follows:
(in millions)
As of and For the Three
Months Ended March 31,
2024
As of and For the Year
Ended December 31,
2023
Balance at beginning of period $ 80 $ 104
Changes due to:
Warranties issued 22 60
Settlements (18) (83)
Currency/Other — (1)
Balance at end of period $ 84 $ 80
Note 15. Asset Impairment and Exit Costs:
For the three months ended March 31, 2024 and 2023, PMI recorded total pre-tax asset impairment and exit costs of $168 million and $109 million,
respectively, related to restructuring activities. These 2024 and 2023 pre-tax charges were included in marketing, administration and research costs in the
condensed consolidated statements of earnings.
Platform 1 (IQOS) products sourcing for the U.S. market
On February 1, 2024 a subsidiary of PMI entered into a settlement agreement (the “Settlement Agreement”) with Nicoventures Trading Limited (“NTV”),
an affiliate of British American Tobacco p.l.c. (“BAT”). In accordance with its terms, the parties to the Settlement Agreement filed a joint motion to rescind
the limited exclusion order and the cease-and-desist order issued by the International Trade Commission (“ITC”) on September 29, 2021, which was
granted on March 11, 2024. Prior to their rescission, the orders prohibited the importation and sales of imported Platform 1 products to the United States of
America (for further details of the Settlement Agreement, ITC order and its rescission, see Note 8. Contingencies). As a result, PMI has initiated a project
in the first quarter of 2024 to restructure the sourcing of Platform 1 products to commercialize IQOS in the United States. For further details on IQOS
commercialization in the U.S. and the related agreement with Altria Group, Inc (“Altria”), see Note 8. Contingencies and Note 18. Acquisitions.
During the first quarter of 2024, PMI recorded pre-tax asset impairment and exit costs of $121 million related to this restructuring activity. This amount
included contract termination costs with suppliers of $61 million, including prepaid commitments of $20 million. The amount also included asset
impairment costs of $60 million, primarily related to machinery and equipment and other assets, which were non-cash charges.
Venezuela
In the first quarter of 2024, PMI ceased its operations in Venezuela and as a result, recorded pre-tax asset impairment and exit costs of $47 million. The
amount primarily included non-cash charges related to the reclassification of accumulated foreign currency translation losses from other comprehensive
losses of $38 million and asset impairment charge of $5 million related to
39
-- 40 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
land and buildings. This amount also included contract termination, severance and other related costs of $4 million, which were paid in cash.
For details on the income tax impact of the transaction, see Note 9. Income Taxes.
e-Vapor Products Manufacturing Optimization
In the first quarter of 2023, PMI initiated a project to fully outsource and restructure the manufacturing of e-vapor devices and consumables. As a result,
PMI recorded pre-tax asset impairment and exit costs of $109 million. This amount included contract termination costs for suppliers of $78 million,
including $21 million of embedded finance lease terminations, payable in cash. This amount also included asset impairment costs of $31 million, primarily
related to machinery and equipment, which were non-cash charges.
Asset Impairment and Exit Costs by Segment
PMI recorded the following pre-tax asset impairment and exit costs by segment:
(in millions) For the Three Months Ended March 31,
2024 2023
Reclassification of accumulated foreign currency translation losses from other comprehensive losses:
Americas $ 38 $ —
Total reclassification of accumulated foreign currency translation losses from other comprehensive losses 38 —
Contract termination charges:
Europe — 34
SSEA, CIS & MEA — 23
EA, AU & PMI DF — 14
Americas 65 7
Total contract termination charges 65 78
Asset impairment charges:
Europe — 13
SSEA, CIS & MEA — 9
EA, AU & PMI DF — 5
Americas 65 4
Total asset impairment charges 65 31
Asset impairment and exit costs $ 168 $ 109
40
-- 41 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Movement in Exit Cost Liabilities
The movement in exit cost liabilities for the three months ended March 31, 2024 was as follows:
(in millions)
Liability balance, January 1, 2024 $ 29
Charges, net 65
Cash spent (20)
Prepaid commitments (20)
Currency/other (1)
Liability balance, March 31, 2024 $ 53
Future cash payments for exit costs incurred to date are anticipated to be substantially paid by the end of 2025, with approximately $45 million expected to
be paid in the remainder of 2024.
Note 16. Leases:
The components of PMI’s lease cost were as follows for the three months ended March 31, 2024 and 2023:
For the Three Months Ended March
31,
(in millions) 2024 2023
Operating lease cost $ 66 $ 67
Finance lease cost:
Amortization of right-of-use assets 25 14
Short-term lease cost 16 14
Variable lease cost 7 7
Total lease cost $ 114 $ 102
Note 17. Supply Chain Financing:
PMI has engaged with unaffiliated global financial institutions that offer a voluntary supply chain financing ("SCF") program to some of our suppliers.
Under the SCF program, the suppliers may elect, at their sole discretion, to sell PMI's payment obligations to these financial institutions. The suppliers
independently negotiate the sale arrangements directly with these financial institutions. PMI does not participate in these negotiations, nor does it have any
economic interest in these agreements, or in the designated suppliers’ voluntary decision to sell PMI's payment obligations to these financial institutions.
No guarantees or securities are provided by PMI or any of its subsidiaries under the SCF programs. PMI's obligations to its suppliers, including amounts
due and scheduled payment terms are not impacted by the suppliers’ decision to sell amounts under the SCF program. The payment terms of PMI’s
suppliers generally do not exceed 120 days. All outstanding payable amounts related to suppliers that are participating in the SCF program are recorded in
accounts payable in PMI's condensed consolidated balance sheets. The associated payments are included in cash flows from operating activities within
PMI's condensed consolidated statement of cash flows. As of March 31, 2024 and December 31, 2023, the total amount due to suppliers participating in the
SCF program was approximately $0.8 billion and $0.9 billion, respectively.
41
-- 42 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 18. Acquisitions:
Transactions With Noncontrolling Interests
Turkey – In the first quarter of 2022, PMI acquired the remaining 25% stake of its holding in Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş.
("PMTM") (formerly Philsa Philip Morris Sabanci Sigara ve Tütüncülük Sanayi ve Ticaret A.Ş.) and 24.75% stake in Philip Morris Pazarlama ve Satiş
A.Ş. ("PMPS") (formerly Philip Morris SA, Philip Morris Sabanci Pazarlama ve Satiş A.Ş.) from its Turkish partners, Sabanci Holding for a total
acquisition price including transaction costs and remaining dividend entitlements of approximately $223 million. As a result of this acquisition, PMI owned
100% of these Turkish subsidiaries as of December 31, 2022. The purchase of the remaining stakes in these holdings resulted in a decrease to PMI's
additional paid-in capital of $30 million and an increase to accumulated other comprehensive losses of $171 million primarily following the reclassification
of accumulated currency translation losses from noncontrolling interests to PMI’s accumulated other comprehensive losses during the first quarter of 2022.
In January 2023, PMI sold the acquired stakes of its holdings in PMTM and PMPS to Pioneers Tutun Yatirim Anonim Sirketi (“Pioneers”) for a
consideration of approximately $258 million, including transaction costs and dividend entitlements. The sale resulted in an increase to PMI's additional
paid-in capital of $36 million and a decrease to accumulated other comprehensive losses of $179 million, following the reclassification of accumulated
other comprehensive losses from PMI’s accumulated other comprehensive losses to noncontrolling interests.
Altria Group, Inc. Agreement
On October 20, 2022, PMI announced that it had reached an agreement with Altria Group, Inc. ("Altria") to end the companies' relationship regarding the
IQOS commercialization rights in the U.S. as of April 30, 2024. As a result of PMI reacquiring these rights, effective May 1, 2024, PMI will hold the full
rights to commercialize IQOS in the U.S. As part of the agreement, PMI agreed to pay a total cash consideration of $2.7 billion, of which $1.0 billion was
paid at the inception of the agreement and the remaining $1.7 billion (plus interest, at a per annum rate equal to six percent (6%)), was paid on July 14,
2023. The cash consideration paid has been accounted for within other assets in PMI's condensed consolidated balance sheets as of March 31, 2024 and
December 31, 2023. PMI will finalize the accounting for this transaction by assigning the consideration to the respective assets in May 2024, when PMI
can exercise its ability to commercialize IQOS in the U.S. For further details on PMI's agreement with Altria, see Note 8. Contingencies.
42
-- 43 of 140 --
Table of Contents
Philip Morris International Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Note 19. New Accounting Standards:
Improvements to Reportable Segment Disclosures
On November 27, 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ASU 2023-07, “Improvements to
Reportable Segment Disclosures” (“ASU 2023-07”). ASU 2023-07 improves reportable segment disclosures, primarily through enhanced disclosures about
significant segment expenses regularly provided to the chief operating decision maker that impact segment profit or loss.
The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15,
2024, on a retrospective basis, with early adoption permitted. PMI is currently evaluating the impact of ASU 2023-07 on its disclosures.
Improvements to Income Tax Disclosures
On December 14, 2023, the FASB issued Accounting Standards Update ASU 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”).
ASU 2023-09 enhances the transparency of income tax disclosures, primarily by requiring public business entities to disclose specific categories in the rate
reconciliation tabular presentation, as well as by providing additional information for reconciling items that meet a quantitative threshold. The ASU also
requires disaggregated disclosures of federal, state and foreign income taxes paid.
ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and early adoption is permitted. The amendments are applicable on a
prospective basis, although retrospective basis is also permitted. PMI is currently evaluating the impact of ASU 2023-09 on its disclosures.
43
-- 44 of 140 --
Table of Contents
Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Description of Our Company
We are a leading international tobacco company, actively delivering a smoke-free future. We are evolving our portfolio for the long term to include
products outside of the tobacco and nicotine sector. Our current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, we
have invested over $12.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise
continue to smoke, with the goal of completely ending the sale of cigarettes. This investment includes the building of world-class scientific assessment
capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, we
acquired Swedish Match AB ("Swedish Match") – a leader in oral nicotine delivery – creating a global smoke-free combination led by the companies’
IQOS and ZYN brands. The U.S. Food and Drug Administration (the "FDA") has authorized versions of our IQOS devices and consumables, and Swedish
Match's General snus, as Modified Risk Tobacco Products ("MRTPs"). We describe the MRTP orders in more detail in the "Business Environment"
section of this Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A").
Following the combination and the progress in 2023 toward the integration of the Swedish Match business into PMI's existing regional structure, PMI
updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments. Our
four geographical segments are as follows:
• Europe Region;
• South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Region ("SSEA, CIS & MEA");
• East Asia, Australia, and PMI Duty Free Region ("EA, AU & PMI DF"); and
• Americas Region.
The Wellness and Healthcare segment ("W&H"), which includes the operating results of our Vectura Fertin Pharma business, remains unchanged.
Our cigarettes are sold in approximately 175 markets, and in many of these markets they hold the number one or number two market share position. We
have a wide range of premium, mid-price and low-price brands. Our portfolio comprises both international and local brands.
Smoke-Free Business ("SFB”) is the term PMI uses to refer to all of its smoke-free products. SFB also includes wellness and healthcare products, as well as
consumer accessories, such as lighters and matches.
Smoke-free products (also referred to herein as "SFPs") is the term PMI uses to refer to all of its products that provide nicotine without combusting
tobacco, such as heat-not-burn, e-vapor, and oral smokeless, and that therefore generate far lower levels of harmful chemicals. As such, these products have
the potential to present less risk of harm versus continued smoking.
IQOS is the leading brand in our SFPs portfolio. As of December 31, 2023, our smoke-free products were available for sale in 84 markets.
In 2021, we laid the foundation for our long-term growth ambitions beyond nicotine in wellness and healthcare, including through acquisitions of Vectura
Group plc ("Vectura") and Fertin Pharma A/S ("Fertin Pharma"), which provide essential capabilities for future product development. Now, with a strong
foundation and significant expertise in life sciences, we aim to expand into wellness and healthcare in areas such as inhalable drugs, nicotine-replacement
therapy, consumer wellness products, medical and pharmaceutical cannabinoids, and non-recreational cannabinoid products (including CBD), in line with
applicable regulatory requirements.
In 2022, we acquired Swedish Match AB, a market leader in oral nicotine delivery with a significant presence in the United States market. The Swedish
Match acquisition is a key milestone in PMI’s transformation to becoming a smoke-free company. Swedish Match has a leading nicotine pouch franchise in
the U.S. under the ZYN brand name. The Swedish Match product portfolio is complementary to our existing portfolio, permitting us to bring together a
leading oral nicotine product with the leading heat-not-burn product. By joining forces with Swedish Match, we expect to accelerate the achievement of our
joint
44
-- 45 of 140 --
Table of Contents
smoke-free ambitions, switching more adults who would otherwise continue to smoke cigarettes to better alternatives faster than either company could
achieve separately.
In 2022, we also completed an agreement with Altria Group, Inc. to end our commercial relationship in the U.S. covering IQOS as of April 30, 2024.
Thereafter, PMI will hold the full rights to commercialize IQOS in the U.S. On July, 14, 2023, we made the final payment to Altria under the terms of the
agreement. For further details, see Note 18. Acquisitions.
We use the term net revenues to refer to our operating revenues from the sale of our products, including shipping and handling charges billed to customers,
net of sales and promotion incentives, and excise taxes. Our net revenues and operating income are affected by various factors, including the volume of
products we sell, the price of our products, changes in currency exchange rates and the mix of products we sell. Mix is a term used to refer to the
proportionate value of premium-price brands to mid-price or low-price brands in any given market (product mix). Mix can also refer to the proportion of
shipment volume in more profitable markets versus shipment volume in less profitable markets (geographic mix).
Our cost of sales consists principally of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost
of devices produced by third-party electronics manufacturing service providers. Estimated costs associated with device warranty programs are generally
provided for in cost of sales in the period the related revenues are recognized.
Our marketing, administration and research costs include the costs of marketing and selling our products, other costs generally not related to the
manufacture of our products (including general corporate expenses), and costs incurred to develop new products. The most significant components of our
marketing, administration and research costs are marketing and sales expenses and general and administrative expenses.
Philip Morris International Inc. is a legal entity separate and distinct from its direct and indirect subsidiaries. Accordingly, our right, and thus the right of
our creditors and stockholders, to participate in any distribution of the assets or earnings of any subsidiary is subject to the prior rights of creditors of such
subsidiary, except to the extent that claims of our company itself as a creditor may be recognized. As a holding company, our principal sources of funds,
including funds to make payment on our debt securities, are from the receipt of dividends and repayment of debt from our subsidiaries. Our principal
wholly owned and majority-owned subsidiaries currently are not limited by long-term debt or other agreements in their ability to pay cash dividends or to
make other distributions that are otherwise compliant with law.
Executive Summary
The following executive summary provides the business update and significant highlights from the "Discussion and Analysis" that follows.
Impairment and Exit Costs
On February 2, 2024, PMI announced that it reached a global settlement with British American Tobacco p.l.c. The settlement led to the rescission of
International Trade Commission orders prohibiting the importation of IQOS products to the U.S. As a result, PMI has restructured the sourcing of IQOS
products to be commercialized in the U.S., and recorded pre-tax asset impairment and exit costs of $121 million related to this restructuring during the first
quarter of 2024.
In the first quarter of 2024, PMI ceased its operations in Venezuela and as a result, recorded pre-tax asset impairment and exit costs of $47 million.
45
-- 46 of 140 --
Table of Contents
Consolidated Operating Results for the Three Months Ended March 31, 2024
• Net Revenues - Net revenues of $8.8 billion for the three months ended March 31, 2024 increased by $0.8 billion, or 9.7%, from the comparable 2023
amount. The change in our net revenues from the comparable 2023 amount was driven by the following (variances not to scale with quarterly results):
During the quarter, net revenues increased by 9.7%. Net revenues, excluding currency, increased by 12.1%, mainly reflecting: a favorable pricing
variance, primarily driven by higher combustible tobacco pricing; and favorable volume/mix, mainly driven by higher HTU and ZYN volume, partially
offset by lower cigarette volume, as well as a favorable comparison to 2023 reflecting a charge in the first quarter of 2023 of $80 million following the
termination of a distribution arrangement in the Middle East, shown in "Other." The termination of a distribution arrangement in the Middle East is
further described in the following "Diluted Earnings Per Share" discussion.
Net revenues by product category for the three months ended March 31, 2024 and 2023, are shown below:
46
-- 47 of 140 --
Table of Contents
• Diluted Earnings Per Share - The changes in our reported diluted earnings per share (“diluted EPS”) for the three months ended March 31, 2024,
from the comparable 2023 amounts, were as follows:
Diluted EPS % Change
For the three months ended March 31, 2023 $ 1.28
2023 Asset impairment and exit costs 0.06
2023 Amortization of intangibles 0.04
2023 Termination of distribution arrangement in the Middle East 0.04
2023 Swedish Match AB acquisition accounting related items 0.01
2023 Income tax impact associated with Swedish Match AB financing (0.05)
Subtotal of 2023 items 0.10
2024 Asset impairment and exit costs (0.09)
2024 Amortization of intangibles (0.06)
2024 Impairment of other intangibles (0.01)
2024 Fair value adjustment for equity security investments 0.08
2024 Income tax impact associated with Swedish Match AB financing (0.07)
2024 Tax items 0.03
Subtotal of 2024 items (0.12)
Currency (0.20)
Interest (0.03)
Change in tax rate (0.02)
Operations 0.37
For the three months ended March 31, 2024 $ 1.38 7.8 %
Asset impairment and exit costs – During the three months ended March 31, 2023, we recorded pre-tax asset impairment and exit costs of $109 million,
representing $96 million net of income tax and a diluted EPS charge of $0.06 per share, related to a project to fully outsource and restructure the
manufacturing of e-vapor devices and consumables. During the three months ended March 31, 2024, we recorded pre-tax asset impairment and exit costs of
$168 million, representing $141 million net of income tax and a diluted EPS charge of $0.09 per share, related to the restructuring of the sourcing of IQOS
products to be commercialized in the U.S., and the cessation of our operations in Venezuela. For further details, see Note 15. Asset Impairment and Exit
Costs.
Amortization of intangibles – During the first quarter of 2023 and 2024, we recorded amortization of intangible expense of $81 million (representing $64
million net of income tax or $0.04 per share decrease in diluted EPS) and $120 million (representing $95 million net of income tax or $0.06 per share
decrease in diluted EPS), respectively. For further details, see Note 4. Goodwill and Other Intangible Assets, net.
Termination of distribution arrangement in the Middle East – Following the termination of a distribution arrangement in the Middle East, we recorded a
pre-tax charge of $80 million in the first quarter of 2023 (representing $70 million net of income tax and a diluted EPS charge of $0.04 per share). The pre-
tax charge was recorded as a reduction of net revenues in the condensed consolidated statements of earnings and was included in the SSEA, CIS & MEA
segment results.
Swedish Match AB acquisition accounting related items – During the first quarter of 2023, we recorded pre-tax purchase accounting adjustments of $18
million related to the sale of acquired inventories stepped up to fair value (representing $13 million net of income tax and a diluted EPS charge of $0.01 per
share). These pre-tax adjustments were recorded in cost of sales in the condensed consolidated statements of earnings for the three months ended March 31,
2023.
Impairment of other intangibles – During the first quarter of 2024, we recorded an impairment charge of $27 million (representing $20 million net of
income tax or $0.01 per share decrease in diluted EPS), primarily reflecting the impairment of non-amortizable intangible assets related to an in-process
research and development project in the Wellness and Healthcare segment. For further details, see Note 4. Goodwill and Other Intangible Assets, net.
47
-- 48 of 140 --
Table of Contents
Fair value adjustment for equity security investments – During the first quarter of 2024, we recorded a favorable fair value adjustment for our equity
security investments in India and Sri Lanka ($0.08 per share increase in diluted EPS). For further details, see Note 12. Related Parties - Equity Investments
and Other.
Income taxes – The Income tax impact associated with Swedish Match financing that increased our 2023 diluted EPS by $0.05 per share and decreased our
2024 diluted EPS by $0.07 per share in the table above was due to a deferred tax impact for unrealized foreign currency gains and losses on intercompany
loans related to the Swedish Match acquisition financing reflected in the condensed consolidated statements of earnings, while the underlying pre-tax
foreign currency movements fully offset in the condensed consolidated statements of earnings and were reflected as currency translation adjustments in the
condensed consolidated statements of stockholders' (deficit) equity. The 2024 tax items that increased our 2024 diluted EPS by $0.03 per share in the table
above were due to a U.S. tax benefit for a worthless stock deduction under section 165(g) of the Internal Revenue Code related to PMI’s investment in C.A.
Tabacalera Nacional, a wholly owned foreign corporation incorporated in Venezuela. The change in the tax rate that decreased our diluted EPS by $0.02 per
share in the table above was primarily due to increases in U.S. state tax expense and repatriation cost differences, partially offset by changes in earnings
mix by taxing jurisdiction.
As of March 31, 2024, many countries have enacted the OECD’s framework on a global minimum tax (referred to as “Pillar Two”). PMI has determined
that Pillar Two should not have a material impact on its 2024 consolidated financial statements. For further details, see Note 9. Income Taxes.
Currency – The unfavorable impact of $0.20 per share during the reporting period primarily results from the fluctuations of the U.S. dollar, especially
against the Egyptian pound, Japanese yen and Russian ruble. This unfavorable currency movement has impacted our profitability across our primary
revenue markets and local currency cost bases.
The unfavorable currency impact in the first quarter of 2024 included a $0.09 impact from the devaluation of the Egyptian pound, including a transactional
impact of approximately $0.06 primarily related to the balance sheet remeasurement of foreign currency payables.
Interest – The unfavorable impact of $0.03 per share from interest in the table above was due primarily to higher average debt levels and higher average
interest rates on debt.
Operations – The increase in diluted EPS of $0.37 from our operations in the table above was due primarily to the following segments:
• EA, AU & PMI DF: Favorable pricing, favorable volume/mix and lower shipping costs;
• Europe: Favorable pricing and favorable volume/mix, partly offset by higher manufacturing costs;
• SSEA, CIS & MEA: Favorable pricing and favorable volume/mix, partly offset by higher manufacturing costs; and
• Americas: Favorable volume/mix, partly offset by higher marketing and administration costs.
For further details, see the “Consolidated Operating Results” and “Operating Results by Business Segment” sections of the following “Discussion and
Analysis.”
48
-- 49 of 140 --
Table of Contents
Discussion and Analysis
Critical Accounting Estimates
For information on our critical accounting estimates, see "Critical Accounting Estimates" in the MD&A included in Item 7 of the Annual Report on Form
10-K for the fiscal year ended December 31, 2023.
Consolidated Operating Results
See pages 82-94 for a discussion of our "Cautionary Factors That May Affect Future Results." Our net revenues and operating income by segment are
shown in the table below:
(in millions)
For the Three Months Ended March
31,
2024 2023
Net revenues:
Europe $ 3,365 $ 3,068
SSEA, CIS & MEA 2,658 2,477
EA, AU & PMI DF 1,684 1,520
Americas 996 868
Wellness and Healthcare 90 86
Net revenues $ 8,793 $ 8,019
Operating income (loss):
Europe $ 1,456 $ 1,215
SSEA, CIS & MEA 772 734
EA, AU & PMI DF 763 637
Americas 99 183
Wellness and Healthcare (45) (38)
Operating income $ 3,045 $ 2,731
49
-- 50 of 140 --
Table of Contents
Our net revenues by product category are shown in the table below:
PMI Net Revenues by Product Category
(in millions) For the Three Months Ended March 31,
2024 2023 Change
Combustible tobacco:
Europe $ 1,931 $ 1,815 6.4 %
SSEA, CIS & MEA 2,346 2,154 8.9 %
EA, AU & PMI DF 597 689 (13.4)%
Americas 534 566 (5.6)%
Total combustible tobacco 5,407 5,223 3.5 %
Smoke-free:
Smoke-free excluding Wellness and Healthcare:
Europe 1,434 1,253 14.4 %
SSEA, CIS & MEA 312 323 (3.5)%
EA, AU & PMI DF 1,087 831 30.8 %
Americas 462 302 52.9 %
Total Smoke-free excluding Wellness and Healthcare 3,296 2,710 21.6 %
Wellness and Healthcare 90 86 4.7 %
Total Smoke-free 3,386 2,796 21.1 %
Total PMI net revenues $ 8,793 $ 8,019 9.7 %
Note: Sum of product categories or Regions might not foot to total PMI due to roundings.
Items affecting the comparability of results from operations were as follows:
• Asset impairment and exit costs – See Note 15. Asset Impairment and Exit Costs for a breakdown of these costs by segment for the three months
ended March 31, 2024 and 2023.
• Termination of distribution arrangement in the Middle East – In the first quarter of 2023, PMI recorded a pre-tax charge of $80 million following
the termination of a distribution arrangement in the Middle East. This pre-tax charge was recorded as a reduction of net revenues in the condensed
consolidated statements of earnings, and was included in the SSEA, CIS & MEA segment results for the three months ended March 31, 2023.
• Swedish Match AB acquisition accounting related items – In the first quarter of 2023, PMI recorded $18 million pre-tax purchase accounting
adjustments related to the sale of acquired inventories stepped up to fair value included in the Americas segment.
Net revenues related to combustible tobacco refer to the operating revenues generated from the sale of these products, including shipping and handling
charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of our cigarettes and
other tobacco products that are combusted. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and
cigarillos and do not include smoke-free products.
Net revenues related to smoke-free, excluding wellness and healthcare, refer to the operating revenues generated from the sale of these products, including
shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes, if applicable. These net revenue amounts consist
of the sale of our products that are not combustible tobacco products, such as heat-not-burn, e-vapor, and oral products, as well as consumer accessories.
Net revenues related to wellness and healthcare consist of operating revenues generated from the sale of products primarily associated with inhaled
therapeutics, and oral and intra-oral delivery systems that are included in the operating results of our
50
-- 51 of 140 --
Table of Contents
Wellness and Healthcare business, Vectura Fertin Pharma.
PMI's heat-not-burn products include licensed KT&G heat-not-burn products.
References to "Cost/Other" in the Consolidated Financial Summary table of total PMI and the five segments throughout this "Discussion and Analysis"
reflects the currency-neutral variances of: cost of sales (excluding the volume/mix cost component); marketing, administration and research costs
(including asset impairment and exit costs); and amortization and impairment of intangibles. “Cost/Other” also includes the currency-neutral net revenue
variance, unrelated to volume/mix and price components, attributable to: fees for certain distribution rights billed to customers in certain markets in the
SSEA, CIS & MEA Region and the revenue adjustment for the termination of a distribution arrangement in the Middle East.
Our consolidated shipment volume is shown in the table below:
Consolidated Shipment Volume
For the Three Months Ended March 31,
Cigarettes and Heated Tobacco Units (million units) 2024 2023 Change
Cigarettes 143,191 143,708 (0.4)%
Heated Tobacco Units 33,134 27,396 20.9 %
Total Cigarettes and Heated Tobacco Units 176,325 171,104 3.1 %
Oral SFP Volume (million cans)
Nicotine Pouches 145.7 81.3 79.3 %
Snus 61.4 55.6 10.5 %
Moist Snuff 34.4 35.2 (2.3)%
Other Oral SFP 1.0 1.3 (16.6)%
Total Oral Products 242.6 173.3 40.0 %
Excluding snuff, snuff leaf and U.S. chew
Note: Sum may not foot due to roundings
Following the deconsolidation of our Canadian subsidiary, we continue to report the volume and corresponding royalty revenues of brands sold by RBH for
which other PMI subsidiaries are the trademark owners. These include HEETS, Next, Philip Morris and Rooftop. The volume and corresponding royalty
revenues of these brands sold by RBH were not material to PMI for all periods presented.
Heated tobacco units ("HTUs") is the term we use to refer to heated tobacco consumables, which include our BLENDS, DELIA, HEETS, HEETS Creations,
HEETS Dimensions (defined collectively as HEETS), SENTIA, TEREA, TEREA CRAFTED and TEREA Dimensions, as well as the KT&G-licensed brands,
Fiit and Miix (outside of South Korea). HTUs also include zero tobacco heat-not-burn consumables (LEVIA).
Unless otherwise stated, market share for HTUs is defined as the in-market sales volume for HTUs as a percentage of the total estimated industry sales
volume for cigarettes and HTUs.
References to total industry (or total market), our shipment volume and our market share performance reflect cigarettes and heated tobacco units, unless
otherwise stated.
Total industry volume, PMI in-market sales volume and PMI market share for the following geographies include the cigarillo category in Japan: the total
international market, EA, AU & PMI DF Region, and Japanese domestic market.
In-market sales ("IMS") is defined as sales to the retail channel, depending on the market and distribution model.
References to total international market, defined as worldwide cigarette and heated tobacco unit volume excluding the United States, total industry (or total
market) and market shares throughout this "Discussion and Analysis" are our estimates for tax-
(1)
(1)
51
-- 52 of 140 --
Table of Contents
paid products based on the latest available data from a number of internal and external sources and may, in defined instances, exclude China and/or our
duty free business.
From time to time, PMI’s shipment volumes are subject to the impact of distributor inventory movements (or wholesaler inventory movements in certain
markets where PMI does not sell to distributors), and estimated total industry/market volumes are subject to the impact of inventory movements in various
trade channels that include estimated trade inventory movements of PMI’s competitors arising from market-specific factors that significantly distort
reported volume disclosures. Such factors may include changes to the manufacturing supply chain, shipment methods, consumer demand, timing of excise
tax increases or other influences that may affect the timing of sales to customers. In such instances, in addition to reviewing PMI shipment volumes and
certain estimated total industry/market volumes on a reported basis, management reviews these measures on an adjusted basis that excludes the impact of
distributor and/or estimated trade inventory movements. Management also believes that disclosing PMI shipment volumes and estimated total
industry/market volumes in such circumstances on a basis that excludes the impact of distributor and/or estimated trade inventory movements improves the
comparability of performance and trends for these measures over different reporting periods.
Key market data regarding total market size, our shipments and market share of cigarettes and heated tobacco units are shown in the table below:
For the Three Months Ended March 31,
PMI Shipments (billion units) PMI Market Share (%)
Market
Total Market
(billion units) Total Cigarette
Heated Tobacco
Unit Total
Heated Tobacco
Unit
2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023
Total 616.1 614.2 176.3 171.1 143.2 143.7 33.1 27.4 28.0 27.2 5.2 4.5
Europe
France 6.3 7.5 2.6 3.8 2.5 3.7 — 0.1 40.2 42.3 0.6 0.8
Germany 16.1 15.9 6.3 6.0 5.3 5.5 1.0 0.5 39.9 39.4 6.3 5.4
Italy 17.5 17.2 8.0 8.9 5.7 6.9 2.2 2.0 52.5 53.8 17.7 16.8
Poland 14.1 13.4 6.1 5.5 4.8 4.3 1.3 1.2 42.9 40.9 9.0 9.4
Spain 9.7 9.9 2.8 2.9 2.6 2.7 0.2 0.2 28.9 29.1 2.7 2.1
SSEA, CIS & MEA
Egypt 19.3 22.5 5.3 5.8 5.0 5.6 0.3 0.2 27.1 25.6 1.9 1.2
Indonesia 73.6 69.2 20.2 19.8 20.0 19.7 0.2 0.1 27.5 28.6 0.3 0.1
Philippines 10.2 11.5 5.5 6.7 5.4 6.6 0.1 0.1 53.2 57.7 0.7 0.5
Russia 46.7 44.9 15.5 14.7 11.5 10.9 4.0 3.8 32.4 31.2 9.5 8.3
Turkey 30.1 26.2 16.0 12.8 16.0 12.8 — — 53.3 48.9 — —
EA, AU & PMI DF
Australia 1.4 1.9 0.5 0.7 0.5 0.7 — — 37.6 35.8 — —
Japan 35.7 35.3 17.9 14.8 4.3 4.7 13.6 10.1 41.1 39.5 29.4 26.3
South Korea 16.5 16.9 3.4 3.3 2.0 2.1 1.4 1.2 20.4 19.6 8.2 6.8
Americas
Argentina 7.1 7.7 4.4 4.9 4.4 4.9 — — 61.5 62.9 — —
Mexico 6.2 6.1 3.7 3.7 3.7 3.7 — — 59.8 60.5 0.8 0.5
(1) Market share estimates are calculated using IMS data, unless otherwise stated
(2) Total market and market share estimates include cigarillos in Japan
(3) PMI market share reflects estimated adjusted IMS volume share, with historical total/HTU results: Italy Q2 53.6%/17.1%, Q3 53.4%/16.0%, Q4 53.7%/17.2%; Poland
Q2 41.1%/8.6%, Q3 42.0%/8.4%, Q4 43.8%/9.9%
(2)
(1) (2)
(3)
(3)
(3)
(2)
52
-- 53 of 140 --
Table of Contents
Consolidated Operating Results for the Three Months Ended March 31, 2024
The following discussion compares our consolidated operating results for the three months ended March 31, 2024, with the three months ended March 31,
2023.
Total Market
During the quarter, estimated international industry volume (excluding China and the U.S.) for cigarettes and HTUs increased by 0.3%, reflecting increases
in the SSEA, CIS & MEA Region and the EA, AU & PMI DF Region, partly offset by a decrease in the Americas Region and the Europe Region, as
described in the Regional sections of this MD&A.
For the full year 2024, we currently expect an estimated total international industry volume decline for cigarettes and HTUs, excluding China and the U.S.,
of -2% to flat.
Shipment Volume
Our total cigarette and HTU shipment volume increased by 3.1%, reflecting a 20.9% increase in HTU shipments across all regions, partly offset by a 0.4%
decline in cigarette shipments, with declines across all regions except the SSEA, CIS & MEA Region. Cigarette shipment volume for Marlboro increased
by 1.7% to 56.9 billion units.
Our total oral product shipment volume in cans increased by 40.0%, primarily reflecting growth in nicotine pouches (primarily in the U.S.) and snus
(mainly in Scandinavia).
For the full year 2024, we currently expect the total cigarette, HTU and oral smoke-free product shipment volume growth for PMI of flat to +1% driven by
smoke-free products.
For the full year 2024, we also expect nicotine pouch shipment volume in the U.S. of approximately 560 million cans.
Nicotine pouch products reflect 15 pouches per can in the U.S. and 21 pouches per can outside the U.S. Oral smoke-free product volume excludes snuff,
snuff leaf and U.S. chew and is measured in cans or, for the purposes of total shipment volumes, in pouches or pouch equivalents.
Adjusted in-market sales for HTUs increased by 12.5%, including growth in Japan of 13.3% and Europe of 9.4%. A net favorable impact of estimated
distributor inventory movements for HTUs shipments was driven most significantly by additional shipments to Japan in light of disruption to Red Sea
shipping routes.
International Share of Market - Cigarette and HTUs (Excluding China and the United States)
First-Quarter
2024 2023 Change
(pp)
Total International Market Share 28.0 % 27.2 % 0.8
Cigarettes 22.9 % 22.7 % 0.2
HTU 5.2 % 4.5 % 0.7
Cigarette over Cigarette Market Share 24.5 % 24.2 % 0.3
(1) Defined as PMI's cigarette and heated tobacco unit in-market sales volume as a percentage of total industry cigarette and heated tobacco unit sales volume, excluding China and the U.S.,
including cigarillos in Japan
(2) Defined as PMI's cigarette in-market sales volume as a percentage of total industry cigarette sales volume, excluding China and the U.S., including cigarillos in Japan
Note: Sum of share of market by product categories might not foot to total due to roundings.
(1)
(2)
53
-- 54 of 140 --
Table of Contents
Financial Summary
Financial Summary -
Quarters Ended March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2024 2023 Total Excl.
Cur-rency Total Cur-
rency Acqui-
sitions Price Vol/
Mix Cost/
Other
(in millions)
Net Revenues $ 8,793 $ 8,019 9.7 % 12.1 % $ 774 $ (194) $ — $ 449 $ 464 $ 55
Cost of Sales (3,195) (3,038) (5.2)% (5.4)% (157) 8 — — (169) 4
Marketing, Administration and
Research Costs (2,553) (2,250) (13.5)% (7.2)% (303) (142) — — — (161)
Operating Income $ 3,045 $ 2,731 11.5 % 23.5 % $ 314 $ (328) $ — $ 449 $ 295 $ (102)
Cost/Other variance includes charges in 2023 of $80 million following the termination of a distribution arrangement in the Middle East.
Cost/Other variance includes charges in 2023 of $18 million related to a Swedish Match AB acquisition accounting related items.
Cost/Other variance includes charges in 2024 and 2023 of $168 million and $109 million related to asset impairment and exit costs, respectively, as well as the 2024
impairment of other intangibles of $27 million. For more details, see Note 4. Goodwill and Other Intangible Assets, net and Note 15. Asset Impairment and Exit Costs.
During the quarter, net revenues increased by 9.7%. Net revenues, excluding currency, increased by 12.1%, mainly reflecting: a favorable pricing variance,
primarily driven by higher combustible tobacco pricing; and favorable volume/mix, mainly driven by higher HTU and ZYN volume, partially offset by
lower cigarette volume, as well as a favorable comparison to 2023 reflecting a charge in the first quarter of 2023 of $80 million following the termination
of a distribution arrangement in the Middle East, shown in "Other."
The unfavorable currency in net revenues was due primarily to the Egyptian pound, Japanese yen and Russian ruble, partially offset by the Euro.
Net revenues include $3.4 billion in 2024 and $2.8 billion in 2023 related to smoke-free.
Operating income increased by 11.5%. Operating income, excluding currency, increased by 23.5%, primarily reflecting: a favorable pricing variance and
favorable volume/mix, mainly driven by higher HTU and ZYN volume, partly offset by lower cigarette volume and unfavorable cigarette mix, as well as a
favorable comparison to 2023 reflecting a charge in 2023 of $80 million following the termination of a distribution arrangement in the Middle East and
charges in 2023 of $18 million related to a Swedish Match AB acquisition accounting related item. The increase was partly offset by higher amortization of
intangibles in 2024, higher asset impairment and exit costs in 2024, higher marketing, administration and research costs (primarily due to inflationary
impacts, notably related to wages) and higher manufacturing costs.
Amortization expense on a pre-tax basis for each of the next five years is estimated to be approximately $479 million or less, assuming no additional
transactions occur that require the amortization of intangible assets. Additionally, the estimated future amortization expense could significantly increase
following the reacquisition of IQOS commercialization rights in the U.S. from Altria Group, Inc. (see Note 18. Acquisitions and the "Business
Environment" section of this MD&A), the accounting for which will depend on the facts and circumstances effective May 1, 2024, when PMI will hold the
full rights. We currently estimate that the incremental increase in amortization expense in 2024, as a result of the reacquisition of IQOS commercialization
rights in the U.S., will be approximately $370 million on a pre-tax basis for the remaining 8 months of the year. For full year 2025 through 2028, we
currently estimate that this incremental increase will be approximately $555 million on a pre-tax basis.
Interest expense, net, of $299 million increased by $69 million or 30.0%, primarily due to higher average debt levels and higher average interest rates on
debt.
Our effective tax rate increased by 7.5 percentage points to 24.8%. For further details, see Note 9. Income Taxes. PMI estimates that its full-year 2024
effective tax rate will be approximately 21% to 22%, excluding discrete tax events. Changes in currency exchange rates, earnings mix by taxing jurisdiction
or future legislative or regulatory developments may have an impact on the effective tax rates, which PMI monitors each quarter. Significant judgment is
required in determining income tax provisions and in evaluating tax positions.
(1)
(2)
(3)
(1)
(2)
(3)
54
-- 55 of 140 --
Table of Contents
Income from equity investments and securities increased by $140 million or over 100%, primarily driven by a favorable fair value adjustment for our
equity security investments in India and Sri Lanka.
Net earnings attributable to PMI of $2.1 billion increased by $153 million or 7.7%. This increase was due primarily to a higher operating income and
higher income from equity investments and securities, partly offset by a higher effective tax rate and higher interest expense, net, as discussed above. Basic
and diluted EPS of $1.38 increased by 7.8%. Excluding an unfavorable currency impact of $0.20, diluted EPS increased by 23.4%.
Overall, our results of operations in the first quarter of 2024 were favorably impacted by three main factors. The first is the net revenue and profit impact of
better volumes following the industry-leading performance of ZYN, the strong shipment growth of IQOS HTUs, and a resilient combustible delivery.
Second is the benefit of our pricing actions to mitigate currency headwinds and third is on cost including a stepped-up focus on manufacturing and back-
office efficiencies to prioritize growth investments. These factors are expected to continue to impact performance for the remainder of the year.
Operating Results by Business Segment
Business Environment
Taxes, Legislation, Regulation and Other Matters Regarding the Manufacture, Marketing, Sale and Use of Tobacco Products
The tobacco industry and our company face a number of challenges that may adversely affect our business, volume, results of operations, cash flows and
financial position. These challenges, which are discussed below and in “Cautionary Factors That May Affect Future Results,” include:
• regulatory restrictions on our products, including restrictions on the packaging, marketing, and sale of tobacco or other nicotine-containing
products or related devices that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or even ban certain
of our products;
• fiscal challenges, such as excessive excise tax increases and discriminatory tax structures;
• illicit trade in cigarettes and other tobacco and nicotine-containing products, including counterfeit, contraband and so-called “illicit whites”;
• intense competition, including from non-tax paid volume by certain local manufacturers;
• pending and threatened litigation as discussed in Note 8. Contingencies; and
• governmental investigations.
Regulatory Restrictions: The tobacco industry operates in a highly regulated environment. The well-known risks of smoking have led regulators to impose
significant restrictions and high excise taxes on cigarettes.
Much of the regulation that shapes the business environment in which we operate is driven by the World Health Organization's (the "WHO") Framework
Convention on Tobacco Control (the "FCTC"), which entered into force in 2005. The main objective of the FCTC is to establish a global agenda for
tobacco regulation, with the purpose of reducing tobacco use. To date, 182 countries and the European Union ("EU") are Parties to the FCTC. The treaty
requires Parties to have in place various tobacco control measures and recommends others. The FCTC governing body, the Conference of the Parties
(“CoP”), has also adopted non-binding guidelines and policy recommendations related to certain articles of the FCTC that go beyond the text of the treaty.
In October 2018, the CoP recognized the need for more scientific assessment and improved reporting to define policy on heated tobacco products. Similar
to its previous policy recommendations on e-cigarettes, the CoP invited countries to regulate, restrict or prohibit heated tobacco products, as appropriate
under their national laws.
The Tenth Session of the CoP to the FCTC took place in February 2024. According to reports and decisions published, neither new decisions nor new
policy recommendations on novel and emerging tobacco products were adopted. Specific Guidelines were adopted to address cross-border Tobacco
Advertising, Promotion, and Sponsorship (“TAPS”) and the depiction of tobacco in entertainment media. The Eleventh session of the CoP is currently
scheduled to take place in 2025. The WHO’s reports and other FCTC guidelines or recommendations are not binding on the WHO Member States or on
parties to the FCTC.
55
-- 56 of 140 --
Table of Contents
We believe that when better alternatives to cigarettes exist, the discussion should not be whether these alternatives should be made available to the more
than one billion people who smoke cigarettes today, but how fast, and within what regulatory framework to maximize their adoption while minimizing
unintended use. Therefore, we advocate for regulatory frameworks that are based on a continuum of risk where non-combustible products fall below
combustible cigarettes. Product regulation should include measures that encourage and accelerate switching to non-combustible products, for example, by
allowing adult consumers who would not otherwise quit smoking cigarettes to receive truthful and non-misleading information about such alternatives to
enable them to make informed decisions and by applying uniform product standards to enable manufacturers to demonstrate the reduction in harmful and
potentially harmful constituents, as well as the absence of combustion. Regulation should also include specific rules for ingredients, labeling and consumer
communication, and should ensure that the public is informed about the health risks of all combustible and non-combustible tobacco and nicotine-
containing products. Importantly, regulation must include measures designed to prevent initiation by youth and non-smokers. We support mandated health
warnings, minimum age laws, restrictions on advertising, and smoking restrictions in public spaces. We also support regulatory measures that help reduce
illicit trade.
Certain measures are discussed in more detail below and in the Smoke-Free Products (SFPs) section.
Fiscal Challenges: Excessive and disruptive excise, sales and other tax increases and discriminatory tax structures are expected to continue to have an
adverse impact on our profitability, due to lower consumption and consumer down-trading to non-premium, discount, other low-price or low-taxed
combustible tobacco products such as fine cut tobacco and illicit cigarettes. In addition, in certain jurisdictions, some of our combustible tobacco products
are subject to tax structures that discriminate against premium-price products and manufactured cigarettes. We believe that such tax policies undermine
public health by encouraging consumers to turn to illicit trade, and ultimately undercut government revenue objectives, disrupt the competitive
environment, and encourage criminal activity. Other jurisdictions have imposed, or are seeking to impose, levies or other taxes specifically on tobacco
companies, such as taxes on revenues and/or profits.
World Customs Organization Developments: In 2020, the World Customs Organization (the “WCO”) amended the Harmonized System ("HS")
nomenclature to introduce dedicated custom codes for novel tobacco and nicotine products, including heated tobacco products, e-cigarettes and other
nicotine-containing products. The amendments became effective as of January 1, 2022. The vast majority of countries where our SFPs are commercialized
have adopted the amended HS, creating new dedicated customs codes for novel tobacco and nicotine products.
EU Tobacco Products Directive: In April 2014, the EU adopted a significantly revised TPD, which came into force in May 2016. All EU Member States
have adopted laws transposing the TPD. The TPD sets forth a comprehensive set of regulatory requirements for tobacco products, including:
• health warnings covering 65% of the front and back panels of cigarette packs, with an option for Member States to further standardize tobacco
packaging, including the introduction of plain packaging;
• a ban on characterizing flavors in some tobacco products, with a transition period for menthol that expired in May 2020;
• security features and tracking and tracing measures that became effective in May 2019; and
• a framework for the regulation of novel tobacco products and e-cigarettes, including requirements for health warnings and information leaflets, a
prohibition on product packaging text related to reduced risk, and the introduction of notification requirements or authorization procedures in
advance of commercialization.
In May 2021, the European Commission published its first report on the application of the TPD. The report identifies significant progress made due to the
implementation of the TPD and where there is still room for improvement. Most notably, it finds that the EU legislation has enhanced tobacco control,
which contributed to protecting the health of EU citizens by providing Member States with strong rules to address the use of tobacco products in the EU.
The TPD reportedly achieved the 2% reduction target of the impact assessment with decreased smoking prevalence among youth. The report also
concludes that there is scope for improvement in certain areas, such as enforcement at national level, assessment of ingredients, and a better consideration
for novel and emerging products.
In February 2024, the European Commission published an updated implementation roadmap to Europe's Beating Cancer Plan (the "Plan"). According to
the updated Plan, the evaluation of the current TPD is expected to be finalized in 2024.
EU Tobacco Excise Directive ("TED"): The EU Commission is preparing a legislative proposal for the revision of the 2011 EU Tobacco Excise Directive
that may include definitions and tax treatment for novel tobacco and nicotine-containing products,
56
-- 57 of 140 --
Table of Contents
including heated tobacco products, e-cigarettes and nicotine pouches. The proposal, after several delays, could be adopted by the new College of
Commissioners after the 2024 EU elections. The timeline for the revision has not been announced. Any final amendments to TED require unanimous
agreement by all EU Member States, followed by transposition of TED into national legislation. A potential enforcement date for any changes to TED,
after the transposition in Member States' national legislation, could be 2027.
Plain Packaging and Other Packaging Restrictions: Plain packaging legislation bans the use of branding, logos and colors on packaging other than the
brand name and variant that may be printed only in specified locations and in a uniform font. To date, plain packaging laws have been adopted in certain
markets in all of our operating segments, including the key markets of Australia, France, Saudi Arabia and Turkey. Some countries, such as Canada,
Denmark and Israel, adopted plain packaging regulations that apply to all tobacco products, including SFPs. Other countries are also considering plain
packaging legislation.
Some countries have adopted, or are considering adopting, packaging restrictions that could have an impact similar to plain packaging. Examples of such
restrictions include standardizing the shape and size of packages, prohibiting certain colors or the use of certain descriptive phrases on packaging, and
requiring very large graphic health warnings that leave little space for branding.
Restrictions and Bans on the Use of Ingredients: The WHO and others in the public health community have recommended restrictions or total bans on the
use of some or all ingredients in tobacco products, including menthol. Broad restrictions and ingredient bans would require us to reformulate our American
blend tobacco products and could reduce our ability to differentiate these products in the market in the long term. In many countries, menthol bans would
eliminate the entire category of mentholated tobacco products. The EU banned cigarettes and roll-your-own tobacco products with characterizing flavors.
Other tobacco products, including heated tobacco products, are currently exempted from this characterizing flavor ban. However, on November 23, 2022,
the EU Commission published a delegated directive that will eliminate this exemption. All EU Member States are required to apply the delegated directive
as of October 23, 2023, which bans the use of characterizing flavors in heated tobacco products, impacting a significant proportion of our SFP products
currently sold in the EU. Based on high consumer switching to non-flavored products in reaction to past bans on flavors in other categories and markets, we
anticipate that, while short-term volatility is possible, including in year-end trade inventories, the ban’s impact on our shipment volumes in the EU will be
relatively limited in the near term. Our fundamental view remains that we do not expect a meaningful change in the structural growth of the category with
consumers switching to non-flavored products partially mitigating the effect of the ban. A majority of EU Member States have transposed this directive, or
are in the final stages of transposing it, withdrawing the heated tobacco product exemption from the characterizing flavor ban into national law. The
remaining markets are expected to adopt this directive in 2024, and we will continue to actively monitor relevant developments in the EU market. Other
countries may follow the EU’s approach toward tobacco product ingredients. Turkey banned menthol as of May 2020. Broader ingredient bans have been
adopted by Brazil and Canada.
Bans on Display of Tobacco Products at Retail: In a number of our markets, including, but not limited to, Australia and Russia, governments have banned
the display of tobacco products at the point of sale. Other countries are considering similar bans.
Bans and Restrictions on Advertising, Marketing, Promotions and Sponsorships: For many years, the FCTC has called for, and countries have imposed,
partial or total bans on tobacco advertising, marketing, promotions and sponsorships, including bans and restrictions on advertising on radio and television,
in print and on the Internet. The FCTC's non-binding guidelines recommend that governments prohibit all forms of communication with adult smokers.
Restrictions on Product Design: Some members of the public health community are calling for the further standardization of tobacco products by requiring,
for example, that cigarettes have a certain minimum diameter, which would result in a ban on slim cigarettes, or requiring the use of standardized filter and
cigarette paper designs. In addition, at its meeting in November 2016, the CoP adopted non-binding guidelines recommending that countries regulate
product design features that increase the attractiveness of tobacco products, such as the diameter of cigarettes and the use of flavor capsules. In March
2024, the EU Commission approved a draft national decree submitted by Belgium banning disposable e-cigarettes in Belgium as required by TPD. This
ban will be limited to the jurisdiction of Belgium.
Restrictions on Public Smoking and Use of Nicotine-Containing Products in Public: The pace and scope of restrictions on the use of our products have
increased significantly in most of our markets. Many countries around the world have adopted, or are likely to adopt, regulations that restrict or ban
smoking and use of nicotine-containing products in public and/or work places, restaurants, bars and nightclubs. Some public health groups have called for,
and some countries, regional governments and municipalities have adopted or proposed, bans on smoking in outdoor places, as well as bans on smoking in
cars (typically, when minors are present) and private homes.
57
-- 58 of 140 --
Table of Contents
Other Regulatory Issues: Some regulators are considering, or in some cases have adopted, regulatory measures designed to reduce the supply of tobacco
products. These include regulations intended to reduce the number of retailers selling tobacco products by, for example, reducing the overall number of
tobacco retail licenses available or banning the sale of tobacco products within specified distances of certain public facilities. Other regulators are also
considering generation sales bans, which prohibit the sale of certain tobacco or nicotine products to people born after a certain year.
On December 13, 2022 the New Zealand parliament passed a bill introducing regulatory measures restricting the sale and supply of smoked tobacco
products, including reducing the number of retail outlets licensed to sell smoked tobacco products, imposing a maximum limit of nicotine content for
smoked tobacco products and prohibiting the sale of smoked tobacco products to anyone born on or after January 1, 2009. These measures are limited to
smoked tobacco products and do not apply to heated tobacco products and e-cigarettes. On February 28, 2024, the New Zealand parliament passed a law
repealing the three above-mentioned measures.
In Mexico, a new law came into force on December 12, 2022, prohibiting imports and exports of certain nicotine and non-nicotine delivery and
consumption systems, as well as the consumables used in those systems, including much of our SFP portfolio.
On December 16, 2022, the Mexican Federal Government enacted an implementation regulation for the tobacco control law, which includes (i) a point of
sale display ban of tobacco products; (ii) restrictions on where tobacco products can be consumed, and (iii) prohibition to communicate corporate social
responsibility programs funded by the tobacco industry.
On January 1, 2023, a law regulating the marketing of nicotine pouches went into effect in Slovakia. The regulatory framework contains a minimum legal
age (18 years) to purchase, a nicotine limit, and a labelling requirement. In Belgium, a Royal Decree banning nicotine pouches entered into force on July 1,
2023, with a sell-off period from retail to consumer as of October 1, 2023.
On March 22, 2023, a bill amending the Tobacco Hazards Prevention and Control Act in Taiwan went into effect. It regulates heated tobacco products and
bans e-cigarettes. The amendment particularly specifies that designated tobacco products (including heated tobacco products) that are not cigarettes, cut
tobacco, cigars, snuff nor chewing tobacco, must undergo a health risk assessment as part of an authorization system.
On March 28, 2023, the Argentinian Ministry of Health prohibited the import, distribution, commercialization and advertisement of heated tobacco
products, including related devices. The country had previously banned the use of e-cigarettes in 2011.
In a limited number of markets, most notably Japan, we are dependent on governmental approvals that may limit our pricing flexibility.
The EU Single-Use Plastics Directive, which will require tobacco manufacturers and importers to cover the costs of public collection systems for tobacco
product filters, under Extended Producer Responsibility ("EPR") schemes, came into force on July 2, 2019. To date, some member states transposed the
Directive into national legislation. By the end of 2024, most EU Member States are expected to bring into force national legislation for mandatory EPR
schemes and related EPR costs for tobacco manufacturers and importers. We currently expect further adoption of similar laws in other jurisdictions, and we
are monitoring developments in this area. We do not estimate a material impact to our business in the EU as a result of compliance with these mandatory
EPR schemes.
On March 14th, 2024 the Court of Justice of the European Union (the "CJEU") ruled that the German fiscal regulation imposing an additional excise tax on
HTPs does not contravene EU law. Fiscal Court in Dusseldorf (the "FCD") had previously referred that question to the CJEU. The decision on the matter
lies with the FCD and we expect a judgement in the coming months.
In some countries, including in the EU, cigarettes are subject to testing, disclosure and mandatory emissions limits for tar, nicotine, carbon monoxide and
other smoke constituents. In the Netherlands, several public health organizations have requested that the Dutch enforcement body enforce the requirements
for maximum tar, nicotine, and carbon monoxide ("TNCO") emissions levels for cigarettes using a test method other than the method currently set forth in
the EU TPD and transposed into national legislation. This request followed publication of a report by the Dutch State Institute for Public Health &
Environment, which found that all cigarette brands sold in the Netherlands exceeded the maximum TNCO levels when measured under an alternative
method. The Dutch enforcement body declined the request, and the applicants have challenged such decision in pending legal proceedings. The case is
currently pending before the Trade and Industry Appeals Tribunal in the Netherlands. In February 2024, the Dutch court submitted preliminary questions to
the Court of Justice of the European Union. While we cannot predict the outcome, a decision to enforce the existing TNCO ceilings using the alternative
test method could impact a
58
-- 59 of 140 --
Table of Contents
significant portion of the manufactured cigarettes available on the market in the Netherlands and could lead to similar actions in other EU countries.
Illicit Trade: Illicit tobacco trade creates a cheap and unregulated supply of tobacco products, undermines efforts to reduce smoking prevalence, especially
among youth, damages legitimate businesses and intellectual property rights, stimulates organized crime, increases corruption and reduces government tax
revenue. We generally estimate that, excluding China and the U.S., illicit trade may account for as much as 14% of global cigarette consumption; this
includes counterfeit, contraband and the persistent problem of “illicit whites,” which are cigarettes legally purchased in one jurisdiction for the sole purpose
of being exported and illegally sold in another jurisdiction where they have no legitimate market. Currently, we estimate that illicit trade in the EU
accounted for approximately 8% of total cigarette consumption in 2023.
A number of jurisdictions are considering actions to prevent illicit trade. In November 2012, the FCTC adopted the Protocol to Eliminate Illicit Trade in
Tobacco Products (the “Protocol”), which includes supply chain control measures, such as licensing of manufacturers and distributors, enforcement of these
control measures in free trade zones, controls on duty free and Internet channels and the implementation of tracking and tracing technologies. To date, 68
Parties, including the EU, have ratified it. The Protocol came into force in September 2018. Since then, implementation in national legislations has been
ongoing. In February 2024, the third Meeting of the Parties to the Protocol took place. No additional restrictive measures were adopted, and a mandate to
conduct further work will be considered at the next session, currently scheduled to take place in 2025.
We devote substantial resources to help prevent illicit trade in combustible tobacco products and SFPs. For example, we engage with governments, our
business partners and other stakeholders to implement effective measures to combat illicit trade and, in some instances, pursue legal remedies to protect our
intellectual property rights.
The tracking and tracing regulations for cigarettes and roll-your-own products manufactured or destined for the EU became effective on May 20, 2019. The
effective date for other tobacco-containing products, including some of our SFPs such as heated tobacco units, is May 20, 2024. While we expect that this
regulation will increase our operating expenses, we do not expect this increase to be significant.
In 2009, our Colombian subsidiaries entered into an Investment and Cooperation Agreement with the national and regional governments of Colombia to
promote investment in, and cooperation on, anti-contraband and anti-counterfeit efforts. The agreement provides $200 million in funding over a 20-year
period to address issues such as combating illegal cigarette trade and increasing the quality and quantity of locally grown tobacco.
Smoke-Free Products (SFPs)
Our Approach to SFPs: We recognize that smoking cigarettes causes serious diseases and that the best way to avoid the harm of smoking is to never start or
to quit. Nevertheless, it is predicted that by 2025, the number of smokers will remain largely unchanged from the current estimate of 1.1 billion, despite
considerable efforts to discourage smoking.
Cigarettes burn tobacco, which produces smoke. As a result of the combustion process, the smoker inhales various toxic substances. In contrast, SFPs do
not burn tobacco and therefore contain significantly lower levels of harmful and potentially harmful constituents ("HPHCs") than found in cigarette smoke.
Our SFPs and commercial activities for these products are designed for, and directed toward, current adult smokers and users of nicotine-containing
products. We put significant effort to restrict access to our products from non-smokers and youth.
For adult smokers who would otherwise continue to smoke cigarettes, we believe that SFPs, while not risk-free, offer a much better choice. Accordingly,
our key strategic priorities are to: (i) continue developing and commercializing products that have the potential to present less risk of harm to adult smokers
who switch to such products versus continued cigarette smoking; and (ii) educate and encourage current adult smokers who would otherwise continue to
smoke cigarettes to switch to those products.
We recognize that this transformation from cigarettes to SFPs will take time and that the speed of transformation will depend in part upon factors beyond
our control, such as the willingness of governments, regulators and other policy groups to embrace SFPs as a desired alternative to continued cigarette
smoking. As a leading international cigarette manufacturer, we will continue to accelerate this transformation by using our extensive commercial and
distribution infrastructure as an effective platform for the commercialization of our SFPs and communication with adult smokers and trade partners about
the substantiated benefits of switching to our SFPs. As long as a significant number of adult smokers continue to smoke cigarettes, responsible leadership
of
59
-- 60 of 140 --
Table of Contents
the category is critical. We aim to maintain our competitive position in the cigarette market through selective investment. We are judiciously reallocating
resources from cigarettes to SFPs and are streamlining our cigarette portfolio.
We have a range of SFPs in various stages of development, scientific assessment, and commercialization. We are committed to conducting rigorous
scientific assessments of our SFP platforms to substantiate that they reduce exposure to HPHCs and, ultimately, that these products present, are likely to
present, or have the potential to present less risk of harm to adult smokers who switch to them versus continued cigarette smoking. We draw upon a team of
expert scientists and engineers from a broad spectrum of scientific disciplines and our extensive learnings of adult consumer preferences to further develop
and assess our SFPs. Our efforts are guided by the following key objectives:
• to develop SFPs that adult smokers who would otherwise continue to smoke cigarettes find to be satisfying alternatives to smoking;
• for those adult smokers, our goal is to offer SFPs with a scientifically substantiated risk-reduction profile that approaches as closely as possible the
risk-reduction profile associated with smoking cessation;
• to substantiate the reduction of risk for the individual adult smoker and the reduction of harm to the population as a whole, based on scientific
evidence of the highest standard that is made available for scrutiny and review by external independent scientists and relevant regulatory bodies;
and
• to advocate for the development of science-based regulatory frameworks for the development and commercialization of SFPs, including the
communication of scientifically substantiated information to enable adult smokers to make better choices.
Our SFP Platforms: Our product development is based on the elimination of combustion via tobacco heating and other innovative systems, as well as
through oral tobacco and nicotine products, which we believe are the most promising path to providing a better consumer choice for those who would
otherwise continue to smoke cigarettes. We recognize that no single product will appeal to all adult smokers. Therefore, we are developing a portfolio of
products intended to appeal to a variety of distinct adult consumer preferences and achieve population harm reduction.
Five PMI-developed or improved SFP platforms are in various stages of development and commercialization readiness:
Platform 1 uses a precisely controlled heating device incorporating our IQOS HeatControl technology, into which a specially designed and
proprietary tobacco unit is inserted in a holder and heated to generate an aerosol. We have conducted a series of clinical studies for this platform, the results
of which were included in our submissions to the U.S. Food and Drug Administration (“FDA”). In addition to the original version of Platform 1 which
relies on a heating technology using a blade, a newer version of Platform 1 is now available using induction. Most of the studies referenced above were
conducted with the blade version of Platform 1 and additional research was conducted with the induction technology. We believe that there is full
comparability between the subsequent Platform 1 versions, and that the data from the studies conducted with the blade version of Platform 1 remain valid
and applicable to the newer and adjacent versions of Platform 1. In 2022, we also began the initial launch of a heated tobacco product, which utilizes
external resistive heating technology and that is commercialized under the BONDS brand.
Platform 2 used a pressed carbon heat source which, when ignited, generated a nicotine-containing aerosol by heating tobacco. As a result of consumer
testing feedback, the design of our current Platform 2 technology has been discontinued. We are assessing alternative designs for this consumer segment.
Platform 3 uses a nicotine salt and is composed of two parts: (1) a consumable that contains a highly soluble encapsulated nicotine salt powder and (2) a
non-electric device that activates it. Once a consumable is inserted into the mechanical device, the nicotine salt powder is aerosolized upon inhalation. The
results of our pharmacokinetic and pharmacodynamic studies related to this version indicate that, subject to a period of adaptation to the product, the
product has potential as an acceptable alternative to continued cigarette smoking in terms of product satisfaction. We are working on product modifications
to enable adult smokers, who are looking for better alternatives to cigarettes, to switch to a Platform 3 product.
Platform 4 covers e-vapor products, which are battery-powered devices that produce an aerosol by vaporizing a tobacco-free liquid solution. We
developed new e-liquids for our e-vapor products to deliver real tobacco taste satisfaction. Using patented technology, flavors and nicotine are extracted
directly from the tobacco leaves and captured in a tobacco-free liquid solution, without having to add flavoring ingredients.
60
-- 61 of 140 --
Table of Contents
In the first quarter of 2023, we initiated a project to fully outsource and restructure the manufacturing of e-vapor devices and consumables. As a result, PMI
recorded pre-tax asset impairment and exit costs of $109 million. We intend to focus on commercializing these products in select markets, with an
emphasis on profitability.
We also entered into a licensing agreement with Kaival Brands International, LLC, in June 2022 to distribute an e-vapor product, known in the U.S. as the
BIDI® Stick. The agreement grants PMI certain intellectual property rights relating to the premium e-vapor devices and, potentially, other newly developed
devices, to permit PMI to manufacture, promote, sell, and distribute the e-vapor device and, to the extent included, other newly developed devices in
international markets outside of the U.S.
Platform 5 covers snus and modern oral nicotine pouches. Snus refers to dried loose tobacco, or snuff, which is consumed by sniffing the product
through the nose, moist loose tobacco which is put in the mouth between the lower or upper lip and gum, and snus pouches which contain ground tobacco,
water, salt and flavors. Modern oral nicotine pouches consist of white pre-conditioned pouches containing nicotine derived from tobacco. Users place a
pouch between the upper lip and gum and leave it there while the nicotine and flavor are being released. At the end of the use, the user can dispose of the
pouch. Nicotine pouches are inherently smoke-free as they are consumed orally, and no combustion process occurs during use. They contain primarily
nicotine, flavors, and cellulose substrate. The nicotine used in the pouches is of pharmaceutical-grade like the nicotine used in medicinal products, such as
gums and inhalers, while the flavors are approved for use in food in accordance with the product quality standards for nicotine pouches developed by the
Swedish Institute for Standards and the British Standards Institute. In 2021, PMI acquired AG Snus Aktieselskab ("AG Snus"), as well as Fertin Pharma
A/S, two companies manufacturing and/or marketing nicotine pouches. In 2022, we significantly expanded our Platform 5 products portfolio with the
acquisition of Swedish Match. The acquisition also represents an expansion of our SFP presence in the U.S. market, where Swedish Match's ZYN brand is
the leading nicotine pouch franchise.
We aim to expand our brand portfolio and market positions with additional SFPs. In addition, we continue to use our expertise, technology and capabilities
to explore new growth opportunities beyond our current business, including products that do not contain nicotine or tobacco.
Commercialization of SFPs: We are continuing to develop a multiplatform approach and tailoring our commercialization strategy to the characteristics of
each specific market. We focus our commercialization efforts on consumer retail experience, guided consumer trials and customer care, and increasingly,
digital communication programs and e-commerce. In order to accelerate switching to our Platform 1 products, our initial market introductions typically
entail one-on-one consumer engagement (in person or by digital means) and device discounts. These initial commercialization efforts require substantial
investment, which we believe will moderate over time and further benefit from the increased use of digital engagement capabilities. PMI has, and continues
to, accelerate its investments in digital consumer engagement.
In 2014, we introduced our Platform 1 product in pilot city launches in Nagoya, Japan, and in Milan, Italy. Since then, we have continuously expanded our
commercialization activities.
As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets.
Data shows that only a very small percentage of adult smokers who convert to our Platform 1 product switch back to cigarettes.
We have integrated the production of our heated tobacco units into several of our existing manufacturing facilities, are progressing with our plans to build
manufacturing capacity for our other SFP platforms, and continue to optimize our manufacturing infrastructure and expand our commercialization activities
for new products and markets. We discuss certain risks related to the commercialization and supply of our SFP portfolio in “Cautionary Factors That May
Affect Future Results”.
We discuss product warranties in more detail in Note 14. Product Warranty. The significance of warranty claims depends on a number of factors, including
device version mix, product failure rates, logistics and service delivery costs, and warranty policies, and may increase with the number of devices sold.
On October 20, 2022, PMI announced that it had reached an agreement with Altria Group, Inc., ("Altria") to end the companies' commercial relationship
with respect to Platform 1 in the U.S. as of April 30, 2024 (the “2022 Agreement”). Thereafter, under the 2022 Agreement, PMI will hold the full rights to
commercialize Platform 1 in the United States - the world’s largest smoke-free market. The 2022 Agreement provides a clear path to expanding Platform
1's international success in a market where approximately 30 million adults continue to smoke cigarettes.
61
-- 62 of 140 --
Table of Contents
The U.S. government contacted Altria and its affiliate, Philip Morris USA, Inc. (“PM USA”) in connection with the 2022 Agreement. Altria and its
subsidiary PM USA are parties to a 2006 order (“2006 Order”) in the United States District Court for the District of Columbia holding that they violated
the Racketeer Influenced and Corrupt Organizations Act (“RICO”). The 2006 Order imposes restrictions on defendants from selling or transferring their
cigarette brands, brand names, cigarette product formulas or cigarette businesses without the transferee submitting to the jurisdiction of the court and
subjecting itself to the 2006 Order as of the date of sale or transfer. The U.S. government informed Altria that it believed the transaction contemplated by
the 2022 Agreement (the “Transaction”) falls within the scope of this provision and that before the Transaction could be effectuated, PMI must submit to
the 2006 Order. To date, the U.S. government has not pursued the matter with or sought any relief from the court. We believe that there are strong
arguments as to why the provision cited by the U.S. government is inapplicable to the Transaction and we also believe that there would be paths available
to minimize or eliminate potential impact on the timing or effectuation of the Transaction were the U.S. government to pursue the matter in court.
Our commercialization efforts for the other PMI-developed SFP platforms are as follows:
• In late 2022, we began commercializing our BONDS product in the Philippines and Colombia.
• Since August 2020, we have launched and expanded our portfolio of vaping products (branded VEEV) in 28 markets.
• Following our acquisition of Swedish Match, we have access to a strong portfolio of Swedish Match brands in both the snus and nicotine pouch
categories. Nicotine pouches are currently available in 27 markets.
SFP Regulation and Taxation: SFPs contain nicotine and are not risk-free. As we describe in more detail above, we support science-based regulation and
taxation of SFPs, and believe that regulation and taxation should differentiate between cigarettes and products that present, are likely to present, or have the
potential to present less risk of harm to adult smokers who switch to these products versus continued smoking and should recognize a continuum of risk for
tobacco and other nicotine-containing products. Regulation, as well as industry practices, should reflect the fact that youth should not consume nicotine in
any form.
Some governments have banned or are seeking to ban or severely restrict emerging tobacco and nicotine-containing products such as our SFPs and
communication of truthful and non-misleading information about such products. These regulations might foreclose or unreasonably restrict adult consumer
access even to products that might be shown to be a better consumer choice than continuing to smoke cigarettes.
We oppose blanket bans and unreasonable restrictions of products that have the potential to present less risk of harm compared to continued cigarette
smoking. By contrast, we support regulation that sets clear standards for all SFP categories and propels innovation to benefit adult smokers who would
otherwise continue to smoke cigarettes.
In the United States, an established regulatory framework for assessing “Modified Risk Tobacco Products” ("MRTP") and “New Tobacco Products” exists
under the jurisdiction of the FDA. We submitted to the FDA a Modified Risk Tobacco Product Application (“MRTPA”) for our Platform 1 product in
December 2016, and a Premarket Tobacco Product Application (“PMTA”) for our Platform 1 product in March 2017.
On April 30, 2019, the FDA determined that a version of our Platform 1 product, namely, IQOS 2.4 and three related consumables, is appropriate for the
protection of public health and authorized it for sale in the United States. The FDA’s decision followed its comprehensive assessment of our PMTA. On
December 7, 2020, the FDA reached the same determination for the IQOS 3 device and authorized that version of our Platform 1 product for sale in the
United States.
On July 7, 2020, the FDA determined that the available scientific evidence demonstrates that the issuance of an exposure modification order would be
appropriate for the promotion of public health and authorized the marketing of a version of our Platform 1 product, namely IQOS 2.4 and three related
consumables, as an MRTP. The FDA authorized the marketing of this product in the U.S. with the following information:
"AVAILABLE EVIDENCE TO DATE:
• the IQOS system heats tobacco but does not burn it.
• this significantly reduces the production of harmful and potentially harmful chemicals.
• scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s
exposure to harmful or potentially harmful chemicals."
62
-- 63 of 140 --
Table of Contents
The FDA may issue two types of MRTP orders: a “risk modification” order or an “exposure modification” order. We had requested both types of orders for
IQOS 2.4 and an initial selection of 3 consumables' variants. After review, the FDA determined that the evidence did not support issuing a "risk
modification" order at this time but that it did support issuing an "exposure modification" order for the product. This determination included a finding that
issuance of the exposure modification order is expected to benefit the health of the population as a whole. We also received an exposure modification order
for IQOS 3. We look forward to working with the FDA to provide any additional information they may require to market Platform 1 products with reduced
risk claims.
The FDA’s PMTA and MRTP orders do not mean that the agency “approved” our Platform 1 product. These authorizations are subject to strict marketing,
reporting and other requirements, and are not a guarantee that the product will remain authorized, particularly if there is a significant uptake in youth or
non-smoker initiation. The FDA will monitor the marketing of the product.
On March 18, 2021, we submitted to the FDA a supplemental MRTPA ("sMRTPA") for IQOS 3 requesting authorization to market this version of the
device as a MRTP with reduced exposure information like IQOS 2.4. In June 2021, the FDA formally accepted and filed our sMRTPA for substantive
scientific review, following a period for the public to provide comments on our application. The FDA authorized our sMRTPA for IQOS 3 by issuing a
Modified Risk Granted Order – Exposure Modification on March 11, 2022.
On January 26, 2023, the FDA authorized the marketing of two new tobacco-flavored consumables (Marlboro Sienna HeatSticks and Marlboro Bronze
HeatSticks) and a modified version of the authorized Marlboro Amber HeatSticks. These products are line extensions and/or modified versions of the
tobacco-flavored consumables for which the FDA had previously issued a marketing granted order. In its assessment, the FDA determined that the three
variants of HeatSticks were comparable to the previously authorized tobacco-flavored consumables.
On April 28, 2023, we submitted the Annual Report for the IQOS Tobacco Heating System ("THS") to the FDA. The report included a systematic review
of the literature covering publications related to the IQOS THS between March 1, 2022 and February 28, 2023. The report concluded that, although the
scientific evidence continues to develop and evolve, the extensive data reviewed confirms that while Heated Tobacco Products (“HTPs”) are not risk-free,
the use of HTPs are likely to present less risk of harm for both users and non-users against the well-proven risks of continued cigarette smoking, and
therefore continues to support the "appropriate for the promotion of public health" status of IQOS THS.
On July 5, 2023, we submitted a renewal application to the FDA requesting re-authorization to continue to market those IQOS products that previously
received a modified exposure order with a modified exposure claim in the U.S. This renewal request was received by the FDA 360 days prior to the stated
July 2024 expiration date of the original modified exposure claim orders. As our application proceeds through the review process, the FDA may request
additional information or conduct subsequent inspections to verify the information we submitted. We do not believe the FDA will issue a decision on our
MRTP renewal application prior to the stated July 2024 expiration date of the original modified exposure claim orders. In the event that the FDA does not
act on our MRTP renewal application before July 2024, we believe that we should be permitted to continue to use the modified exposure claim with respect
to those products that received modified exposure orders until the FDA decides on our MRTP renewal application.
On October 20, 2023, we submitted bundled PMTAs for our IQOS ILUMA THS products together with MRTPAs requesting authorization of the exposure
reduction marketing order previously granted for IQOS blade versions. We submitted these applications at the same time in order to allow the FDA to
evaluate the PMTAs and MRTPAs concurrently. In March 2024, the FDA formally accepted our bundled PMTAs and MRTPAs. As our applications
proceed through the review process, the FDA may request additional information or conduct subsequent inspections to verify the information we
submitted.
On January 19, 2024, the FDA completed its review of our Requests for Exemption from Substantial Equivalence (the “EX REQs”) for the five submitted
IQOS consumables and determined that these tobacco products were exempt from the requirements outlined for substantial equivalence (a regulatory
pathway that can be used to introduce new tobacco products which have the same characteristics as a product previously authorized by the FDA). These
submissions were made in November 2022 (for the three initial IQOS consumables) and February 2023 (for the two new IQOS consumables) to enable
domestic manufacturing of IQOS consumables utilizing materials purchased from vendors operating in the United States.
Some states and municipalities in the U.S. have introduced stringent restrictions on the sale of certain e-cigarettes and other smoke-free products, including
those authorized by the FDA. We believe that such restrictions on FDA-authorized products
63
-- 64 of 140 --
Table of Contents
will not advance public health and will unreasonably limit adult consumer access to products that are shown to be a better alternative to continued cigarette
smoking.
In March 2020, the FDA issued a final rule to require new text and graphic health warnings on cigarette packs and advertisements. HTPs are technically
covered by this rule, however the FDA stated that it would make product-specific decisions about health warnings when issuing or revising individual
product or marketing orders. This approach would be consistent with the original marketing order granted for Heatsticks where the FDA required Philip
Morris Products S.A. to remove the Surgeon General’s health warning for carbon monoxide from its packaging and advertising, and to use a nicotine
addiction health warning instead. Philip Morris Products S.A. is committed to providing adult consumers with complete, accurate, and non-misleading
information about possible health risks associated with its products. We shared our views with the FDA on the application of the new warnings to our
HTPs. The final rule is the subject of litigation in the U.S. and was previously vacated nationwide by a federal court in December 2022. In March 2024, the
decision to vacate was reversed and a lower court was directed to consider additional issues. Proceedings remain ongoing. Philip Morris Products S.A. is
not a party to this litigation.
On March 8, 2023, the FDA proposed new requirements for tobacco product manufacturers regarding the manufacture, design, packing and storage of their
products. The FDA stated that these proposed requirements would help protect public health by, among other things, minimizing or preventing
contamination and limiting additional risks by ensuring product consistency. The FDA held a public hearing on April 12, 2023, to gather additional
comments from stakeholders, including the industry, the scientific community, advocacy groups, and the public. The proposed rule was also made available
for public comment for 180 days. The FDA will review all comments as part of the rulemaking process for this rule. PMI welcomes the FDA’s rule under
section 906(e) of the Federal Food, Drug, and Cosmetic Act and plans to share its views with the FDA on this important foundational rule.
In April 2022, the FDA issued a proposed product standard that would prohibit menthol as a characterizing flavor in cigarettes. In doing so, the FDA
specifically requested comments as to whether the rule should contain an exemption process for certain tobacco products, including heated tobacco
products, that meet the definition of cigarette and thus fall within the scope of the proposed rule. We submitted comments to the FDA in August 2022,
explained why we believe any prohibition should not extend to FDA-authorized smoke-free products, and otherwise advocated for an automatic exemption
for smoke-free products authorized through the PMTA or MRTP review pathways. The FDA has not completed rulemaking with respect to this proposed
product standard. In October 2023, the FDA submitted the proposed product standard to the White House Office of Management and Budget for review. It
is possible that the FDA will not accept our comments to the proposed product standard and that the menthol product standard, if finalized, will encompass
menthol heated tobacco consumables.
FDA actions may influence the regulatory approach of other governments and regulatory agencies.
Currently, national standards in certain countries set minimum quality and safety requirements for heat-not-burn products with technical heat-not-burn
specifications and/or methods for demonstrating the absence of combustion. These standards are mandatory in Armenia, Bahrain, Egypt, Jordan, Saudi
Arabia, Tajikistan, Tunisia, the UAE and Uzbekistan, and voluntary in Algeria, Colombia, Costa Rica, Dominican Republic, Indonesia, Kazakhstan,
Kyrgyzstan, Morocco, the Philippines, Russia, Vietnam, the U.K. and Ukraine. In Japan, a voluntary standard sets minimum safety requirements for
tobacco heating devices.
For e-vapor products (e-cigarettes) national standards setting minimum quality and safety requirements have been adopted in several markets. These
standards are mandatory in Armenia, Bahrain, China, Egypt, Jordan, New Zealand, United Arab Emirates, and Saudi Arabia and Tajikistan, and voluntary
in Azerbaijan, Costa Rica, France, Indonesia, Kazakhstan, the Philippines, Russia, the U.K. and Ukraine.
Currently, industry standards setting minimum quality and safety requirements for tobacco-free oral nicotine products (nicotine pouches) have been
adopted in Pakistan, Sweden, the U.K., and Ukraine. These standards are voluntary.
We expect other governments to consider similar product standards for all novel tobacco and nicotine-containing products and encourage making them
mandatory.
All EU member states have transposed the EU TPD, including the provisions on novel tobacco products, such as heated tobacco units, and e-cigarettes.
Most of the EU member states require a notification submitted six months before the intended placing on the market of such products, while some require
pre-market authorizations for the introduction of such products. To date, we have filed a comprehensive dossier summarizing our scientific assessment of
our Platform 1 product in over 20 member states.
64
-- 65 of 140 --
Table of Contents
On March 23, 2023, the Greek Ministry of Health authorized a claim for IQOS with HEETS AMBER to inform Greek IQOS users about reduction in
emissions of toxicants when using such product compared to cigarette smoking. The decision authorized the following claim: “The concentration of
chemical substances with recognized toxicity produced when using IQOS with HEETS AMBER tobacco sticks is lower compared to conventional smoking.
A reduction in the concentration of chemical substances with recognized toxicity does not mean a corresponding reduction in risk for health. The aerosol of
this tobacco product contains nicotine and other hazardous chemicals. This tobacco product harms your health and is addictive. The best choice is to quit
tobacco and nicotine use altogether.” With this authorization, Greece is the second country officially recognizing the reduction in level of toxicants in the
IQOS aerosol compared to cigarette smoke.
On September 12, 2022, Norway rejected a submission for authorization of HEETS as a novel tobacco product. Norway partially transposed the EU TPD
under the European Free Trade Association agreement and introduced an authorization system for novel tobacco products following Article 19 of TPD. To
date, Norway has not granted authorization of any novel tobacco product, and e-cigarettes and tobacco free nicotine pouches have not been granted access,
either.
On October 31, 2019, our Australian subsidiary, Philip Morris Limited (“PML”), submitted an application to the Scheduling Committee of the Therapeutic
Goods Administration of Australia (“TGA”) seeking to exempt HTPs from being prohibited in Australia. In August 2020, the TGA issued its decision
denying the application and stating that the application did not present compelling evidence to establish a public health benefit from greater access to
nicotine in HTPs.
To date, several governmental agencies have published their scientific findings that analyze the harm-reduction potential of certain SFPs versus continuing
to smoke cigarettes, including:
In December 2017, at the request of the U.K. Department of Health and Public Health England, the U.K. Committee on Toxicity published its assessment
of the risk of heat-not-burn products relative to cigarette smoking. This assessment included analysis of scientific data for two heat-not-burn products, one
of which was our Platform 1 product. The assessment concluded that, while still harmful to health, compared with the known risks from cigarettes, heat-
not-burn products are probably less harmful. Subsequently, in February 2018, Public Health England published a report stating that the available evidence
suggests that heat-not-burn products may be considerably less harmful than cigarettes but more harmful than e-cigarettes.
In May 2018, the German Federal Institute for Risk Assessment (“BfR”) published a study on the Platform 1 aerosol relative to cigarette smoke using the
Health Canada Intense Smoking Regimen. BfR found reductions in selected HPHCs in a range of 80-99%. This publication indicates that significant
reductions in the levels of selected toxicants are likely to reduce toxicant exposure, which BfR stated might be regarded as a discrete benefit compared to
combustible cigarettes.
In May 2018, the Dutch National Institute for Public Health and Environment (“RIVM”) published a factsheet on novel tobacco products that heat rather
than burn tobacco, focusing on our Platform 1 product. RIVM analyzed the aerosol generated by our Platform 1 product and concluded that the use of this
product, while still harmful to health, is probably less harmful than continuing to smoke cigarettes.
In June 2018, the Korean Food and Drug Administration (“KFDA”) issued a statement on products that heat rather than burn tobacco. The KFDA tested
three heat-not-burn products, one of which was our Platform 1 product. The KFDA confirmed that the levels of the nine HPHCs tested in the aerosol of
these products were on average approximately 90% lower compared to those measured in the cigarette smoke of the top five cigarette brands in South
Korea. However, the KFDA stated that it could not establish that the tested heat-not-burn products are less harmful than cigarettes. In October 2018, our
Korean subsidiary filed a request with a local court seeking information underlying KFDA’s analysis, conclusions and public statements. In May 2020, the
court ordered KFDA to produce certain records. Subsequent to that decision, and after exchanges between the parties, the case was closed.
In August 2018, the Science & Technology Committee of the U.K. House of Commons published a report of its inquiry into e-cigarettes and heat-not-burn
products. The report concluded that e-cigarettes are significantly less harmful to health than smoking tobacco. The report also observed that for those
smokers who do not accept e-cigarettes, heat-not-burn products may offer a public health benefit despite their relative risk. The report called for a risk-
proportionate regulatory environment for both e-cigarettes and heat-not-burn products and noted that e-cigarettes should remain the least taxed, cigarettes
the most taxed, with heat-not-burn products falling between the two. The U.K. Committee on Advertising Practice announced the removal of a prohibition
of health claims in the advertising of e-cigarettes in the U.K., effective November 2018.
In November 2018, the Eurasian Economic Commission (regulatory body of the Eurasian Union consisting of Armenia, Belarus, Kazakhstan, Kyrgyzstan
and Russia) published the results of its commissioned study on novel nicotine-containing
65
-- 66 of 140 --
Table of Contents
products, including our Platform 1 product. The study confirms significantly lower levels of HPHCs in the aerosol generated by this product compared to
cigarette smoke.
In January 2019, scientific media published the results of the study of the China National Tobacco Quality Supervision and Test Centre (“CNTQST”)
comparing the aerosol generated by our Platform 1 product with cigarette smoke. The CNTQST found that the former contained fewer, and lower levels of,
harmful constituents than the latter and concluded that the lower temperature of heating tobacco in our Platform 1 product contributed to the difference.
The CNTQST stated that the reduction in emissions of harmful constituents cannot be interpreted as a harm/risk reduction for cigarette smokers in the same
proportion.
In April 2020, the Superior Health Council of Belgium (“SHC”) published results of its inquiry into heat-not-burn products. The SHC concluded that heat-
not-burn products, while not safe, have a more favorable toxicity profile than cigarettes. However, in light of the uncertainty of such products’ short and
long-term impacts, the toxic effects of the dual use with cigarettes, and the existence of approved smoking cessation tools, the SHC recommended that
current regulations for cigarettes should apply to heat-not-burn products.
In June 2022, the SHC published new advice on e-cigarettes in which they confirm that e-cigarettes are substantially less harmful than smoking cigarettes
and, therefore, a better alternative for smokers. The SHC underlines that the vast majority of the risks of tobacco smoking are not caused by nicotine, but by
the harmful substances that are released by the combustion of tobacco. Based on the cited science, the SHC calls for legislation that makes a clear
distinction between cigarettes and e-cigarettes by focusing on better informing smokers about the benefits of the lower-risk (but not risk-free) alternative, as
well as on protecting non-smokers and young people.
The foregoing scientific findings of government agencies may not be indicative of the measures that the relevant government authorities could take in
regulating our products.
We make our scientific findings publicly available for scrutiny and peer review through several channels, including our websites. From time to time, adult
consumers, competitors, members of the scientific community, and others inquire into our scientific methodologies, challenge our scientific conclusions or
request further study of certain aspects of our SFPs and their health effects. We are committed to a robust and open scientific debate and believe that such
debate should be based on accurate and reliable scientific information. We seek to provide accurate and reliable scientific information about our SFPs;
nonetheless, we may not be able to prevent third-party dissemination of false, misleading or unsubstantiated information about these products. The
dissemination of scientifically unsubstantiated information or studies with a strong confirmation bias by third parties may cause confusion among adult
smokers and affect their decision to switch to better alternatives to continued smoking, such as our SFPs.
To date, we have been largely successful in demonstrating to regulators that our heated tobacco units are not cigarettes due to the absence of combustion,
and as such, they are generally taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than
cigarettes. Although we believe that this is sensible from the public health perspective, we cannot guarantee that regulators will continue this approach.
There can be no assurance that we will succeed in our efforts to replace cigarettes with SFPs or that regulation will allow us to commercialize SFPs in all
markets, to communicate about our SFPs, including making scientifically substantiated risk-reduction claims, or to treat SFPs differently from cigarettes.
Legal Challenges to SFPs: We face various administrative and legal challenges related to certain SFP activities, including allegations concerning product
classification, advertising restrictions, corporate communications, product coach activities, scientific substantiation, product liability, and unfair
competition. While we design our programs to comply with relevant regulations, we expect these or similar challenges to continue as we expand our
efforts to commercialize SFPs and to communicate with the public. The outcomes of these matters may affect our SFP commercialization and public
communication activities and performance in one or more markets.
In April 2020, affiliates of British American Tobacco p.l.c. ("BAT") filed a complaint against PMI, Philip Morris Products S.A., Altria Group, Inc., and its
subsidiaries before the International Trade Commission ("ITC"). On September 29, 2021, the ITC issued its Final Determination ("FD"), Limited Exclusion
Order ("LEO") and Cease and Desist Order ("CDO"). The ITC upheld the finding of infringement in the FD and found a subsequent violation. The ITC
issued a LEO against Philip Morris Products S.A., prohibiting the importation of infringing tobacco heating articles and components thereof, and CDOs
against Altria Client Services, LLC, and certain of its affiliates, which went into effect at the end of the 60-day Presidential review period on November 28,
2021. We appealed the patent issues. Furthermore, lawsuits based on the same patent families were
66
-- 67 of 140 --
Table of Contents
repeatedly and universally rejected in European courts and the European Patent Office. The decision has no bearing outside the United States.
On February 1, 2024 we entered into a global settlement with BAT that resolves all ongoing patent infringement litigation between the parties related to
heated tobacco and vapor products. Among other matters, under the settlement PMI and BAT requested rescission of the LEO and CDO, which was
granted on March 11, 2024. For further details, see Note 8. Contingencies to our condensed consolidated financial statements.
Our SFP Business Development Initiatives: In December 2013, we established a strategic framework with Altria Group, Inc. (“Altria”) setting out terms on
how the parties would collaborate to develop and commercialize e-vapor products and commercialize two of our SFPs in the U.S. In late 2018, Altria
announced that it will participate in the e-vapor category only through another e-vapor company in which Altria acquired a minority interest. In September
2019, Altria's subsidiary, Philip Morris USA Inc. (“PM USA”), began commercialization of a version of our Platform 1 product in the U.S. Under the
agreement, PM USA was required to achieve certain milestones in order to maintain its exclusive distribution right and additional milestones in order to
extend the agreement after the initial 5-year term. On October 20, 2022, PMI announced that it had reached an agreement with Altria to terminate the
companies' commercial relationship covering IQOS in the U.S., as of April 30, 2024. Thereafter, PMI will hold the full rights to commercialize IQOS in the
U.S. For more details, see Note 8. Contingencies and Note 18. Acquisitions to our condensed consolidated financial statements.
In January 2020, we announced an agreement with KT&G, a leading tobacco and nicotine company in South Korea, for the commercialization of KT&G’s
smoke-free products outside of South Korea on an exclusive basis. On January 30, 2023, we announced a renewal and extension of this arrangement. For
more information, see Acquisitions and Other Business Arrangements below.
Other Developments: In September 2017, we announced our support of the Foundation for a Smoke-Free World (the "Foundation"). The Foundation is an
independent, nonprofit organization dedicated to reducing the health impacts of smoking as set out in its Articles of Incorporation and its Bylaws. In
September 2020, our pledge agreement with the Foundation was amended. We contributed $45 million in 2020, $40 million in 2021, $17.5 million in 2022,
and had expected to contribute up to $35 million annually from 2023 through 2029, as specified in the amended pledge agreement. In 2023, the Foundation
and PMI agreed to terminate the existing pledge agreement and PMI has made final grant payments totaling $140 million, commensurate with the early
termination of the pledge agreement.
Governmental Investigations
From time to time, we are subject to governmental investigations on a range of matters, including tax, customs, antitrust, advertising, and labor practices.
We describe certain matters pending in Thailand in Note 8. Contingencies.
In November 2010, a World Trade Organization ("WTO") panel issued its decision in a dispute between the Philippines and Thailand, concerning a series
of Thai customs and tax measures affecting cigarettes imported by Philip Morris (Thailand) Limited ("PM Thailand") into Thailand. The decision
concluded that Thailand had no basis to find that PM Thailand's declared customs values and taxes paid were too low, as alleged by the Thai government
and created obligations for Thailand to revise its laws, regulations, or practices affecting the customs valuation and tax treatment of future cigarette
imports. Thailand agreed to fully comply with the decision, but the Philippines asserts that to date Thailand has not fully complied with the WTO panel
decision and commenced challenges at the WTO Appellate Body. The WTO Appellate Body is not operational, and the appeals by Thailand are suspended
indefinitely. In December 2020, the Philippines and Thailand agreed to pursue facilitator-assisted discussions aimed at progressing and resolving
outstanding issues and the countries have since agreed to seek the establishment of a bilateral consultative mechanism, with the goal of reaching a
comprehensive settlement of their dispute, consistent with their rights and obligations under the WTO Agreements, as well as the recommendations and
rulings of the WTO Dispute Settlement Body.
In July 2020, the Public Prosecutor’s office of Rome, Italy, notified our Italian subsidiary, Philip Morris Italia S.r.l. (“PM Italia”), as well as three former or
current employees and a former external consultant of PM Italia in March 2020, that it concluded a preliminary investigation against them for alleged
contravention of anti-corruption laws and related disruption of trade freedom. The Public Prosecutor alleges that the individuals involved promised certain
personal favors to government officials from January to July of 2018 in exchange for favorable treatment for PM Italia, and that PM Italia lacked
appropriate organizational controls to prevent the alleged actions by the individuals. In September 2020, the Prosecutor issued his indictment and referred
the matter to the court. At the preliminary hearing held on May 11, 2021, the judge decided to refer all charges/defendants (including our affiliate) to trial.
The first trial hearing took place on September 22, 2021. BAT has filed a civil claim against PM Italia claiming vicarious liability for any wrongdoing of its
former or current employees and seeking
67
-- 68 of 140 --
Table of Contents
EUR 50 million (approximately $55.2 million) in damages. The court admitted the claim and issued summons for PM Italia to appear in the case. The court
proceeded with the examination of witnesses beginning in September 2023. PM Italia believes the charges brought against it by the Public Prosecutor are
without merit and will defend them vigorously.
War in Ukraine
In Ukraine, our main priority remains the safety and security of our employees and their families in the country. We continue commercial activities in select
locations where safety allows, in order to provide product availability and service to adult consumers, and supplies the market from production centers
outside Ukraine, as well as through a contract manufacturing arrangement. Production at our factory in Kharkiv remains suspended. On June 20, 2023, we
announced the investment of $30 million in a new production facility in the Lviv region, in Western Ukraine. Preparatory work for the facility began in
July 2023. The new production facility was completed at the end of the first quarter of 2024 and local production commenced in April 2024. As of
March 31, 2024, our Ukrainian operations had approximately $0.5 billion in total assets, excluding intercompany balances.
In Russia, we are continuously assessing the evolving situation in the country. This includes regulatory constraints in the market entailing very complex
terms and conditions that must be met for any divestment transaction to be granted approval by the authorities, and restrictions resulting from international
regulations. In the event of a divestment, our ability to fully realize the value of the business would likely be subject to material impairment. As of
March 31, 2024, our Russian operations had approximately $2.6 billion in total assets, excluding intercompany balances, of which approximately $0.6
billion consisted of cash and equivalents held mostly in local currency (Russian rubles).
Additionally, we hold a 23% equity interest in Megapolis Distribution BV, the holding company of CJSC TK Megapolis, PMI's distributor in Russia. For
further details, see Note 12. Related Parties – Equity Investments and Other.
These developments above have and will continue to have a material adverse impact on our business, results of operations, cash flows and financial
position, and may result in impairment charges.
For further details, see "Trade Policy" and "Cautionary Factors That May Affect Future Results" sections of this MD&A.
Impact of Inflation on Our Business and Mitigation Efforts
Like many other global companies, we have experienced inflationary pressures in 2022, 2023 and the first quarter of 2024, including: growing pressures on
the cost of certain direct materials, wages, energy, transportation, and logistics as well as an increased cost of capital due to interest rate increases driven by
the response to increased inflation. For the year ended December 31, 2023, the impact on cost of sales was approximately $580 million and while tobacco
leaf costs remain a headwind we expect certain inflationary elements to ease, with a more moderate overall increase in 2024. This impact has been, and we
expect it to continue to be, significantly offset by the positive elements of pricing, productivities and the mitigating factors as we progress through the year.
The net result of the inflationary impacts and our efforts to mitigate these impacts were not material to PMI during these periods.
Inflationary impacts driven by higher wages have resulted from merit increases that reflect local inflation as we continuously evaluate our compensation
and benefit offerings to be competitive with the current market. Increased transportation costs resulted from increased shipping rates for all modes of
transportation (air, ocean and inland) due to ocean and air capacity constraints. Increases in cost of sales resulted from higher cost of direct materials due to
the pass on of energy, transportation, labor and commodity price increases from suppliers as well as increases in utility costs, including gas and electricity
prices, primarily in Europe resulting from the war in Ukraine. Raw materials such as tobacco leaf have longer inventory durations which resulted in
insignificant inflationary impacts to our cost of sales in 2022; however tobacco leaf purchases in both 2022 and 2023 have been at higher prices due to
inflationary impacts on fertilizer prices and labor costs, thus resulting in increases in the cost of inventory with corresponding impacts on our financial
results in 2023 and continuation in 2024. In addition, our cash flow from operating activities in 2023 was impacted by the net working capital investment
related to the procurement of tobacco leaf inventory and higher cost of direct materials. We expect certain of these inflationary elements to ease in 2024 as
noted above.
We have taken several actions to mitigate these inflationary pressures. Mitigation efforts have included (i) indexation clauses related to commodity costs
and energy pricing within contracts, (ii) tactical inventory purchases, (iii) identification of new suppliers in different geographical locations for incremental
sourcing, (iv) increasing tobacco leaf inventory durations to secure
68
-- 69 of 140 --
Table of Contents
additional volumes at favorable prices, (v) optimizing the mix of tobacco leaf origins and suppliers, (vi) continuous evaluation of shipping routes and
methods of shipment, (vii) supplier negotiations, (viii) variable contract durations for energy costs, (ix) hedging strategies, and (x) other pricing,
productivity and procurement initiatives.
Asset Impairment and Exit Costs
We discuss asset impairment and exit costs related to restructuring activities in Note 15. Asset Impairment and Exit Costs to our condensed consolidated
financial statements.
U.S. GAAP Treatment of Highly Inflationary Economies
We apply highly inflationary accounting to the results of operations of our subsidiaries in Argentina, Turkey and Lebanon as the cumulative inflation rate in
these economies for a three-year period meets or exceeds 100%, in accordance with U.S. GAAP. As a result, monetary assets and liabilities denominated in
local currencies are remeasured to the U.S. Dollar at each balance sheet date, with remeasurement gains and losses recognized in consolidated statement of
earnings.
This impact of currency fluctuations could negatively impact our financial condition and results of operations. For the three months ended March 31, 2024
and 2023, we recognized exchange gains (losses) of $15 million and $(14) million, respectively, resulting from remeasurement adjustments related to
highly inflationary accounting.
Climate Change Laws and Regulations
While, to date, the effect of climate-related laws and regulations on PMI has not been material to our business, results of operations or financial condition,
consideration of environmental and climate-related laws and regulations is an integral aspect of PMI’s climate-related risk assessment process. To this end,
we actively monitor the existing and potential impact on PMI of significant pending or existing climate change-related legislation, regulations, international
accords, reporting frameworks, standards, principles, and other forms of guidance. Examples include, but are not limited to, the EU Emissions Trading
System, the 2015 Paris Climate Agreement, the work of the International Financial Reporting Standards Foundation, including the International
Sustainability Standards Board proposed climate standard and the recommendations of the Task Force on Climate-related Financial Disclosures, the SEC’s
rules regarding climate-related disclosures, the California Climate Corporate Accountability Act, the California Greenhouse Gases: Climate-Related
Financial Risk Act, the Task Force on Nature-related Financial Disclosures, the EU Corporate Sustainability Reporting Directive, the EU Taxonomy
Regulation, the EU Deforestation Regulation, the EU Proposal for a Corporate Sustainability Due Diligence Directive, CDP, the GHG Protocol, and carbon
tax programs in Europe and Canada.
Acquisitions and Other Business Arrangements
We discuss our acquisitions in Note 18. Acquisitions to our condensed consolidated financial statements.
KT&G
On January 30, 2023, PMI announced a long-term collaboration with KT&G, South Korea’s leading tobacco and nicotine manufacturer, to continue to
commercialize KT&G’s innovative smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea).
The agreement covers fifteen years, to January 29, 2038, with performance-review cycles and associated commitments, based on volume, to be confirmed
for each three-year period, to allow flexibility for evolving market conditions.
The agreement gives PMI continued exclusive access to KT&G’s smoke-free brands and product-innovation pipeline, including offerings for low- and
middle-income markets, that will enhance PMI’s existing portfolio of smoke-free products.
Products sold under the agreement will be subject to assessment to ensure they meet the regulatory requirements in the markets where they are launched, as
well as PMI’s high standards of quality and scientific substantiation. PMI and KT&G will seek any necessary regulatory approvals that may be required on
a market-by-market basis.
69
-- 70 of 140 --
Table of Contents
Equity Investments
We discuss our equity investments in Note 12. Related Parties - Equity Investments and Other to our condensed consolidated financial statements.
Trade Policy
PMI complies with all applicable trade restrictions and requirements, including sanctions, in the markets in which it operates. We have taken appropriate
actions in response to the latest sanctions to ensure full compliance with the relevant restrictions.
We are subject to various trade restrictions imposed by the U.S., the EU, Switzerland, the U.K., and other jurisdictions in which we do business (“Trade
Sanctions”), including the trade and economic sanctions administered by the U.S. Department of the Treasury's Office of Foreign Assets Control (“OFAC”)
and the U.S. Department of State. It is our policy to comply fully with these Trade Sanctions.
Pursuant to specific exemptions or licenses, or where sanctions do not apply to our business, PMI may make sales in countries subject to Trade Sanctions.
We do not do business or sell products in Iran, North Korea or Syria.
We sell cigarettes in Cuba under a distribution agreement. These sales are permitted by U.S. law under a License Exception for Agricultural Commodities,
issued by the U.S. Department of Commerce (Bureau of Industry and Security), and specifically granted to our distributor.
Certain states within the U.S. have enacted legislation permitting or requiring state pension funds to divest or abstain from future investment in stocks of
companies that do business with certain countries that are sanctioned by the U.S. Because we do business in certain of these countries, consistent with our
policy to fully comply with Trade Sanctions and as described above, these state pension funds may have divested of our stock or may not invest in our
stock. We do not believe such legislation has had a material effect on the price of our shares.
On June 24, 2021, the EU introduced sanctions in relation to Belarus aimed at specific sectors of the Belarus economy, including the tobacco sector.
Subsequently, seven non-EU countries (Norway, Iceland, Liechtenstein, North Macedonia, Bosnia and Herzegovina, Montenegro, and Albania) announced
that they “aligned themselves” with the majority of the EU sanctions. Switzerland and the U.K. have also imposed sanctions similar in scope to the EU
sanctions.
On August 9, 2021, the U.S. imposed blocking sanctions on certain Belarusian individuals and entities pursuant to an Executive Order, which expanded the
bases for the imposition of sanctions, including, among others, by authorizing the imposition by OFAC of blocking sanctions on persons operating in the
tobacco sector of the Belarus economy. From 2021 to 2023, the U.S., the EU, the U.K., Switzerland and several other jurisdictions supplemented their
respective sanctions lists by including additional Belarusian sanctions targets.
Following the start of the conflict in Ukraine on February 24, 2022, the U.S., the EU, the U.K., Switzerland, Canada, Australia, New Zealand, Singapore,
South Korea, Japan and other countries introduced extensive economic sanctions and export controls in relation to Russia. While the introduced sanctions
slightly vary from jurisdiction to jurisdiction, they are largely aligned. The restrictions target, among others, the Russian financial, banking, oil, military,
aviation and marine sectors. The U.S. has also introduced a prohibition on new investment in the Russian Federation by a U.S. person, wherever located,
and authorized the imposition of blocking sanctions on anyone operating in the Russian manufacturing sector. Among sanctions targets are Russian
political figures and military personnel, certain oligarchs and journalists, and companies operating in the above-mentioned sectors. Export to Russia of
certain luxury goods, and goods and technology which might contribute to Russia’s technological enhancement was banned. Seven non-EU countries
(Norway, Iceland, Liechtenstein, North Macedonia, Bosnia and Herzegovina, Montenegro, and Albania) announced that they “aligned themselves” with
the majority of the EU sanctions. The U.S., the EU, Switzerland and Japan introduced additional trade restrictions banning, among many other goods, the
export of certain non-tobacco materials used to produce cigarettes and heated tobacco consumables in Russia. The EU, Switzerland and the U.K. also
prohibited technical assistance and other services related to restricted goods. The EU, Switzerland and the U.K. prohibited import into their territories of
certain goods, including cigarettes, among others, which might generate significant revenues for Russia if they originate in Russia or are exported from
Russia. The EU and Switzerland prohibited
70
-- 71 of 140 --
Table of Contents
transfer and licensing of intellectual property rights in relation to restricted goods. Additionally, the EU, the U.S., the U.K., Switzerland, Canada, Australia,
New Zealand and Ukraine imposed sanctions on Mr. Igor Kesaev, a non-majority shareholder of Megapolis Distribution B.V.
The U.S., the U.K., Switzerland and the EU banned the export of electric accumulators and static converters to Russia. In addition, the U.S. and the U.K.
banned the export of electronic cigarettes and similar personal electric vaporizing devices to Russia. Certain countries also banned the delivery of services
to Russia, such as information technology consultancy services, accounting and business and management consulting services, or required licenses to
continue delivering these services to Russian persons or entities after June 20, 2024. We are working to mitigate any potential impacts from these
restrictions.
Russia introduced certain countermeasures aimed at reducing the effect of Western sanctions. Countermeasures include restrictions on export of certain
goods from Russia, including tobacco-related production equipment, restrictions on lending to foreign borrowers, repatriation of dividends and transactions
with securities and real estate involving companies from “hostile” countries (i.e., those which introduced sanctions in relation to Russia).
PMI continues to monitor the development of new sanctions and ensure full compliance.
Segment Operating Results – Three Months Ended March 31, 2024
The following discussion compares operating results within each of our segments for the three months ended March 31, 2024, with the three months ended
March 31, 2023.
Europe:
Financial Summary
Financial Summary -
Quarters Ended March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2024 2023 Total
Excl.
Cur-rency Total
Cur-
rency Acqui-
sitions Price
Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 3,365 $ 3,068 9.7 % 7.1 % $ 297 $ 78 $ — $ 163 $ 56 $ —
Operating Income $ 1,456 $ 1,215 19.8 % 18.7 % $ 241 $ 14 $ — $ 163 $ 64 $ —
During the quarter, net revenues increased by 9.7%. Net revenues, excluding currency, increased by 7.1%, reflecting: a favorable pricing variance, mainly
driven by higher combustible tobacco pricing; and favorable volume/mix, primarily driven by higher HTU volume, partly offset by lower cigarettes
volume.
The pricing variance for the full year 2023 and the first three months of 2024 was negatively impacted by the supplemental tax surcharge on heated tobacco
units in Germany, which went into effect in 2022. The negative impact will continue until a ruling on the legality of the surcharge is issued. On March 14,
2024 the Court of Justice of the European Union (the "CJEU") ruled that the German fiscal regulation imposing an additional excise tax on HTPs does not
contravene EU law. Fiscal Court in Dusseldorf (the "FCD") had previously referred that question to the CJEU. The decision on the matter lies with the
FCD and we expect a judgement in the coming months. PMI currently accounts for the surcharge as a reduction in net revenues and in accrued liabilities in
its results. The accrued liability balance will continue to increase with the continuation of the HTU selling activities and in the case of an unfavorable ruling
would negatively impact PMI’s future cash provided by operating activities. A favorable ruling would positively impact future PMI’s operating results.
Operating income increased by 19.8%. Operating income, excluding currency, increased by 18.7%, primarily reflecting: a favorable comparison to 2023 of
$47 million related to asset impairment and exit costs, a favorable pricing variance, mainly driven by higher combustible tobacco pricing; and favorable
volume/mix, primarily driven by higher HTU volume and favorable HTU mix, partly offset by lower cigarette volume, as well as unfavorable cigarette
mix; partly offset by higher manufacturing costs, including the impact of the EU single-use plastics directive.
Europe - Total Market, PMI Shipment Volume and Market Share Commentaries
71
-- 72 of 140 --
Table of Contents
In the first quarter, the estimated total market for cigarettes and HTUs in the Region decreased by 0.4% to 124.5 billion units, reflecting a 2.1% decline for
cigarettes, largely offset by an increase for HTUs. The decrease in the estimated total market was predominantly due to France (down by 16.1%) and the
UK (down by 11.1%), largely offset by Poland (up by 4.7%) and Bulgaria (up by 9.7%).
Europe Key Data First-Quarter
Change
2024 2023 % / pp
PMI Market Share
Cigarettes 29.9 % 30.3 % (0.4)
Heated Tobacco Units 10.1 % 9.0 % 1.1
Total Europe 40.0 % 39.3 % 0.7
Note: Sum may not foot due to roundings.
In the first quarter, our total cigarette and HTU shipment volume in the Region decreased by 1.7% to 48.4 billion units. Total cigarette and HTU shipment
volume decreased notably in France (down by 31.7%) and Italy (down by 10.4%) driven by cigarettes, and increased notably in Poland (up by 10.0%) and
Germany (up by 4.8%).
Our estimated HTU adjusted in-market sales volume in the Region increased by 9.4% in the quarter, reflecting continued growth momentum for IQOS,
partly offset by the impact from the EU characterizing flavor ban.
Our HTU share of the total cigarette and HTU market in the Region increased by 1.1 points, or by 0.9 points on an adjusted basis.
72
-- 73 of 140 --
Table of Contents
Other Oral SFP includes chew bags and tobacco bits
Note: Sum may not foot due to roundings.
Oral SFP shipments increased by 16.5% with growth of snus (up by 11.6%) and nicotine pouches (up by 55.9%), benefiting from timing of shipments and
underlying category growth in the Nordics.
SSEA, CIS & MEA:
Financial Summary
Financial Summary -
Quarters Ended March 31,
Change
Fav./(Unfav.)
Variance
Fav./(Unfav.)
2024 2023 Total
Excl.
Cur-rency Total
Cur-
rency
Acqui-
sitions Price
Vol/
Mix
Cost/
Other (in millions)
Net Revenues $ 2,658 $ 2,477 7.3 % 15.1 % $ 181 $ (194) $ — $ 155 $ 144 $ 76
Operating Income $ 772 $ 734 5.2 % 38.0 % $ 38 $ (241) $ — $ 155 $ 46 $ 78
During the quarter, net revenues increased by 7.3%. Net revenues, excluding currency, increased by 15.1%, primarily reflecting: a favorable comparison to
2023 reflecting a 2023 charge of $80 million following the termination of a distribution arrangement in the Middle East, a favorable pricing variance,
mainly driven by higher combustible tobacco pricing; and favorable volume/mix, driven by higher HTU and cigarettes volume and favorable HTU and
cigarettes mix.
Operating income increased by 5.2%. Operating income, excluding currency, increased by 38.0%, primarily reflecting: a favorable pricing variance, mainly
driven by higher combustible tobacco pricing; and favorable volume/mix, driven by higher HTU volume, favorable HTU mix and favorable cigarette
volume, partly offset by unfavorable cigarette mix; partly offset by higher manufacturing costs (primarily due to inflationary impacts).
73
-- 74 of 140 --
Table of Contents
SSEA, CIS & MEA - Total Market, PMI Shipment Volume and Market Share Commentaries
In the first quarter, the estimated total market for cigarettes and HTUs in the Region increased by approximately 1% to 371.0 billion units. The increase in
the estimated total market was mainly due to Indonesia (up by 6.4%) and Turkey (up by 14.8%), partly offset by Egypt (down by 14.2%) and Pakistan
(down by 20.7%).
In the first quarter, our total cigarette and HTU shipment volume in the Region increased by 5.2% to 86.3 billion units, mainly driven by Turkey (up by
25.0%), partly offset by the Philippines (down by 18.1%). PMI's estimated HTU adjusted in-market sales volume increased by 14.6%, with 11.6% HTU
shipment volume growth.
EA, AU & PMI DF:
Financial Summary
Financial Summary - Quarters
Ended March 31,
Change
Fav./(Unfav.)
Variance
Fav./(Unfav.)
2024 2023 Total
Excl.
Cur-rency Total
Cur-
rency
Acqui-
sitions Price
Vol/
Mix
Cost/
Other
(in millions)
Net Revenues $ 1,684 $ 1,520 10.8 % 18.0 % $ 164 $ (109) $ — $ 130 $ 143 $ —
Operating Income $ 763 $ 637 19.8 % 39.4 % $ 126 $ (125) $ — $ 130 $ 72 $ 49
During the quarter, net revenues increased by 10.8%. Net revenues, excluding currency, increased by 18.0%, reflecting: a favorable pricing variance and
favorable volume/mix, mainly driven by higher HTU volume.
Operating income increased by 19.8%. Operating income, excluding currency, increased by 39.4%, mainly reflecting: the same factors as for net revenues,
as well as lower shipping costs and a favorable comparison to 2023 of $19 million related to asset impairment and exit costs.
EA, AU & PMI DF - Total Market, PMI Shipment Volume and Market Share Commentaries
In the first quarter, the estimated total market for cigarettes and HTUs in the Region, excluding China, increased by around 1% to 75.9 billion units, with
growth for HTUs partly offset by a decline for cigarettes. The increase in the estimated total market was mainly driven by International Duty Free (up by
17.6%) and Taiwan (up by 15.0%).
74
-- 75 of 140 --
Table of Contents
In the first quarter, our total cigarette and HTU shipment volume in the Region increased by 9.3% to 27.2 billion units, driven by Japan (up by 21.1%).
Our estimated HTU adjusted in-market sales volume in the Region increased by 14.6% in the quarter, including growth in Japan of 13.3%.
Americas:
Financial Summary
Financial Summary -
Quarters Ended March 31,
Change
Fav./(Unfav.) Variance
Fav./(Unfav.)
2024 2023 Total
Excl.
Cur-rency Total
Cur-
rency Acqui-
sitions Price
Vol/
Mix Cost/
Other (in millions)
Net Revenues $ 996 $ 868 14.7 % 11.4 % $ 128 $ 29 $ — $ (1) $ 121 $ (21)
Operating Income $ 99 $ 183 (45.9)% (57.9)% $ (84) $ 22 $ — $ (1) $ 113 $ (218)
During the quarter, net revenues increased by 14.7%. Net revenues, excluding currency, increased by 11.4%, primarily reflecting: favorable volume/mix,
mainly due to growth of ZYN nicotine pouches in the U.S., partly offset by lower cigarette volume and unfavorable cigarette mix outside of the U.S.
Operating income decreased by 45.9%. Operating income, excluding currency, decreased by 57.9%, mainly reflecting: higher asset impairment and exit
costs, higher amortization of intangibles and higher marketing and administration costs, including incremental investment in the U.S. The decrease was
partly offset by a favorable volume/mix, mainly due to the same factors as for net revenues, and a favorable comparison to 2023 of $18 million related to
Swedish Match AB acquisition accounting related items.
Americas - Total Market, PMI Shipment Volume and Market Share Commentaries
In the first quarter, the estimated total market for cigarettes and HTUs in the Region, excluding the U.S., decreased by around 3% to 44.7 billion units,
primarily reflecting a decline for cigarettes. The decrease in the estimated total market was mainly due to Argentina (down by 7.8%) and Canada (down by
13.1%), partly offset by Brazil (up by 3.5%) and Mexico (up by 1.8%).
75
-- 76 of 140 --
Table of Contents
In the first quarter, our total cigarette and HTU shipment volume in the Region decreased by 3.7% to 14.5 billion units, mainly due to Argentina (down by
9.8%).
Cigar shipment volume declined by 23%, versus a difficult comparison due to prior year trade inventory movements.
(1) Excluding U.S. chew
Note: Sum may not foot due to roundings.
Oral products shipments increased by 52.1%, driven by ZYN nicotine pouches (up by 79.7%) in the U.S., partly offset by moist snuff (down by 2.3%)
driven by a declining category and pricing.
76
-- 77 of 140 --
Table of Contents
Wellness and Healthcare:
The operating results of PMI’s Vectura Fertin Pharma business are reported in the Wellness and Healthcare segment. The business operations of our
Wellness and Healthcare segment are evaluated separately from the geographical segments.
Financial Summary
Financial Summary -
Quarters Ended March 31,
Change
Fav./(Unfav.)
Variance
Fav./(Unfav.)
2024 2023 Total
Excl.
Cur-rency Total
Cur-
rency
Acqui-
sitions Price
Vol/
Mix
Cost/
Other (in millions)
Net Revenues $ 90 $ 86 4.7 % 2.3 % $ 4 $ 2 $ — $ 2 $ — $ —
Operating Income / (Loss) $ (45) $ (38) (18.4)% (23.7)% $ (7) $ 2 $ — $ 2 $ — $ (11)
During the quarter, net revenues increased by 4.7%. Net revenues, excluding currency, increased by 2.3%.
The operating loss of $45 million in 2024 was primarily due to investments in research and development, and administration costs, as well as a charge for
impairment of other intangible assets of $26 million and the amortization of acquired intangibles.
77
-- 78 of 140 --
Table of Contents
Financial Review
Cash Flow Highlights
For the Three Months Ended March 31,
(in millions) 2024 2023
Net cash provided by (used in) operating activities $ 241 $ (955)
Net cash provided by (used in) investing activities (193) (591)
Net cash provided by (used in) financing activities 1,135 864
Net Cash Provided by (Used in) Operating Activities
During the first three months of 2024, net cash provided by operating activities was $241 million as compared to $955 million of net cash used in the first
three months of 2023. Excluding unfavorable currency movements of $364 million, the favorable variance of $1.6 billion was due primarily to lower
working capital requirements of $1.0 billion and higher currency-neutral net earnings, excluding non-cash depreciation and amortization expense and other
intangible impairment charges.
The unfavorable currency movements primarily related to the currency impact on net earnings and represented the fluctuations of the U.S. dollar, especially
against the Egyptian pound, Japanese yen and Russian ruble.
The lower working capital requirements in 2024 as compared with 2023 were primarily due to less cash used in accrued liabilities and other current assets,
net of more cash provided by inventories, mainly reflecting the timing of excise tax-paid inventory movements primarily related to excise tax increases and
the timing of the corresponding excise tax payments, as well as tactical stock increases for certain direct materials in 2023. These changes in the working
capital requirements were partly offset by more cash used in accounts receivable mainly reflecting lower usage of our factoring arrangements to sell trade
receivables, as well as the timing of sales and cash collections. For further detail on our factoring arrangements, see Note 13. Sale of Accounts Receivable.
For the full year 2024, we currently expect net cash provided by operating activities of $10 billion to $11 billion at prevailing exchange rates, subject to
year-end working capital requirements.
Net Cash Provided by (Used in) Investing Activities
During the first three months of 2024, net cash used in investing activities was $193 million as compared to $591 million in the first three months of 2023.
This decrease in net cash used was primarily due to changes in the cash collateral posted for derivative instruments, partially offset by higher capital
expenditures.
Capital expenditures of $417 million during the first three months of 2024 increased by $138 million as compared with the first
78
-- 79 of 140 --
Table of Contents
three months of 2023. The 2024 capital expenditures were primarily related to our ongoing investments in smoke-free product manufacturing capacity. We
expect total capital expenditures in 2024 to be approximately $1.2 billion, partly reflecting investments in ZYN capacity in the U.S.
Net Cash Provided by (Used in) Financing Activities
During the first three months of 2024, net cash provided by financing activities was $1.1 billion as compared to $0.9 billion in the first three months of
2023. The increase in net cash provided was primarily due to favorable comparisons to 2023 reflecting: repayment on the bridge facility in 2023 related to
the Swedish Match acquisition; payments in 2023 to acquire the remaining issued and outstanding shares in Swedish Match; and the 2023 repayments of
long-term debt. These increases in net cash provided was partly offset by lower net borrowings in 2024 reflecting lower long-term debt proceeds and lower
net short-term borrowings (primarily commercial paper).
Debt and Liquidity
We define cash and cash equivalents as short-term, highly liquid investments, readily convertible to known amounts of cash that mature within a maximum
of three months and have an insignificant risk of change in value due to interest rate or credit risk changes. As a policy, we do not hold any investments in
structured or equity-linked products. Our cash and cash equivalents are predominantly held with institutions that have investment-grade long-term credit
rating.
In a number of jurisdictions, including Argentina, Egypt and Russia, we are impacted by various capital controls and/or foreign currency exchange
constraints that affect the ability of our subsidiaries in these jurisdictions to settle foreign currency denominated imports of goods and services and/or to
pay dividends. These factors increase foreign currency devaluation risks, which may have a negative impact on our financial condition, net assets and
results of operations in these jurisdictions.
We utilize long-term and short-term debt financing, including a commercial paper program that is regularly used to finance ongoing liquidity requirements,
as part of our overall cash management strategy. Our ability to access the capital and credit markets as well as overall dynamics of these markets may
impact borrowing costs. We expect that the combination of our long-term and short-term debt financing, the commercial paper program and the committed
credit facilities, coupled with our operating cash flows, will enable us to meet our liquidity requirements.
In August 2021, we published a business transformation-linked financing framework (“Framework”), which integrates PMI's smoke-free transformation
into its financing strategy. The Framework outlines the guidelines that we will follow in issuing business transformation-linked financing instruments in the
debt capital and loan markets, which may include public notes offerings, private placements, loans, and other relevant financing instruments.
Credit Ratings – The cost and terms of our financing arrangements as well as our access to commercial paper markets may be affected by applicable credit
ratings. At March 31, 2024, our credit ratings and outlook by major credit rating agencies were as follows:
Short-term Long-term Outlook
Moody’s P-1 A2 Stable
Standard & Poor’s A-2 A- Stable
Fitch F1 A Negative
79
-- 80 of 140 --
Table of Contents
Revolving Credit Facilities
At March 31, 2024, our committed revolving credit facilities were as follows:
Type (in billions)
Committed
Revolving Credit
Facilities
364-day revolving credit, expiring January 28, 2025 $ 1.7
Multi-year revolving credit, expiring February 10, 2026 2.0
Multi-year revolving credit, expiring September 29, 2026 2.5
Total facilities $ 6.2
On January 28, 2022, we entered into an agreement, effective February 10, 2022, to amend and extend the term of our $2.0 billion multi-year revolving credit facility, for
an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion.
Includes business transformation-linked pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit
agreement if PMI achieves, or fails to achieve, certain specified targets based on its business transformation goals.
On September 20, 2022, we entered into an agreement, effective September 29, 2022, to amend and extend the term of our $2.5 billion multi-year revolving credit facility,
for an additional year covering the period September 30, 2026 to September 29, 2027, in the amount of $2.3 billion. On September 20, 2023, we entered into an agreement,
effective September 29, 2023, to amend and further extend the term to September 29, 2028.
At March 31, 2024, there were no borrowings under the committed revolving credit facilities, and the entire committed amounts were available for
borrowing.
All banks participating in our committed revolving credit facilities have an investment-grade long-term credit rating from the credit rating agencies. We
continuously monitor the credit quality of our banking group, and at this time we are not aware of any potential non-performing credit provider.
These committed revolving credit facilities do not include any credit rating triggers, material adverse change clauses or any provisions that could require us
to post collateral. We expect to continue to meet our covenants.
In addition to the committed revolving credit facilities discussed above, PMI maintains certain short-term credit arrangements, including uncommitted
credit lines, to primarily meet working capital needs. These credit arrangements amounted to approximately $2.1 billion at March 31, 2024, and
approximately $2.7 billion at December 31, 2023. Borrowings under these arrangements and other bank loans amounted to $130 million at March 31,
2024, and $283 million at December 31, 2023.
Credit Facilities related to the Financing of the Swedish Match Acquisition
In connection with PMI's all-cash recommended public offer to the shareholders of Swedish Match, on May 11, 2022, PMI entered into a credit agreement
relating to a 364-day senior unsecured bridge facility. The facility provided for borrowings up to an aggregate principal amount of $17 billion, expiring 364
days after the occurrence of certain events unless extended. On June 23, 2022, PMI entered into a €5.5 billion (approximately $5.8 billion at the date of
signing) senior unsecured term loan credit agreement consisting of a €3.0 billion (approximately $3.2 billion at the date of signing) tranche expiring three
years after the occurrence of certain events and a €2.5 billion (approximately $2.6 billion at the date of signing) tranche expiring on June 23, 2027. In
connection with the term loan facility, the aggregate principal amount of commitments under the 364-day senior unsecured bridge facility was reduced
from $17 billion to $11 billion. On November 11, 2022, PMI acquired a controlling interest of 85.87% of the total issued shares in Swedish Match and
acquired 94.81% of its outstanding shares as of December 31, 2022. In accordance with the Swedish Companies Act, PMI subsequently exercised its right
to compulsorily redeem the remaining shares for which acceptances were not received and obtained legal title to 100% of the shares in Swedish Match on
February 17, 2023.
(1)
(2) (3)
(1)
(2)
(3)
80
-- 81 of 140 --
Table of Contents
PMI borrowed $8.4 billion under the bridge facility by delivering notices of borrowing for advances of $7.9 billion and $0.5 billion on November 7, 2022
and November 10, 2022, respectively. On November 21, 2022 and February 17, 2023, PMI repaid $4.0 billion and $4.4 billion, respectively, under the
bridge facility. Effective February 20, 2023, the remaining outstanding commitments under the bridge facility were fully canceled and the bridge facility
agreement was terminated in accordance with its terms.
On November 7, 2022, PMI also delivered notices of borrowing for advances totaling €5.5 billion under the term loan facility, of which €3.0 billion will
become due on November 9, 2025 and €2.5 billion will become due on June 23, 2027 unless prepaid pursuant to the terms of the credit agreement. As of
March 31, 2024 and December 31, 2023, the €5.5 billion (approximately $6 billion) term loan facility was fully drawn and remained outstanding.
The proceeds under the bridge facility and the term loan facility were used, directly or indirectly, to finance the acquisition, including, the payment of
related fees and expenses.
Commercial Paper Program – We continue to have access to liquidity in the commercial paper market through programs in place in the U.S. and in Europe
having an aggregate issuance capacity of $8.0 billion. At March 31, 2024, we had $149 million of commercial paper outstanding. At December 31, 2023,
we had $1.7 billion commercial paper outstanding. The average commercial paper balance outstanding during the first three months of 2024 was $2.9
billion. The average commercial paper balance outstanding during 2023 was $3.6 billion.
Sale of Accounts Receivable – To mitigate credit risk and enhance cash and liquidity management, we sell trade receivables to unaffiliated financial
institutions. For further details, see Note 13. Sale of Accounts Receivable to our condensed consolidated financial statements.
Supply Chain Financing – We engage with unaffiliated global financial institutions that offer a voluntary supply chain financing program to some of our
suppliers. For further details, see Note 17. Supply Chain Financing to our condensed consolidated financial statements.
Debt – Our total debt was $50.4 billion at March 31, 2024 and $47.9 billion at December 31, 2023.
On February 10, 2023, we filed a shelf registration statement with the U.S. Securities and Exchange Commission, under which we may from time to time
sell debt securities and/or warrants to purchase debt securities over a three-year period.
PMI's debt issuances in the first three months of 2024 were as follows:
(in millions)
Type Face Value Interest Rate Issuance Maturity
U.S. dollar notes (a) $750 4.750% February 2024 February 2027
U.S. dollar notes (a) $1,000 4.875% February 2024 February 2029
U.S. dollar notes (a) $1,250 5.125% February 2024 February 2031
U.S. dollar notes (a) $1,750 5.250% February 2024 February 2034
(a) Interest is payable semi-annually, commencing in August 2024
The net proceeds from the sale of the securities listed in the table above have been or will be used for general corporate purposes, including working capital
requirements, repayment of commercial paper and to refinance certain of our outstanding notes due in 2024.
Guarantees – At March 31, 2024, we have guarantees of our own performance, which are primarily related to excise taxes on the shipment of our products.
There is no liability in the condensed consolidated financial statements associated with these guarantees. These guarantees have not had, and are not
expected to have, a significant impact on PMI’s liquidity.
Swedish Match Notes Consent Solicitation and PMI Guarantee
On June 15, 2023, our wholly owned subsidiary, Swedish Match AB ("Swedish Match"), initiated a public consent solicitation of eligible holders of certain
outstanding series of its notes to amend certain terms and conditions of these respective notes. The eligible noteholders provided the requisite irrevocable
consent instructions voting in favor of the amendments, which were subsequently passed by way of extraordinary resolution at the noteholders’ meeting
held on July 28, 2023. As a result of the
81
-- 82 of 140 --
Table of Contents
passage of the extraordinary resolution, Philip Morris International Inc. entered into a guarantee, which guarantees unconditionally and irrevocably to the
noteholders the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of the principal, premium, if any, and interest on the
notes.
Equity and Dividends
We discuss our stock awards as of March 31, 2024 in Note 2. Stock Plans to our condensed consolidated financial statements.
On May 11, 2022, we announced the suspension of our three-year share repurchase program following the recommended public offer to acquire the
outstanding shares of Swedish Match from its shareholders. We did not make any share repurchases in 2023 and we do not currently anticipate restarting
our share repurchase program during 2024.
Dividends paid in the first three months of 2024 were $2.0 billion. During the third quarter of 2023, our Board of Directors approved a 2.4% increase in the
quarterly dividend to $1.30 per common share. As a result, the present annualized dividend rate is $5.20 per common share.
Market Risk
Counterparty Risk - We predominantly work with financial institutions with strong short- and long-term credit ratings as assigned by Standard & Poor’s
and Moody’s. These banks are also part of a defined group of relationship banks. Non-investment grade institutions are only used in certain emerging
markets to the extent required by local business needs. We have a conservative approach when it comes to choosing financial counterparties and financial
instruments. As such, we do not invest or hold investments in any structured or equity-linked products. The majority of our cash and cash equivalents is
currently invested with maturities of less than 30 days.
We continuously monitor and assess the credit worthiness of all our counterparties.
Derivative Financial Instruments - We operate in markets globally with manufacturing and sales facilities in various locations around the world.
Consequently, we use certain financial instruments to manage our foreign currency and interest rate exposure. We use derivative financial instruments
principally to reduce our exposure to market risks resulting from fluctuations in foreign exchange and interest rates by creating offsetting exposures. We are
not a party to leveraged derivatives and, by policy, do not use derivative financial instruments for speculative purposes.
See Note 5. Financial Instruments to our condensed consolidated financial statements for further details on our derivative financial instruments and the
related collateral arrangements.
Contingencies
See Note 8. Contingencies to our condensed consolidated financial statements for a discussion of contingencies.
Cautionary Factors That May Affect Future Results
Forward-Looking and Cautionary Statements
We may from time to time make written or oral forward-looking statements, including statements contained in filings with the SEC, in reports to
stockholders and in press releases and investor webcasts. You can identify these forward-looking statements by use of words such as "strategy," "expects,"
"continues," "plans," "anticipates," "believes," "will," "aspires," "estimates," "intends," "projects," "aims," "goals," "targets," "forecasts" and other words of
similar meaning. You can also identify them by the fact that they do not relate strictly to historical or current facts.
82
-- 83 of 140 --
Table of Contents
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Our
SFPs constitute a relatively new product category that is less predictable than our mature cigarette business. Achievement of future results is subject to
risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove
inaccurate, actual results could vary materially from those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-
looking statements and whether to invest in or remain invested in our securities. In connection with the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995, we are identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ
materially from those contained in any forward-looking statements made by us; any such statement is qualified by reference to the following cautionary
statements. We elaborate on these and other risks we face throughout this document, particularly in the "Business Environment" section. You should
understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider the following to be a complete discussion of
all potential risks or uncertainties. We do not undertake to update any forward-looking statement that we may make from time to time, except in the normal
course of our public disclosure obligations.
Overall Business Risks
We may be unsuccessful in our attempts to introduce, commercialize, and grow smoke-free products in existing and new markets, and regulators may
prohibit or significantly restrict the commercialization of these products or the communication of scientifically substantiated information and claims.
Our key strategic priorities are to: (i) continue developing and commercializing products that present less risk of harm to adult smokers who switch to
smoke-free products versus continued cigarette smoking; and (ii) encourage and educate current adult smokers who would otherwise continue to smoke
cigarettes to switch to those products. For our efforts to be successful, we must:
• develop SFPs that adult smokers who would otherwise continue to smoke cigarettes find to be satisfying alternatives to smoking;
• for those adult smokers, our goal is to offer SFPs with a scientifically substantiated risk-reduction profile that approaches as closely as possible the
risk-reduction profile associated with smoking cessation;
• substantiate the reduction of risk for the individual adult smoker and the reduction of harm to the population as a whole, based on scientific
evidence of the highest standard that is made available for scrutiny and review by external independent scientists and relevant regulatory bodies; and
• advocate for the development of science-based regulatory frameworks for the development and commercialization of SFPs, including the
communication of scientifically substantiated information to enable adult smokers to make better choices.
We might not succeed in our effort to introduce, commercialize, and grow our SFPs in existing and new markets. If we do not succeed, but others do, or if
heat-not-burn products are inequitably regulated compared to other SFP categories without regard to the totality of the scientific evidence available for such
products, we may be at a competitive disadvantage. In addition, actions of some market participants, such as the inappropriate marketing of e-vapor
products to youth, as well as alleged health consequences associated with the use of certain e-vapor products, may unfavorably impact public opinion
and/or mischaracterize the health consequences of all e-vapor products or other SFPs to consumers, regulators and policy makers without regard to the
totality of scientific evidence available for specific products. This may impede our efforts to advocate for the development of science-based regulatory
frameworks for the development and commercialization of SFPs. We cannot predict the extent to which regulators will permit the sale and/or marketing of
SFPs. Regulatory restrictions could limit the success of our SFPs.
The World Health Organization (the "WHO") study group on tobacco product regulation published their eighth report on the scientific basis of tobacco
product regulation in May 2021. The report is based on a review of scientific evidence related to novel and emerging nicotine and tobacco products, such as
electronic nicotine delivery systems ("ENDS"), electronic non-nicotine delivery systems and HTPs. The report concludes by making a number of policy
recommendations on HTPs and ENDS that, if implemented, could restrict both the availability of these products and the access to accurate information
about them. In August 2021, the FCTC Secretariat published two reports on novel and emerging tobacco products to the Ninth Session of the CoP of the
FCTC, which are not materially different from the WHO study group report. Substantive decisions based on these reports were deferred to the Tenth
Session of the CoP ("CoP 10"). CoP 10 to the FCTC took place in February 2024. According to reports and decisions published, neither new decisions nor
new policy recommendations on novel and emerging tobacco products were adopted. Specific Guidelines were adopted to address cross-border Tobacco
Advertising,
83
-- 84 of 140 --
Table of Contents
Promotion, and Sponsorship ("TAPS") and the depiction of tobacco in entertainment media. The Eleventh session of the CoP is currently scheduled to take
place in 2025.
The WHO’s reports and other FCTC guidelines or recommendations are not binding on the WHO Member States or on parties to the FCTC, and so it is not
possible to predict the extent to which any proposals it adopts will be implemented. However, the WHO proposals could lead to restrictions on the
availability of certain of our SFPs and access to accurate information about them in one or more of our markets, which could have a material adverse effect
on our results of operations.
Additionally, any claims, regardless of merit, challenging our research and clinical data available to date, may impact the development of science-based
regulatory frameworks for the commercialization of the SFP category and the commercialization of the SFP category in general.
Our SFPs and commercial activities for these products are designed for, and directed toward, current adult smokers and users of nicotine-containing
products. We put significant effort to restrict access of our products from non-smokers and youth. Despite our efforts, technological, operational, regulatory
and/or commercial developments might impact the implementation or effectiveness of youth access prevention mechanisms and surrounding infrastructure.
If there is significant usage, whether actual or perceived, of our products or competitive products among youth or non-smokers, even in situations over
which we have no control, our reputation and credibility may suffer, the regulatory approach to our products may become more restrictive, and our efforts
to advocate for the development of science-based regulatory frameworks for the development and commercialization of SFPs may be significantly
impacted.
Moreover, the FDA’s premarket tobacco product and modified risk tobacco product authorizations of two versions of our Platform 1 product are subject to
strict marketing, reporting and other requirements. Although we have received these authorizations from the FDA, there is no guarantee that the product
will remain authorized for sale in the U.S., or that new versions of the product (Platform 1 or other smoke-free platforms) will receive necessary
authorizations, particularly if there is a significant uptake in youth or non-smoker initiation.
Premarket tobacco applications for certain ZYN products, which are currently marketed in the U.S., were submitted in March 2020. The FDA has not
completed its review of such applications but, consistent with its practice concerning products with respect to which applications were filed prior to a
September 9, 2020 deadline, the FDA has not taken enforcement action to prevent these ZYN products from being marketed or indicated that it intends to
do so. We also submitted additional premarket tobacco applications for other ZYN products after the deadline, and we are unable to market these products
until the FDA authorizes such applications. There is no guarantee that the ZYN products will receive the necessary authorizations from the FDA or that the
FDA will allow us to continue to sell the ZYN products currently in the market, pending its review of the applications.
The commercialization of our products in the United States is dependent on successfully managing compliance with federal, state, and local laws,
regulations, legal agreements, and related interpretations. Failure to successfully manage compliance and to resolve any disputes that may arise regarding
the application of legal and administrative requirements to our products could negatively impact the timing, manner, or success of our SFP
commercialization in the United States.
The financial and business performance of our smoke-free products is less predictable than our cigarette business.
Our SFPs are novel products in a relatively new category, and the pace at which adult smokers adopt them may vary, depending on the competitive,
regulatory, fiscal and cultural environment, and other factors in a specific market. There may be periods of accelerated growth and periods of slower growth
for these products, the timing and drivers of which may be more difficult for us to predict versus our mature cigarette business. The impact of this lower
predictability on our projected results for a specific period may be significant, due to geopolitical or macroeconomic events that negatively impact SFP
availability or adoption, which in turn may have a material adverse effect on our results of operations.
We may be unsuccessful in our efforts to differentiate smoke-free products and cigarettes with respect to taxation.
To date, we have been largely successful in demonstrating to regulators that our SFPs are not cigarettes due to the absence of combustion, and accordingly
they are generally taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than cigarettes.
Nevertheless, we are unable to predict whether regulators will be issuing new regulations under which SFPs will be equally taxed in line with other tobacco
products such as conventional cigarettes. If we cease to be successful in these efforts, SFP unit margins may be materially adversely affected, which in turn
may have a material adverse effect on our results of operations, revenues, cash flows, and profitability.
84
-- 85 of 140 --
Table of Contents
Consumption of tax-paid cigarettes continues to decline in many of our markets.
This decline is due to multiple factors, including increased taxes and pricing, governmental actions, the diminishing social acceptance of smoking, health
concerns, competition, continuing economic and geopolitical uncertainty, and the continuing prevalence of illicit products. These factors and their potential
consequences are discussed more fully below and in the "Business Environment" section in this Form 10-Q. A continuous decline in the consumption of
cigarettes could have a material adverse effect on our revenue, cash flow and profitability, which in turn may have a material adverse effect on our ability to
fund our smoke-free transformation.
Cigarettes are subject to substantial taxes. Significant increases in cigarette-related taxes have been proposed or enacted and are likely to continue to be
proposed or enacted in numerous jurisdictions. These tax increases may disproportionately affect our profitability and make us less competitive versus
certain of our competitors.
Tax regimes, including excise taxes, sales taxes and import duties, can disproportionately affect the retail price of cigarettes versus other combustible
tobacco products, or disproportionately affect the relative retail price of our cigarette brands versus cigarette brands manufactured by certain of our
competitors. Because our portfolio is weighted toward the premium-price cigarette category, tax regimes based on sales price can place us at a competitive
disadvantage in certain markets. Furthermore, our volume and profitability may be adversely affected in these markets.
In addition, increases in cigarette taxes are expected to continue to have an adverse impact on our sales of cigarettes, due to resulting lower consumption
levels, a shift in sales from manufactured cigarettes to other combustible tobacco products and from the premium-price to the mid-price or low-price
cigarette categories, where we may be under-represented, from local sales to cross-border purchases of lower price products, or to illicit products such as
contraband, counterfeit and "illicit whites."
Each of these risks could have a material adverse effect on our business, operations, results of operations, revenues, cash flow and profitability.
Our business faces significant governmental action aimed at increasing regulatory requirements with the goal of reducing or preventing the use of tobacco
or nicotine-containing products.
Governmental actions, combined with the diminishing social acceptance of smoking and private actions to restrict smoking, have resulted in reduced
industry volumes for our products in many of our markets, and we expect that such factors will continue to reduce consumption levels and will increase
down-trading and the risk of counterfeiting, contraband, "illicit whites" and cross-border purchases. Significant regulatory developments will continue to
take place over the next few years in most of our markets, driven principally by the Framework Convention on Tobacco Control (the "FCTC"). Since it
came into force in 2005, the FCTC has led to increased efforts by tobacco control advocates and public health organizations to promote increasingly
restrictive regulatory measures on the marketing and sale of tobacco and nicotine-containing products to adult nicotine users. Regulatory initiatives that
have been proposed, introduced or enacted by governmental authorities in various jurisdictions include:
• restrictions on or licensing of outlets permitted to sell tobacco or nicotine-containing products;
• the levying of substantial and increasing tax and duty charges;
• restrictions or bans on advertising, marketing and sponsorship;
• the display of larger health warnings, graphic health warnings and other labeling requirements;
85
-- 86 of 140 --
Table of Contents
• restrictions on packaging design, including the use of colors, and mandating plain packaging;
• restrictions on packaging and cigarette formats and dimensions;
• restrictions or bans on the display of product packaging at the point of sale and restrictions or bans on vending machines;
• generation sales bans, under which the sale of certain tobacco or nicotine-containing products to people born after a certain year would be
prohibited;
• requirements regarding testing, disclosure and performance standards for tar, nicotine, carbon monoxide and/or other smoke or product
constituents;
• disclosure, restrictions, or bans of tobacco product ingredients, including bans on the flavors of certain tobacco and nicotine-containing
products;
• increased restrictions on smoking and use of tobacco and nicotine-containing products in public and work places and, in some instances, in
private places and outdoors;
• restrictions or prohibitions of novel tobacco or nicotine-containing products or related devices;
• elimination of duty free sales and duty free allowances for travelers;
• restrictions in terms of importing or exporting our products impacting our logistics activities and ability to ship our products;
• encouraging litigation against tobacco companies; and
• excluding tobacco companies from transparent public dialogue regarding public health and other policy matters.
Our financial results could be materially affected by regulatory initiatives resulting in a significant decrease in demand for our brands. More specifically,
requirements that lead to a commoditization of tobacco products or impede adult consumers' ability to convert to our SFPs, as well as any significant
increase in the cost of complying with new regulatory requirements could have a material adverse effect on our financial results.
Changes in the earnings mix and changes in tax laws may result in significant variability in our effective tax rates. Our ability to receive payments from
foreign subsidiaries or to repatriate royalties and dividends could be restricted by local country currency exchange controls and other regulations.
We are subject to income tax laws in the United States and numerous foreign jurisdictions. Changes in the U.S. tax system, including significant increases
in the U.S. corporate income tax rate and the minimum tax rate on certain earnings of foreign subsidiaries could be enacted. Such changes could have a
material adverse impact on our effective tax rate thereby reducing our net earnings. Further changes in the tax laws of foreign jurisdictions could arise as a
result of the base erosion and profit shifting project undertaken by the Organisation for Economic Co-operation and Development, which recommended
changes to numerous long-standing tax principles, and could have a material adverse impact on our effective tax rate thereby reducing our net earnings. As
of March 31, 2024, many countries have enacted the OECD’s framework on a global minimum tax (referred to as “Pillar Two”), effective for taxable years
beginning after December 31, 2023. While we have determined that Pillar Two should not have a material impact on our 2024 consolidated financial
statements, we will continue to evaluate and monitor as additional guidance and clarification becomes available. If implemented, such changes, as well as
changes in taxing jurisdictions’ administrative interpretations, decisions, policies, or positions, could also have a material adverse impact on our effective
tax rate thereby reducing our net earnings. In future periods, our ability to recover deferred tax assets could be subject to additional uncertainty as a result
of such developments. Furthermore, changes in the earnings mix or applicable foreign tax laws may result in significant variability in our effective tax
rates.
As a result of Russia’s invasion of Ukraine, certain taxing jurisdictions, including the U.S., have proposed punitive tax legislation applicable to companies
doing business in Russia, which could also have a material adverse impact on our effective tax rate if enacted thereby reducing our net earnings.
Because we are a U.S. holding company, our most significant source of funds is distributions from our non-U.S. subsidiaries. Certain countries in which we
operate have adopted or could institute currency exchange controls and other regulations or policies that limit or prohibit our local subsidiaries' ability to
convert local currency into U.S. dollars or to make payments outside the country. This could subject us to the risks of local currency devaluation and
business disruption.
Disruptions in the credit markets or changes to our credit ratings may adversely affect our business.
We currently generate significant cash flows from ongoing operations and have access to global credit markets through our various short- and long- term
financing activities. Our financial performance, credit ratings, interest rates, the stability of
86
-- 87 of 140 --
Table of Contents
financial institutions with which we partner, geopolitical or national developments, the stability and liquidity of the credit markets and the state of the
global economy could affect the availability and cost of financing.
Disruption in the credit markets, limitations on our ability to borrow, slower than anticipated debt deleveraging, or a downgrade of our current credit rating
could increase our future borrowing costs which could materially and adversely affect our financial condition and results of operations. In addition, tighter
or more volatile credit markets may lead to business disruptions for certain of our suppliers, contract manufacturers or trade customers which could, in turn,
adversely impact our business, results of operations, cash flow and financial condition.
We could decide, or be required to, recall products, which could have a material adverse effect on our business, reputation, results of operations, cash flows
or financial position.
We could decide, or laws or regulations could require us, to recall products due to the failure, or alleged failure, to meet quality standards or specifications,
suspected or confirmed and deliberate or unintentional product contamination, manufacturing defects, or other product adulteration, misbranding or
tampering. A product recall or a product liability or other claim (even if unsuccessful or without merit) could generate negative publicity about us and our
products, and our Company’s reputation or that of our brands may be adversely affected. In addition, if another company recalls or experiences negative
publicity related to a product in a category in which we compete, adult nicotine consumers might reduce their overall consumption of products in that
product category. Any of these events could have a material adverse effect on our business, reputation, results of operations, cash flows or financial
position.
We may be required to write down assets due to impairment, which could have a material adverse effect on our results of operations or financial position.
We continuously monitor the values of our long-lived assets, reporting units, intangible assets, as well as investments in equity securities, including our
continuing investment in Rothmans, Benson & Hedges ("RBH"), to determine whether events or changes in circumstances indicate that an impairment
exists. Additionally, we test goodwill and non-amortizable intangible assets for impairment annually. The values of these assets may be affected by several
factors, including general macroeconomic and geopolitical conditions; regulatory and legal developments; changes in product volume growth rates;
changes in pricing strategies and costs bases; discount rates; success of planned new product expansions; competitive activity; and income and excise taxes.
If an impairment is determined to exist, we will incur impairment losses, which could have a material adverse effect on our results of operations or
financial position. See Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates of
our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for additional information concerning impairment determination and
calculation.
Risks Related to the Impact of the War in Ukraine on our Business
Our business, results of operations, cash flows and financial position may be adversely impacted by the continuation and consequences of the war in
Ukraine.
In 2023, Russia accounted for around 9% of our total cigarette and heated tobacco unit shipment volume, and around 6% of our total net revenues. Ukraine
accounted for around 2% of our total cigarette and heated tobacco unit shipment volume, and around 1% of our total net revenues. Historically, we also
produced finished goods in Ukraine for export and manufactured products in Russia. In 2022, as a result of Russia’s invasion of Ukraine, we suspended
planned investments and scaled down our manufacturing operations in Russia.
The full implications of the Russian invasion of Ukraine for our operations in those countries are impossible to predict at this time. The likelihood of
retaliatory action by the Russian government against companies, including PMI, as a result of actions and statements made in response to the Russian
invasion or otherwise, including the possibility of legal action against us or our employees; the deprivation of rights in, or access to, our Russian assets; or
nationalization of foreign businesses or assets (including cash reserves held in Russia and intangible assets such as trademarks), is impossible to predict.
We are continuously assessing the evolving situation in Russia, including regulatory constraints in the market entailing very complex terms and conditions
that must be met for any divestment transaction to be granted approval by the authorities, and restrictions resulting from international regulations. In the
event of a divestment, our ability to fully realize the value of the business would likely be subject to material impairment. In Ukraine, there is no way to
know when and to what extent we will be able to fully normalize our operations or to what extent our workforce, facilities, inventory, and other assets will
remain intact. These developments have and will continue to have a material adverse impact on our business, results of operations, cash flows and financial
position, and may result in further impairment charges.
87
-- 88 of 140 --
Table of Contents
The conflict also continues to elevate the likelihood of supply chain disruptions, both in the region and globally, and may inhibit our ability to timely source
materials and services needed to make and sell our products. For example, historically we sourced certain finished goods, production materials and
components from both Russia and Ukraine, including printed materials and filters, and the invasion has, and may continue to, disrupt the availability of and
impact our supply chain for these materials. These disruptions, to the extent we are unable to find alternative sources or otherwise address these supply
constraints, may impact the availability and cost of our products in other markets, which would adversely impact our business, results of operations, cash
flows and financial position, and may result in impairment charges. Furthermore, the imposition of various restrictions on transactions with parties from
certain jurisdictions, the ban on exports of various products, and other economic and financial restrictions may adversely affect certain third parties with
which we do business in Russia, such as customers, suppliers, intermediaries, service providers and banks.
The broader consequences of the invasion are also impossible to predict, but could include reputational consequences, further sanctions, financial or
currency restrictions, punitive tax law changes, embargoes, regional instability, and geopolitical shifts as well as adverse effects on macroeconomic
conditions, security conditions, currency exchange rates, and financial markets. Given the nature of our business and global operations, such geo-political
instability and uncertainty could increase the costs of our materials and operations; reduce demand for our products; have a negative impact on our supply
chains, manufacturing capabilities, or distribution capabilities; increase our exposure to currency fluctuations; constrain our liquidity or our ability to access
capital markets; create staffing or operations difficulties; or subject us to increased cyber-attacks. While we will continue to monitor this fluid situation and
develop contingency plans as necessary to address any disruptions to our business operations as they develop, the extent of the conflict’s effect on our
business and results of operations as well as the global economy, cannot be predicted.
The conflict may also heighten many other risks disclosed in this Form 10-Q, any of which could adversely affect our business, results of operations, cash
flows or financial position. Such risks could affect, without limitation, the achievement of our strategic priorities, including achievement of our smoke-free
business growth targets; the availability of third-party manufacturing resources; the availability of attractive acquisition and strategic business opportunities
and our ability to fully realize the benefits of these transactions; our ability to attract, motivate, and retain the best global talent; and our loss of revenue
from counterfeiting and similar illicit activities.
Risks Related to Sourcing and Distribution of Products, Services and Materials
Use of third-parties may negatively impact the distribution, quality, and availability of our products and services, and we may be required to replace third-
party contract distributors, manufacturers or service providers.
We increasingly rely on third-parties and their subcontractors/suppliers, sometimes concentrated in a specific geographic area, for product distribution and
to manufacture some of our products and product parts (particularly, the electronic devices and accessories), as well as to provide services, including to
support our finance, commercialization and information technology processes. While many of these arrangements improve efficiencies and decrease our
operating costs, they also diminish our direct control. Such diminished control may lead to disruption in the distribution of our products and may have a
material adverse effect on the quality and availability of products or services, our supply chain, and the speed and flexibility in our response to changing
market conditions and adult consumer preferences, all of which may place us at a competitive disadvantage. In addition, we may be unable to renew these
agreements on satisfactory terms for numerous reasons, including government regulations, and the distribution of our products may be disrupted in certain
markets or our costs may increase significantly if we must replace such third parties with other partners or our own resources.
The effects of climate change, other environmental issues, and related legal or regulatory responses may have a negative impact on our business and results
of operations.
While we seek to mitigate our business risks associated with environmental issues, such as climate change, by establishing environmental goals and
standards and seeking business partners, including within our supply chain, that are committed to operating in ways that protect the environment or
mitigate environmental impacts, we recognize that there are inherent environmental-related risks, including climate change-related risks, wherever business
is conducted. Among other potential impacts, climate change could influence the quality and volume of the agricultural products we rely on, including
tobacco, due to several factors beyond our control, including more frequent variations in weather patterns, extreme weather events causing unexpected
downtime and inventory losses, other adverse weather conditions, and governmental restrictions on trade, all of which may lead to disruption of operations
at factories, warehouses and other premises.
Furthermore, nature-related risks, including those related to natural ecosystems degradation, decreased agricultural productivity in certain regions of the
world, biodiversity loss, water resource depletion and deforestation, which are partially driven or
88
-- 89 of 140 --
Table of Contents
exacerbated by climate change, may negatively impact the resilience of, or otherwise disrupt, our business operations or those of our suppliers and business
partners.
There is an increased focus by foreign, federal, state and local regulatory and legislative bodies on environmental policies, including those relating to
climate change. New environmental-related legal or regulatory requirements may lead to additional carbon taxation, raw or other materials taxation, energy
price increases, new compliance costs, increased distribution and supply chain costs, and other expenses impacting our cost of operations. Moreover, given
that the regulatory framework in this regard is highly dynamic, additional uncertainties may be driven by further upcoming regulatory changes on which we
might have limited visibility or limited time to implement, which could have an impact on several elements of our business, including elevating the cost or
complexity of our operations. Even if we make changes to align ourselves with legal or regulatory requirements, we may still be subject to significant
penalties if such laws or regulations are interpreted and applied in a manner inconsistent with our practices.
Government mandated prices, production control programs, and shifts in crops driven by economic conditions may increase the cost or reduce the quality
of the tobacco and other agricultural products used to manufacture our products.
As with other agricultural commodities, the price of tobacco leaf and cloves can be influenced by imbalances in supply and demand and the impacts of
natural disasters and pandemics such as COVID-19. Tobacco production in certain countries is subject to a variety of controls, including government
mandated prices and production control programs. Changes in the patterns of demand for agricultural products could cause farmers to produce less tobacco
or cloves. Any significant change in tobacco leaf and clove prices, quality and quantity could affect our profitability and our business.
A prolonged disruption of our production facilities could have a material adverse effect on our business, financial condition and results of operations.
A prolonged disruption at or shut-down of one or more of our production facilities, especially our ZYN production facility in Kentucky, which currently
supplies substantially all of our capacity for ZYN sales in the U.S., due to natural- or man-made disasters or other events outside of our control, such as
equipment malfunction or widespread outbreaks of acute illness, including COVID-19, or for any other reason, could limit our capacity to meet customer
demands. Such an event could disrupt our operations; delay production, shipments and revenue; and result in significant expense to repair or replace our
affected facilities. As a result, we could forgo revenue opportunities and potentially lose market share, which could materially and adversely affect our
business, financial condition and results of operations.
Risks Related to our International Operations
Because we have operations in numerous countries, our results may be adversely impacted by economic, regulatory and political developments, natural
disasters, pandemics or conflicts.
Some of the countries in which we operate face the threat of civil unrest and can be subject to regime changes. In others, nationalization, terrorism, conflict
and the threats of war or acts of war may have a significant impact on the business environment. Factors beyond our control, such as, without limitation,
natural disasters, extreme weather events, pandemics (including COVID-19), economic, political, regulatory, acts of war or threats of war, or other
developments could disrupt or increase the expenses related to our supply chain, manufacturing capabilities, distribution capabilities, or the energy and
other utility services required to operate our factories, warehouses, and other premises. Our business continuity plans and other safeguards might not
always be effective to fully mitigate their impact. For example, the global pandemic outbreak of the COVID-19 virus in 2020 created significant societal
and economic disruption and the closure of stores, factories and offices, restrictions on manufacturing, distribution and travel, and supply chain disruptions,
among other impacts. Such developments – including the impact of geopolitical disruptions resulting from the conflict in the Middle East and the impact on
energy prices and availability in the EU and elsewhere resulting from the invasion of Ukraine by Russia – could cause significant volume declines in our
duty-free business and certain other key markets; disrupt or delay our distribution, manufacturing or supply chain; increase currency volatility; increase
costs of our materials and operations and lead to loss of property or equipment that are critical to our business in certain markets and difficulty in staffing
and managing our operations, all of which could have a material adverse effect on our business, operations, volumes, revenue, cash flows, financial
position, net earnings and profitability. We discuss additional risks associated with Russia's invasion of Ukraine and climate change, above.
In certain markets, we are dependent on governmental approvals of various actions such as price changes, and failure to obtain such approvals could impair
growth of our profitability.
89
-- 90 of 140 --
Table of Contents
In addition, despite our high ethical standards and rigorous controls and compliance policies aimed at preventing and detecting unlawful conduct, given the
breadth and scope of our international operations, we may not be able to detect all potential improper or unlawful conduct by our employees and partners.
Such improper or unlawful conduct (actual or alleged) could lead to litigation and regulatory action, cause damage to our reputation and that of our brands,
and result in substantial costs.
Our reported results could be adversely affected by unfavorable currency exchange rates and currency fluctuations could impair our competitiveness. Our
results could also be adversely affected by capital controls or by foreign currency exchange constraints or devaluations.
We conduct our business primarily in local currency and, for purposes of financial reporting, the local currency results are translated into U.S. dollars based
on average exchange rates prevailing during a reporting period. Foreign currencies may fluctuate significantly against the U.S. dollar, reducing our net
revenues, operating income and EPS. Our primary local currency cost bases may be different from our primary currency revenue markets, and U.S. dollar
fluctuations against various currencies may have disproportionate negative impact on cash flows and on net revenues as compared to our gross profit and
operating income margins.
Capital controls and/or foreign currency exchange constraints may affect the ability of our subsidiaries in impacted jurisdictions to settle foreign currency
denominated imports of goods and services and/or to pay dividends and royalties. These factors may also increase foreign currency devaluation risks,
which may have a negative impact on our net assets and results of operations in these jurisdictions. All of which could have a material adverse effect on our
financial condition, including our leverage ratios, cash flows, net earnings, and profitability.
A sustained period of elevated inflation across the markets in which we operate could result in higher operating and financing costs and lead to reduced
demand for our products.
Increasing inflationary pressures has and may continue to result in significant increases to our expenses, including direct materials, wages, energy, and
transportation costs. While we take actions, wherever possible, to reduce the impact of the effects of inflation, in cases of sustained and elevated inflation
across several of our major markets, it may be difficult to effectively control the increases to our costs. In recent periods, increased inflation has and may
continue to lead to growing pressures on the cost of certain direct materials, wages, energy, transportation, and logistics as well as an increased cost of
capital due to interest rate increases driven by the response to increased inflation. Inflationary pressures may also negatively impact consumer purchasing
power, which could result in reduced demand for our products. We expect certain inflationary elements to ease, with a moderate increase in 2024. If we are
unable to increase our prices sufficiently or take other actions to mitigate the effect of inflationary pressures, our profitability and financial position could
be negatively impacted.
Risks Related to Legal Challenges and Investigations
Litigation related to tobacco products and nicotine products could substantially reduce our profitability and could severely impair our liquidity.
There is litigation related to tobacco products and/or nicotine products pending in certain jurisdictions in which we operate. Damages claimed in some
tobacco-related litigation are significant and, in certain cases in Canada and Nigeria, range into the billions of U.S. dollars. As of March 2024, we also face
litigation related to our oral nicotine products before certain courts in the United States. We anticipate that new cases will continue to be filed. The FCTC
encourages litigation against tobacco product manufacturers. It is possible that our consolidated results of operations, cash flows or financial position could
be materially adversely affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. We face
various administrative and legal challenges related to certain SFP activities, including allegations concerning product classification, advertising restrictions,
corporate communications, product coach activities, scientific substantiation, product liability, antitrust, and unfair competition. While we design our
programs to comply with relevant regulations, we expect these or similar challenges to continue as we expand our efforts to commercialize SFPs and to
communicate with the public. The outcomes of these matters may affect our SFP commercialization and public communication activities and performance
in one or more markets. Also, see Note 8. Contingencies to our consolidated financial statements for a discussion of pending litigation.
From time to time, we are subject to governmental investigations on a range of matters.
Investigations include allegations of contraband shipments of cigarettes, allegations of unlawful pricing activities within certain markets, allegations of
underpayment of income taxes, customs duties and/or excise taxes, allegations of false and misleading usage of descriptors, allegations of unlawful
advertising, and allegations of unlawful labor practices. We cannot predict the outcome of those investigations or whether additional investigations may be
commenced, and it is possible that our business
90
-- 91 of 140 --
Table of Contents
could be materially adversely affected by an unfavorable outcome of pending or future investigations. See Note 8. Contingencies—Other Litigation to our
condensed consolidated financial statements and the “Management's Discussion and Analysis of Financial Condition and Results of Operations—Operating
Results by Business Segment—Business Environment—Governmental Investigations” in this Form 10-Q for a description of certain governmental
investigations to which we are subject.
We may be unable to adequately protect our intellectual property rights, and disputes relating to intellectual property rights could harm our business.
Our intellectual property rights are valuable assets, their protection is important to our business, and that protection may not be equally available in every
country in which we operate or in which our products are sold. If the steps we take to protect our intellectual property rights globally, including through
applying for, prosecuting, maintaining and enforcing, where relevant, a combination of trademark, design, copyright, patent, trade secrets and other
intellectual property rights, are inadequate, or if others infringe or misappropriate our intellectual property rights, notwithstanding legal protection, our
business, financial condition, and results of operations could be adversely impacted. Moreover, failing to manage our existing and/or future intellectual
property may place us at a competitive disadvantage. Intellectual property rights of third parties may limit our ability to develop, manufacture and/or
commercialize our products in one or more markets. Competitors or other third parties may claim that we infringe their intellectual property rights. Any
such claims, regardless of merit, could divert management’s attention, be costly, disruptive, time-consuming and unpredictable and expose us to significant
litigation costs and damages, and may impede our ability to develop, manufacture and/or commercialize new or existing SFPs and improve our products,
and thus have a material adverse effect on our revenue and our profitability. In addition, if, as a result, we are unable to manufacture or sell our SFPs or
improve their quality in one or more markets, our ability to convert adult smokers to our SFPs in such markets would be adversely affected. See Note 8.
Contingencies— Other Litigation to our condensed consolidated financial statements for a description of certain intellectual property proceedings.
Risks Related to our Competitive Environment
We face intense competition, and our failure to compete effectively could have a material adverse effect on our profitability and results of operations.
We are subject to highly competitive conditions in all aspects of our business. We compete primarily on the basis of product quality, brand recognition,
brand loyalty, taste, R&D, innovation, packaging, customer service, marketing, advertising and retail price and, increasingly, adult smoker willingness to
convert to our SFPs. The competitive environment and our competitive position can be significantly influenced by weak economic conditions; erosion of
consumer confidence; competitors' introduction of lower-price products or innovative products; novel products which given their taste characteristics may
be more commercially successful; higher product taxes; higher absolute prices and larger gaps between retail price categories; and product regulation that
diminishes the ability to differentiate tobacco products, restricts adult consumer access to truthful and non-misleading information about our SFPs, or
disproportionately impacts the commercialization of our products in relation to our competitors.
Competitors in our industry include British American Tobacco plc, Japan Tobacco Inc., Imperial Brands plc, new market entrants, particularly with respect
to innovative products, several regional and local tobacco companies and, in some instances, state-owned tobacco enterprises, principally in Algeria, Egypt,
China, Taiwan, Thailand and Vietnam. Some competitors have different profit, volume and regulatory objectives, some international competitors may be
less susceptible than PMI to changes in currency exchange rates, and some competitors may sell products in circumvention of applicable regulations that
compete directly with our products. Certain new market entrants in the non-combustible product category may alienate consumers from innovative
products through inappropriate marketing campaigns, messaging and inferior product satisfaction, and without scientific substantiation based on
appropriate R&D protocols and standards. The growing use of digital media could increase the speed and extent of the dissemination of inaccurate and
misleading information about our SFPs, all of which could have a material adverse effect on our profitability and results of operations. See Item 1, Business
—Competition of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for a description of the competitive environment in which
we operate.
91
-- 92 of 140 --
Table of Contents
We may be unable to anticipate changes in adult consumer preferences.
Our business is subject to changes in adult consumer preferences, which may be influenced by local economic conditions, accessibility to our products and
availability of accurate information related to our products.
To be successful, we must:
• promote brand equity successfully;
• anticipate and respond to new adult consumer trends;
• ensure that our products meet our quality standards;
• develop new products and markets and broaden brand portfolios;
• improve productivity;
• educate and encourage adult smokers to convert to our SFPs;
• ensure effective adult consumer engagement, including communication about product characteristics and usage of SFPs;
• mitigate the impact of developments that cause damage to our reputation and that of our brands;
• provide excellent customer care;
• ensure adequate production capacity to meet demand for our products; and
• be able to protect or enhance margins through price increases.
In periods of economic uncertainty, adult consumers may tend to purchase low-price brands, and the volume of our premium-price and mid-price brands
and our profitability could be materially adversely impacted as a result. Such down-trading trends may be reinforced by regulation that limits branding,
communication and product differentiation. In addition to economic uncertainty (including recessions and inflation) unusual weather events and global or
local epidemics, endemics or pandemics (such as COVID-19) has and may change the preferences of our adult consumers and lower demand for our
products, particularly for our mid-price or premium-price brands.
Our ability to grow profitability may be limited by our inability to introduce new products, enter new markets, maintain sufficient production capacity, or
improve our margins through higher pricing and improvements in our brand and geographic mix.
Our profit growth may be materially adversely impacted if we are unable to introduce new products or enter new markets successfully, to meet the demand
for our products with increased production capacity, to raise prices, or to improve the proportion of our sales of higher margin products and in higher
margin geographies.
We may be unable to expand our brand portfolio through acquisitions or the development of strategic business relationships, and the intended benefits from
our investments may not materialize.
One element of our growth strategy is to expand our brand portfolio and market positions through selective acquisitions and the development of strategic
business relationships. Acquisition and strategic business development opportunities are limited and present risks of failing to achieve efficient and
effective integration, strategic objectives and/or anticipated revenue improvements and cost savings. There is no assurance that we will be able to acquire
attractive businesses or enter into strategic business relationships on favorable terms ahead of our competitors, or that such acquisitions or strategic
business development relationships will be accretive to earnings or improve our competitive position. In addition, we may not have a controlling position in
certain strategic investments or relationships, which could impact the extent to which the intended financial growth and other benefits from these
investments or relationships may ultimately materialize.
Our ability to achieve our strategic goals may be impaired if we fail to attract, motivate and retain the best global talent and effectively align our
organizational design with the goals of our transformation.
To be successful, we must continue transforming our culture and ways of working, align our talent and organizational design with our increasingly complex
business needs, and innovate and transform to a consumer-centric business. We compete for talent, including in areas that are relatively new to us such as
digital, information technology, and life sciences, with companies in the consumer products, technology, pharmaceutical and other sectors that enjoy greater
societal acceptance. As a result, we may be unable to attract, motivate and retain the best global talent with the right degree of diversity, experience and
skills to achieve our strategic goals.
92
-- 93 of 140 --
Table of Contents
Risks Related to Illicit Trade
We lose revenues as a result of counterfeiting, contraband, cross-border purchases, "illicit whites," non-tax-paid volume produced by local manufacturers,
and counterfeiting of our smoke-free products' devices and consumables.
Large quantities of counterfeit cigarettes are sold in the international market. We believe that Marlboro is the most heavily counterfeited international
cigarette brand, although we cannot quantify the revenues we lose as a result of this activity. In addition, our revenues are reduced by contraband, cross-
border purchases, "illicit whites" and non-tax-paid volume produced by local manufacturers. Our revenues and consumer satisfaction with our smoke-free
products' devices and consumables may be materially adversely affected by counterfeit products that do not meet our product quality standards and
scientific validation procedures.
Risks Related to Cybersecurity and Data Governance
We are significantly dependent on our and third-party information technology networks and systems, and a cybersecurity incident or attack against those
networks or systems may adversely impact our business and operations.
We and our business partners heavily rely on information technology networks and systems, including those connected to the Internet, to help manage
business processes and operations, including the collection, storage, interpretation, and processing of confidential, sensitive, personal and other data;
internal and external communications; marketing and e-commerce activities; the manufacture, sale, and distribution of our products; management of third-
party business relationships; engagement with governmental authorities; innovation through research and development; and other activities necessary for
business operations. Some of these information systems and networks are developed, supplied, or managed by third-party service providers that may make
us vulnerable to “supply chain” style cyberattacks. The failure or disruption of our information technology networks and systems, or those managed by
third-party service providers or owned by our business partners and used in furtherance of PMI’s business, due to cybersecurity attacks; unauthorized
attempts to corrupt or extract data; security vulnerabilities; misconfigurations; human error; or failure or inability by us, third-parties, or our business
partners to adhere to cybersecurity industry best practices, could place us at a competitive disadvantage, cause reputational damage, impact our operations,
result in data breaches, significant business disruption, litigation, regulatory action including significant fines or penalties, financial impact, loss of revenue
or assets including our intellectual property, personal, confidential, or sensitive data.
Cyberattacks, security incidents and vulnerabilities impacting PMI, newly acquired companies, our business partners, or our third-party providers, continue
to dynamically evolve in sophistication and volume, making it difficult for us to predict probability, frequency, and impact severity of security incidents.
Further, it may be inherently difficult to detect vulnerabilities during due diligence, for long periods of time, or soon enough to mitigate exploitation. There
can be no assurance that such security incidents or vulnerabilities will not have a material adverse effect on us in the future. While PMI works to mitigate
these risks by implementing a cybersecurity risk program and a third-party cybersecurity risk management program, there can be no assurance that these
programs are comprehensive or accurately identify and sufficiently mitigate all cybersecurity risks.
We continue to make investments in administrative, technical, and physical safeguards to maintain information security protections in line with industry
standards and best practices. We evaluate the adequacy of preventative actions to reduce security incidents on an ongoing basis.
Our safeguards may not, however, be effective in mitigating the impact of service disruptions or other failures of these information technology networks
and systems. Failure to timely respond and mitigate security incidents, could result in wide-ranging business interruptions. Such security incidents could
place us at a competitive disadvantage; result in financial impacts, a loss of revenue, assets, including our intellectual property, personal or other sensitive
data; result in litigation and regulatory action including significant fines or penalties; impact our operations; cause damage to our reputation and that of our
brands; and result in significant remediation and other costs. See Item 1C. Cybersecurity of our Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 for a description of our cybersecurity risk management and strategy and governance.
Our or our business partners’ failure or inability to adhere to privacy, data, artificial intelligence and information security laws could result in business
disruption, loss of reputation and consumer trust, litigation, regulatory action including significant fines or penalties, financial impact, and loss of revenue,
assets or personal, confidential, or sensitive data.
An actual or alleged failure to comply with complex and changing privacy, data, artificial intelligence and information security laws and regulations under
the EU General Data Protection Regulation, various U.S. state and federal laws, and other similar privacy and information security laws across the
jurisdictions in which PMI operates, such as the failure to protect personal
93
-- 94 of 140 --
Table of Contents
data; implement appropriate technological and reasonable security measures; implement and maintain appropriate safeguards for personal data being
transferred internationally; respect the privacy rights of data subjects; provide sufficient detailed notices of personal data processing; retrieve consent and
provide opt-outs; meet stringent timeframe requirements for incident reporting to regulatory authorities; comply with artificial intelligence regulations; and
others, could have a material adverse effect on us, subject us to substantial fines and/or legal challenges, and/or harm our business, reputation, financial
condition, or operating results. Such laws and regulations across the jurisdictions in which PMI operates may vary, resulting in inconsistent or conflicting
legal obligations.
Risks Related to Swedish Match and Vectura Fertin Pharma
We may be unable to fully realize the expected benefits from the acquisitions of Swedish Match or Vectura Fertin Pharma.
Since 2021, we have acquired Swedish Match, OtiTopic, Fertin Pharma and Vectura (collectively, the "Acquisitions"), and subsequently launched Vectura
Fertin Pharma, our new Wellness and Healthcare business, consolidating OtiTopic, Fertin Pharma and Vectura. The anticipated benefits of the Acquisitions
may not be realized fully, or at all, or may take longer to realize than expected. Furthermore, the success of the Acquisitions also depends on the continued
successful commercialization and growth of Swedish Match's products in highly competitive markets and on the success of the research and development
efforts of Vectura Fertin Pharma, including the ability to obtain regulatory approval for new products, and the ability to commercialize or license these new
products developed by them. Moreover, our combustible product portfolio may stand in the way of introducing and growing new Wellness and Healthcare
product categories and may prevent our business from developing a long-term sustainable ecosystem of products in the wellness, therapeutic, and
healthcare categories.
Swedish Match and Vectura Fertin Pharma may have liabilities that are not known to us.
The businesses that we have acquired may have liabilities that we were unable to identify, or were unable to discover, in the course of performing our due
diligence investigations during the acquisitions thereof. There is no assurance that the indemnification available to us under the respective acquisition
agreements, will be sufficient in amount, scope or duration to fully offset the possible liabilities associated with the respective business or property that we
assumed upon consummation of each Acquisition. Furthermore, the acquisition of Swedish Match was structured as a direct purchase of shares from
Swedish Match shareholders and therefore did not include an acquisition agreement or indemnification rights. Any such liabilities, individually or in the
aggregate, could have a material adverse effect on our business, financial condition and results of operations.
Accounting adjustments related to the Acquisitions could adversely affect our financial results.
We accounted for the completion of the Acquisitions using the acquisition method of accounting. Given the nature of the assets acquired in the
Acquisitions, we may not be able to avoid future impairments of those assets, which may also have a material impact on our future results of operation and
financial position.
PMI, Swedish Match and Vectura Fertin Pharma may be subject to uncertainties that could adversely affect our respective businesses, and adversely affect
the financial results of our combined businesses.
Our success following these Acquisitions depends in part upon our ability and the ability of each of Swedish Match and Vectura Fertin Pharma to maintain
business relationships. The effect of the Acquisitions on customers, suppliers, employees and other constituencies of each of Swedish Match, Fertin Pharma
and Vectura, may have a material adverse effect on us and/or the businesses that we have acquired through the Acquisitions. Customers, suppliers and
others who do business with Swedish Match or Vectura Fertin Pharma may delay or defer business decisions, decide to terminate, modify or renegotiate
their relationships, or take other actions, which could negatively affect the revenues, earnings and cash flows of our company or the businesses that we
have acquired. Regulatory changes may have an impact on the development and/or commercialization of products which originate from the Swedish Match
or Vectura Fertin Pharma value chains, as well as our revenues, earnings and cash flow. If we are unable to maintain the business and operational
relationships of Swedish Match, or of Vectura Fertin Pharma, our financial position, results of operations or cash flows upon combining with these
companies could be adversely affected.
94
-- 95 of 140 --
Table of Contents
Item 4. Controls and Procedures.
PMI carried out an evaluation, with the participation of PMI’s management, including PMI’s Chief Executive Officer and Chief Financial Officer, of the
effectiveness of PMI’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the
end of the period covered by this report. Based upon that evaluation, PMI’s Chief Executive Officer and Chief Financial Officer concluded that PMI’s
disclosure controls and procedures are effective. There have been no changes in PMI’s internal control over financial reporting during the most recent fiscal
quarter that have materially affected, or are reasonably likely to materially affect, PMI’s internal control over financial reporting.
95
-- 96 of 140 --
Table of Contents
Part II - OTHER INFORMATION
Item 1. Legal Proceedings.
See Note 8. Contingencies of the Notes to the Condensed Consolidated Financial Statements included in Part I – Item 1 of this report for a discussion of
legal proceedings pending against Philip Morris International Inc. and its subsidiaries.
Item 1A. Risk Factors.
Information regarding Risk Factors appears in “MD&A – Cautionary Factors That May Affect Future Results,” in Part I – Item 2 of this Form 10-Q and in
Part I – Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2023.
96
-- 97 of 140 --
Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Our share repurchase activity for each of the three months in the quarter ended March 31, 2024, was as follows:
Period
Total Number
of Shares
Repurchased
Average
Price Paid
Per Share
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
Approximate Dollar
Value of Shares that
May Yet be Purchased
Under the Plans or
Programs
January 1, 2024 –
January 31, 2024 (1) — $ — 10,481,359 $ 6,016,847,275
February 1, 2024 –
February 29, 2024 (1) — $ — 10,481,359 $ 6,016,847,275
March 1, 2024 –
March 31, 2024 (1) — $ — 10,481,359 $ 6,016,847,275
Pursuant to Publicly
Announced Plans
or Programs — $ —
January 1, 2024 –
January 31, 2024 (2) 10,122 $ 94.05
February 1, 2024 –
February 29, 2024 (2) 314,962 $ 90.07
March 1, 2024 –
March 31, 2024 (2) 2,307 $ 90.99
For the Quarter Ended March
31, 2024 327,391 $ 90.20
(1) On June 11, 2021, our Board of Directors authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7
billion over a three-year period that commenced in July 2021. These share repurchases have been made pursuant to the $7 billion program. On May 11,
2022, we announced the suspension of our three-year share repurchase program following the recommended public offer to acquire the outstanding
shares of Swedish Match from its shareholders.
(2) Shares repurchased represent shares tendered to us by employees who vested in restricted and performance share unit awards and used shares to pay
all, or a portion of, the related taxes.
97
-- 98 of 140 --
Table of Contents
Item 5. Other Information.
During the three months ended March 31, 2024, no director or officer of PMI adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” as such terms are defined in Item 408(a) of Regulation S-K.
98
-- 99 of 140 --
Table of Contents
Item 6. Exhibits.
10.1 Form of Restricted Stock Unit Agreement (2024 Grants) (incorporated by reference to Exhibit 10.91 to the Annual
Report on Form 10-K For the year ended December 31, 2023).
10.2 Form of Performance Share Unit Agreement (2024 Grants) (incorporated by reference to Exhibit 10.92 to the Annual
Report on Form 10-K For the year ended December 31, 2023).
10.3 Form of Restricted Stock Unit Agreement (by tranches) (2024 Grants) (incorporated by reference to Exhibit 10.93 to the
Annual Report on Form 10-K For the year ended December 31, 2023).
10.4 Form of Restricted Stock Unit Agreement (2024 Grant) (Emmanuel Babeau) (incorporated by reference to Exhibit 10.94
to the Annual Report on Form 10-K For the year ended December 31, 2023).
10.5 Form of Performance Share Unit Agreement (2024 Grant) (Emmanuel Babeau) (incorporated by reference to Exhibit
10.95 to the Annual Report on Form 10-K For the year ended December 31, 2023).
10.6 Form of Restricted Stock Unit Agreement (2024 Grant) (Swedish Match) (incorporated by reference to Exhibit 10.96 to
the Annual Report on Form 10-K For the year ended December 31, 2023).
10.7 Form of Performance Share Unit Agreement (2024 Grant) (Swedish Match) (incorporated by reference to Exhibit 10.97
to the Annual Report on Form 10-K For the year ended December 31, 2023).
10.8 Extension Agreement, dated as of January 24, 2024 among PMI, the lenders named therein, and Citibank Europe plc,
UK Branch (legal successor to Citibank International Limited), as administrative agent (incorporated by reference to
Exhibit 10.1 to the Current Report on Form 8-K filed January 24, 2024).
10.9 Settlement Agreement between Philip Morris Products S.A. and Nicoventures Trading Limited, dated February 1, 2024
(incorporated by reference to Exhibit 10.98 to the Annual Report on Form 10-K For the year ended December 31,
2023).*
10.10 Supplemental Letter to the Employment Agreement with Emmanuel Babeau, effective February 1, 2024.
10.11 Employment Agreement with Stacey Kennedy, effective July 1, 2023.
10.12 Supplemental Letter to the Employment Agreement with Stacey Kennedy, effective July 1, 2023.
10.13 Supplemental Letter to the Employment Agreement with Stacey Kennedy, dated March 21, 2024.
10.14 Philip Morris International Inc. Form of Indemnification Agreement with Directors and Executive Officers.
31.1 Certification of the Registrant's Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities
Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of the Registrant's Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange
Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of the Registrant's Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
32.2 Certification of the Registrant's Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002.
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags
are embedded within the Inline XBRL document.
101.SCH XBRL Taxonomy Extension Schema.
101.CAL XBRL Taxonomy Extension Calculation Linkbase.
101.DEF XBRL Taxonomy Extension Definition Linkbase.
101.LAB XBRL Taxonomy Extension Label Linkbase.
101.PRE XBRL Taxonomy Extension Presentation Linkbase.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Schedules and certain portions of this exhibit have been omitted pursuant to Item 601(a)(5) and Item 601(b)(10)(iv) of Regulation S-K.
99
-- 100 of 140 --
Table of Contents
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHILIP MORRIS INTERNATIONAL INC.
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
April 26, 2024
100
-- 101 of 140 --
Exhibit 10.10
PERSONAL AND CONFIDENTIAL
To: Mr. Emmanuel Babeau
Lausanne, January 23, 2024
Dear Emmanuel,
We are pleased to confirm that effective February 1, 2024, your base salary will be increased to
CHF 1’260’012.-- annually, CHF 96’924.-- monthly. This represents a 5% increase and the comparatio at your current
grade 26 will be 122%.
All other conditions relating to your employment with Philip Morris Products S.A. remain as stated in your
employment contract and in any subsequent amendments.
Yours sincerely,
PHILIP MORRIS PRODUCTS S.A.
/s/ CONSTANTIN ROMANOV /s/ RALF ZYSK
Constantin Romanov
Vice President Total Rewards
Ralf Zysk
Vice President Labor Relations
Philip Morris Products S.A., Avenue de Rhodanie 50, 1007 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 102 of 140 --
Exhibit 10.11
CONFIDENTIAL
Ms. Stacey Kennedy Lausanne, June 12, 2023
Dear Stacey,
This le er confirms the terms and condi ons of your employment effec ve as of the date of issue of your work permit or July 1 , 2023,
whichever is the later (the “Effec ve Date”) with Philip Morris Services S.A. (“the Company”).
Compensa on
Your gross annual base salary will be Swiss Francs (CHF) 750,000.-- corresponding to your grade, which is 24. Your base salary will be paid
in twelve (12) equal monthly installments.
As explained in the PMI Global Long Term Assignment Guidelines – Strategic (“Global Guidelines”), when working for the Company on an
assignment outside Switzerland, your compensa on is adjusted in several ways to enable you to maintain a standard of living in the host
loca on which is reasonably comparable to that in your Home Country, allowing for the costs (personal income taxes, social security
contribu ons, par cipa on in other mandatory state schemes, and Home Country contributory benefit schemes and housing and
u li es) for which you would normally be responsible while working in your Home Country. Your Home Country, for the purpose of your
remunera on package, shall be deemed to be Switzerland. Your point of origin for the purposes of home leave will be deemed as
Geneva, Switzerland.
Your assignment package will be calculated in accordance with the Global Guidelines and is no fied to you separately. The assignment
package is reviewed on an ongoing basis in accordance with the provisions of the Global Guidelines.
Incen ve Compensa on Award Program
As a grade 24 employee, you will be eligible to par cipate in the Incen ve Compensa on (“IC”) Award Program, which is administered at
the sole discre on of the Compensa on and Leadership Development Commi ee of the Board of Directors pursuant and subject to the
terms of the 2022 Performance Incen ve Plan (or any similar plan adopted from me to me). Each eligible employee has an annual IC
award target that assumes a PMI company performance ra ng of 100 and target individual performance level.
As a grade 24 employee, for 2023 your target is 100% of your annual base salary. Targets are reviewed annually and are made available
to employees under the PMI 23-G4 Guidelines Global Variable Compensa on Programs Annex 1.
st
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 103 of 140 --
Stock Award Program
As a grade 24 employee, you will be eligible to par cipate in the Stock Award Program, which is administered at the sole discre on of
the Compensa on and Leadership Development Commi ee of the Board of Directors pursuant and subject to the terms of the 2022
Performance Incen ve Plan (or any similar plan adopted from me to me). Each eligible employee has an annual stock award target
that assumes a target individual performance level.
As a grade 24 employee, for 2023 your target is 160% of your annual base salary. Targets are reviewed annually and are made available
to employees under the PMI 23-G4 Guidelines Global Variable Compensa on Programs Annex 2.
The Incen ve Compensa on and Stock Award Programs are discre onary and do not obligate the Company to make an award nor en tle
employees to receive an award. Eligibility to par cipate in the Programs does not guarantee receipt of an award and receiving an annual
award does not guarantee receipt of an award in the future. Any awards that are made may be higher or lower than the targets
men oned above. Targets may be amended at the discre on of the Company at any me without prior no ce.
Fidelity Premium
For each completed year of service, the Company pays a cumula ve bonus of CHF 150.-- on each anniversary of the Effec ve Date, up to
a maximum of CHF 3'000.-- for 20 years of service.
Pension Fund
In accordance with the Swiss Federal Pension Law (“LPP”), you will remain a member of the “Caisse de pension Philip Morris en Suisse”
(the “Pension Fund”), providing old age, disability, and survivor’s benefits. For further details, please refer to the Pension Fund
regula ons.
Your contribu on to the Pension Fund will be deducted each month from your salary according to the current Pension Fund regula ons.
Other Benefits
For the purpose of benefits which are linked to seniority in the Company, but with the excep on of Pension Fund affilia on, your ini al
entry date into Philip Morris Interna onal Inc. or its subsidiaries will be taken into account, i.e. January 1 , 2011.
Accident Insurance
In accordance with Swiss law (LAA) employees are automa cally covered for accident in the event of occupa onal or non-occupa onal
accidents. This cover is paid for by the Company.
st
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 2
-- 104 of 140 --
Health Insurance
You will join the Company group health insurance contract. Employees and their eligible dependents (spouse and dependent unmarried
children up to age 25 if in full- me educa on) are enrolled into this group health insurance scheme. Global Mobility Team will provide
you full details of the coverage.
Salary Con nua on in the Event of Sickness
Subject to the regula ons of the Company’s insurer, 100% of the annual base salary is paid for up to 2 years from the first day you are
unable to work. This cover is paid for by the Company.
Life Insurance
In accordance with the regula ons of the Company’s insurer and, where applicable, in coordina on with the Pension Fund, you are
provided with an insurance cover in case of death and permanent disability paid for by the Company.
Vaca on
You will be en tled to the number of vaca on days in accordance with the Global Guidelines.
Your en tlement to public holidays will be in accordance with local office prac ce.
Privacy Policy and Data Protec on
These provisions complement the provisions on data protec on in the Company’s Employee Privacy Statement.
The Company will, in the course of its business, process (which includes collec ng, storing, using and transferring):
(a) personal data rela ng to you (for example, personnel details, bank account informa on, automated records of your use of
informa on systems, or informa on required for building access control systems);
(b) personal data that you provide to the Company rela ng to other persons (“Your Contacts”) such as your partner or other family
members (for example contact details or informa on in connec on with employee benefits); and
(c) sensi ve personal data rela ng to you or Your Contacts where this is necessary for the administra on of your employment
rela onship and is permi ed by law (for example, health data required to administer health benefits).
Together, all the data men oned above is referred to as “Personal Data”.
You give your consent to the Company to:
(a) process the Personal Data for its, and its Affiliates’, business purposes. Those purposes include legal, personnel, administra ve
and management purposes (including, for example, payroll
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 3
-- 105 of 140 --
administra on, correspondence, IT systems development, opera on and maintenance, building access controls, performance
review, and talent management);
(b) make the Personal Data available to its Affiliates for them to process for their own benefit for the same purposes as described
above;
(c) make the Personal Data available, and to permit the Company’s Affiliates to make Personal Data available, to third par es who
provide products or services to the Company or its Affiliates (such as advisers, payroll administrators, and informa on services
providers) or where required or permi ed by law (such as regulatory authori es; poten al or future employers; and
governmental or quasi-governmental organisa ons); and
(d) transfer the Personal Data either within or outside the country in which you are employed, including where the country or
territory in ques on does not maintain data protec on standards that are equivalent to those of that country.
You confirm that, before providing us with personal data of Your Contacts, you will obtain their consent to the processing of their
personal data as described above. You or Your Contacts may request access to, or the correc on or dele on of, the Personal Data that
we hold, by contac ng your People & Culture Department.
Proprietary Informa on and Innova ons Agreement
Your appointment is subject to your execu ng with the Company the Employee Proprietary Informa on and Innova ons Agreement
a ached as Annexure 1.
Du es of the Employee
You shall complete your tasks and promote the affairs of the Company diligently and carefully, and shall safeguard the interests of the
Company. You have to exercise your responsibili es, func ons, du es and powers in compliance with applicable laws and regula ons
and with the strategies and guidelines of the Company, and will comply with the codes, principles, prac ces and procedures that are
applicable within the Company, as issued or amended during the employment rela onship.
Expatriate Status
In accep ng the terms and condi ons of employment contained herein, you acknowledge that you have accepted an assignment to
work outside Switzerland for an affiliate of the Company or an en ty that does business with the Company. The terms of the assignment
are set out in a separate le er. You acknowledge that your benefits and en tlements as an expatriate are determined in accordance with
the Global Guidelines. Even if you s ll have a contract of employment with a Philip Morris Interna onal affiliate in your Home Country,
you will not be eligible for any duplica on of benefits and en tlements except as specified in this agreement. You acknowledge that you
may also be requested in the future to accept other such assignments outside Switzerland.
You also acknowledge that repatria on will, or any future assignment may entail the termina on of this contract.
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 4
-- 106 of 140 --
Company Property
Upon termina on of your employment, you should return to the Company and/or its affiliates all paper and electronic files and
documents, tapes, CD’s, and copies thereof and other items belonging to the Company and its affiliates, irrespec ve of their source and
origin, including, if any, Company corporate cards, telephone, telephone cards, keys, access and iden fica on cards, computers,
blackberry, car, and, if requested, will cer fy that this has been done to the best of your belief and that you also comply with all
Company Records & Informa on Management (RIM) policies, procedures, and guidelines before your departure.
The se lement of any outstanding expenses due to the Company, including, but not limited to any outstanding balance on the account
of the corporate card issued in your name will be set-off with any payable sums.
Termina on of Employment
This contract shall be terminable in accordance with Swiss law. Each party may terminate the agreement for the end of a month by
giving one month no ce within the first year of employment, two months no ce from the second to ninth year of employment or three
months no ce as of the tenth year of employment.
Miscellaneous
This le er, when countersigned by you, will represent the complete agreement between you and the Company concerning its subject
ma er and will supersede and replace any previous agreements or understandings between you and the Company or any of its affiliates.
This agreement may not be modified or waived in any respect except in a wri en document duly signed by you and the Company.
This agreement will be governed by and construed in accordance with Swiss law.
Please return one copy of this le er duly signed for agreement.
Yours sincerely,
PHILIP MORRIS SERVICES S.A.
/s/ CONSTANTIN ROMANOV
Constan n Romanov
Vice President Total Rewards
/s/ RALF ZYSK
Ralf Zysk
Vice President Labour Rela ons
Acknowledged and agreed:
/s/ STACEY KENNEDY
Stacey Kennedy Date: 22 June 2023
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 5
-- 107 of 140 --
ANNEXURE 1
Employee Proprietary Informa on and Innova ons Agreement
This Employee Proprietary Informa on and Innova ons Agreement (“Agreement”) sets forth in wri ng certain understandings and
procedures applicable to the employment of Mr. Frederic de Wilde (the “Employee”) with the undersigned en ty (the “Company”) and
these understandings and procedures apply from the date of the Employee’s ini al employment with the Company (“Employment
Date”) even if this Agreement is signed by the Employee and the Company a er the Employment Date.
1. Du es. In return for the compensa on and benefits now and herea er paid or provided to the Employee, Employee hereby
agrees to perform those du es for the Company as the Company may designate from me to me. During the Employee’s
employment with the Company, the Employee further agrees that the Employee will (i) devote the Employee’s best efforts to the
interests of the Company, and (ii) not engage in other employment or in any conduct that could either be in direct conflict with
the Company’s interests or that could cause a material and substan al disrup on to the Company and (iii) otherwise abide by all
of the Company’s policies and procedures as they may be established and updated from me to me.
2. Confiden ality.
a. The Employee is engaged in a posi on of trust and confidence in which the Employee may, from me to me, use,
observe, obtain, be provided with, have access to, or develop (alone and/or with others) Confiden al Informa on of the
Company and/or the Company’s parent corpora ons, subsidiaries, holding companies or affiliates (the “Group
Companies”) (and confiden al informa on of partners, collaborators or customers of any of the Group Companies (the
“Third-Party En es”) that has been provided to the Group Companies by or on behalf of the Third-Party En es).
b. The term “Confiden al Informa on” for purposes of this Agreement means and includes any informa on (including
without limita on any formula, pa ern, device, plan, process, or compila on of informa on) in any medium including
wri en or electronic which: (i) is or is designed to be analyzed by, or used, in the business of the Company and/or the
Group Companies or results from the research and development ac vi es of the Company and/or the Group Companies
and/or is provided to any of the Group Companies by any Third-Party En es; or (ii) is private and confiden al in that it is
not known to the public, including but not necessarily limited to business affairs, plans, organiza onal structure, research
and development, product formulas, components and ingredients, product delivery systems, product packaging and
labeling design, product func oning, product health and/or safety informa on, manufacturing systems and informa on,
iden ty of vendors and/or suppliers, trade secrets, financial data, personnel, legal strategies, business strategies, tes ng
systems, protocols, equipment and analyses, safety data and
The Employee should refer to this Agreement’s appendices for specific requirements pertaining to the Employee’s jurisdic on of
employment, if any. Such appendices shall be incorporated into this Agreement and shall have the same force and effect as this
Agreement.
1
1
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 6
-- 108 of 140 --
analyses, unpublished clinical trial informa on, data, endpoints, outcomes and analyses, and informa on services
including retrieval services, etc. (collec vely, the "business affairs, plans, etc."), and further including but not necessarily
limited to dra s and excepts and summaries of any of the foregoing, as well as business affairs, plans, etc. of the Company
that are historical in nature or that for any reason are no longer are being used or pursued or that for any reason are not
used or pursued by the Company. If the Employee is unsure as to whether any par cular ma er, document or informa on
is confiden al, the Employee should ask the Employee’s immediate manager or the Law Department for guidance.
c. The Employee shall not, whether before, during or a er the Employee’s employment with the Company, use for the
Employee’s own benefit, disclose to or use for the benefit of any other person, firm or corpora on, any Confiden al
Informa on. This expressly includes Confiden al Informa on that the Employee may receive or have access to before the
beginning of the Employee’s Employment Date. Notwithstanding the above, such restric ons concerning the disclosure
of Confiden al Informa on do not apply to the following:
i. Disclosures that are required by law and/or compelled by a valid court order or subpoena, or to informa on that
is provided in good faith to a governmental enforcement agency when such disclosure is directly related to and
necessary for the furtherance of the agency’s inves ga on. If disclosure of Confiden al Informa on is sought by
court order or subpoena, Employee shall provide prompt wri en no ce to the Company and agree to reasonably
cooperate with the Company in seeking a protec ve order or other appropriate relief from the court order or
subpoena. The no ce required to be disclosed in this sec on shall be sent to the Company’s Legal Department,
A en on: Intellectual Property, at the address listed at the end of this Agreement or to another address the
Company may, from me to me, specify in wri ng.
ii.Addi onally, the restric ons in this Confiden ality Agreement do not restrict the Employee from discussing or
disclosing the Employee’s wages and/or terms and condi ons of employment (as long as the condi on of
employment is not itself a trade secret or proprietary informa on of the Company or subject to a legal privilege).
iii. Nothing in this Agreement or any Company policy limits the Employee (with or without prior no ce to
the Company) from raising in good faith or par cipa ng in an inves ga on regarding any poten al viola on of
law or regula on with any applicable governmental or regulatory agency. Further, this Agreement does not
prevent the Employee from making other disclosures protected by law under the whistleblower provisions of any
local, state, or federal statutes or regula ons of the Employee’s state or jurisdic on of employment. However,
the Employee agrees that any disclosure of Confiden al Informa on made in these circumstances will be limited
to Confiden al Informa on that is reasonably related to the alleged viola on and/or specifically requested by the
inves ga ng agency.
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 7
-- 109 of 140 --
d. No change in the Employee’s compensa on or other terms of employment will affect the terms of this Agreement.
e. All paper, digital and electronic memoranda, notes, records, reports, photographs, drawings, plans, papers, data,
computer programs, hard drives, data devices, storage media and/or devices, or other documents or media made or
compiled by or made available to the Employee during the course of employment, and any copies or abstracts thereof,
whether or not they contain Confiden al Informa on, are and shall be the property of the Company and shall be
delivered to the Company by the Employee immediately upon termina on of employment regardless of the reason for
the termina on. The above is not intended to be necessarily inclusive and shall include any records whether in wri ng,
electronically or mechanically created, etc.
f. The Employee understands and acknowledges that use or disclosure of Confiden al Informa on in viola on of this
Agreement would result in immediate and irreparable harm to the Company and its compe ve posi on. The Employee
thus acknowledges and agrees that the Company is en tled to seek the entry of a restraining order, preliminary
injunc on or other preliminary, provisional or permanent court order to enforce this Agreement and, to the extent
permi ed by applicable law, the Employee expressly waives any security that might otherwise be required in connec on
with such relief. The Employee also agrees that any request for such relief by the Company shall be in addi on and
without any prejudice to any claim for monetary damages, costs, and other appropriate relief which the Company might
elect to assert. In the event the Employee violates any provision of this Agreement, the Company shall be en tled to
recover all costs and expense of enforcement, including reasonable a orney’s fees.
g. At the termina on of employment, or at any me upon the wri en request of the Company, the Employee agrees to
promptly return all of the Company and the Group Companies’ property, including without limita on, Confiden al
Informa on, and agrees that the Employee will conduct a diligent search and inquiry to locate all originals and all copies
of any business records and property of the Company or the Group Companies which are or were subject to the
Employee’s custody or control, regardless of the sources from which such records were obtained; that the Employee will
return all such documents or property, if any, to the Company; and, that the Employee will cer fy to the Company that to
the best of the Employee’s knowledge and belief all such documents and property have been returned.
h. During the Employee’s employment with the Company, the Employee will not (a) breach any agreement to keep in
confidence any confiden al or proprietary informa on, knowledge or data acquired by the Employee prior to the
Employee’s employment with the Company or (b) disclose to the Company, or use or induce the Company to use, any
confiden al or proprietary informa on or material belonging to any previous employer or any other third party. The
Employee is not currently a party, and will not become a party, to any other agreement that is in conflict, or will prevent
the Employee from complying, with this Agreement.
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 8
-- 110 of 140 --
3. Intellectual Property.
a. Innova ons. In this Agreement, “Innova ons” means all discoveries, designs, developments, improvements, inven ons
(whether or not protectable under patent laws), works of authorship (including, without limita on, computer programs
and drawings, whether manual or electronic), informa on fixed in any tangible medium of expression (whether or not
protectable under copyright laws), findings, conclusions, data, concepts, techniques, formulae, processes, trade secrets,
know-how, ideas (whether or not protectable under trade secret laws), mask works, trademarks, service marks, trade
names and trade dress.
b. Disclosure and License of Prior Innova ons. The Employee has listed on A achment 1 a ached hereto all Innova ons
that were conceived, reduced to prac ce, created, derived, developed, or made by the Employee alone or jointly with
others (or were acquired in whole or in part by the Employee) prior to the Employee’s Employment Date and to which
the Employee retains any ownership rights, interest or control (collec vely referred to as the “Prior Innova ons”). The
Employee represents that the Employee has no rights in any Innova ons other than those Prior Innova ons listed in
A achment 1. If nothing is listed on A achment 1, the Employee represents that there are no Prior Innova ons as of the
Employee’s Employment Date. The Employee hereby grants to the Company and the Company’s designees a royalty-free,
transferable, assignable, irrevocable, worldwide, fully paid-up license (with rights to sublicense through mul ple ers of
sublicensees) to fully use, prac ce and exploit all patent, copyright, moral right, mask work, trade secret and other
intellectual property rights of any sort rela ng to any Innova ons owned by the Employee or in which the Employee has
any other right or interest or control that the Employee – with our without consent of the Company – u lizes or
incorporates, or permits to be u lized or incorporated, in any Innova ons that the Employee, solely or jointly with
others, creates, derives, conceives, develops, makes or reduces to prac ce within the scope of the Employee’s
employment with the Company or with the use of any Company resources, facili es, equipment, or informa on
(including without limita on the Company’s Confiden al Informa on) (the “Company Innova ons”). Notwithstanding
the foregoing, the Employee will not incorporate, or permit to be incorporated, any Innova ons that the Employee owns
or in which the Employee has any other right or interest, in any Company Innova ons without the prior wri en consent
of an officer of the Company.
c. Assignment of the Company Innova ons. The Employee will promptly disclose and fully describe to the Company all
Company Innova ons. To the fullest extent permi ed by law, the Employee hereby does and will irrevocably assign to
the Company or the Company’s designee all of the Employee’s rights, tle, and interest in and to any and all Company
Innova ons, which assignment operates automa cally upon the earliest of the crea on of the Company Innova ons. To
the extent any of the rights, tle and interest in and to the Company Innova ons cannot be assigned by the Employee to
the Company or do not otherwise vest in the Company, the Employee hereby grants to the Company an exclusive,
royalty-free, transferable, assignable, irrevocable, worldwide, fully paid-up license (with rights to sublicense through
mul ple ers of sublicensees) to fully use, prac ce and exploit those non-assignable rights, tle and interest, including,
but not limited to, the right to
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 9
-- 111 of 140 --
make, use, sell, offer for sale, import, have made, and have sold, the Company Innova ons. To the extent any of the
rights, tle and interest in and to the Company Innova ons can neither be assigned nor licensed by the Employee to the
Company (including non-assignable moral rights) and do not otherwise vest in the Company, the Employee hereby
irrevocably waives and agrees never to assert the non-assignable and non-licensable rights, tle and interest against the
Company, any of the Company’s successors in interest, or any of the Company’s customers.
d. Reserva on of Rights to Occasional Innova ons. The Company reserves the right to acquire all Innova ons that the
Employee solely or jointly with others, creates, derives, conceives, develops, makes or reduces to prac ce in the course
of Employee’s work for the Company, but not in performance of the Employee’s contractual obliga ons (“Occasional
Innova ons”). The Employee shall no fy the Company immediately of Occasional Innova ons and the Company shall
inform Employee within six months whether the Company wishes to acquire the Occasional Innova on. The special
remunera on pursuant to Art. 332(4) of the Swiss Code of Obliga ons is reserved.
e. Future Innova ons. The Employee will promptly disclose in wri ng to the Company all Innova ons conceived, reduced to
prac ce, created, derived, developed, or made by the Employee during the Employee’s employment with the Company
and for three (3) months therea er, whether or not the Employee believes the Innova ons are subject to this
Agreement, to permit a determina on by the Company as to whether or not the Innova ons are or should be considered
Company Innova ons. The informa on required to be disclosed in this sec on 3(d) shall be submi ed through the
Company’s processes for submi ng Company Innova ons (e.g. the portal at h ps://pmi-portal.force.com/idf/s/) or sent
to the Company’s Legal Department, A en on: Intellectual Property, at the address listed at the end of this Agreement
or to another address the Company may, from me to me, specify in wri ng. The Company will receive that informa on
in confidence.
f. No ce of Nonassignable Innova ons. This sec on 3 c, d and e does not apply to an Innova on that the Employee cannot
be required to assign by law (including, without limita on, pursuant to the applicable statutory provisions of Employee’s
jurisdic on of employment set forth in the appendices a ached to this Agreement, if any). Employee has reviewed the
appendices a ached to this Agreement and agrees that Employee’s signature on this Agreement cons tutes the
Employee’s assent to the applicable appendices of the Employee’s jurisdic on of employment, if any.
g. Further Assurances. Upon the request and at the expense of the Company, and for the benefit of the Company as
determined by the Company, the Employee shall, during and a er the Employee’s employment, execute and deliver any
and all documents and instruments, and do such other acts, that may be necessary or desirable, as determined by the
Company, to evidence the ownership of rights, and each assignment and transfer described in this Agreement. The
Employee will do the same to enable the Company to secure the Company’s sole and exclusive rights in the Confiden al
Informa on, the Company property, and the Company Innova ons, or to apply for, prosecute, defend and enforce any
intellectual property rights with respect to any Confiden al Informa on, the
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 10
-- 112 of 140 --
Company property, or the Company Innova ons, or to obtain any extension, valida on, re-issue, con nuance or renewal
of any related intellectual property right, in each case in any and all jurisdic ons. The Employee agrees to disclose to the
Company all per nent informa on and data with respect to Confiden al Informa on, the Company property, and the
Company Innova ons. In the event the Employee’s employment or service is terminated, the Employee will do all the
things described in this paragraph without charge to the Company other than a reasonable payment for the Employee’s
me involved. If the Company is unable for any other reason to secure the Employee’s signature on any document
described above, then the Employee hereby irrevocably designates and appoints the Company and the Company’s duly
authorized officers and agents as the Employee’s agent and a orney in fact, to act for and in the Employee’s behalf and
stead to execute and file any such applica ons and to do all other lawfully permi ed acts to further the prosecu on and
issuance of le ers patent or trademark, copyright or other registra ons thereon with the same legal force and effect as if
executed by the Employee. The foregoing is deemed a power coupled with an interest and to the extent permissible by
applicable law is irrevocable.
4. No License. Nothing in this Agreement shall be deemed to cons tute the grant of any license or other right to the Employee with
respect to any Confiden al Informa on, the Company property, the Company Innova ons, or other data, tangible property or
any intellectual property of the Company.
5. Equitable Relief. The Employee agrees that the provisions of this Agreement are reasonably necessary to protect the Company’s
legi mate business interests. The Employee agrees that it would be impossible or inadequate to measure and calculate the
Company’s damages from any breach of the covenants set forth in this Agreement, and that a breach of such covenants could
cause serious and irreparable injury to the Company. Accordingly, the Company shall have available, in addi on to any other
right or remedy available to it, the right to seek an injunc on from a court of competent jurisdic on restraining such a breach (or
threatened breach) and to specific performance of these terms and condi ons. To the extent permi ed by law, the Employee
further agrees that no bond or other security shall be required in obtaining such equitable relief and the Employee hereby
consents to the issuance of such injunc on and to the ordering of specific performance.
6. Blue Pencil. Notwithstanding any provision to the contrary herein, the Employee agrees that the covenants contained in these
terms and condi ons are reasonable covenants under the circumstances, and further agrees that if, in the opinion of any court
of competent jurisdic on such covenants are not reasonable in any respect, such court shall have the right, power and authority
to excise or modify such provision or provisions of these covenants as to the court shall appear not reasonable and to enforce
the remainder of these covenants as so amended.
7. Survival. This Agreement (a) shall survive the Employee’s employment by the Company; (b) does not in any way restrict the
Employee’s right to resign or the right of the Company to terminate the Employee’s employment at any me, for any reason or
for no reason; (c) inures to the benefit of successors and assigns of the Company; and (d) is binding upon the Employee’s heirs
and legal representa ves.
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 11
-- 113 of 140 --
8. Severability; Waiver. If any provision or provisions of this Agreement shall be held to be unenforceable by any court, the
remaining provisions shall con nue in full force and effect. The Employee and the Company agree that those provisions should
be and are reformed to the extent permi ed by applicable law and expressly authorize the court to reform those provisions in
that manner. Any waiver of a breach of this Agreement shall not cons tute a waiver of a future breach, whether of a similar or
dissimilar nature.
9. Modifica on. This Agreement may not, on behalf of or with respect to the Company, be changed, modified, released,
discharged, abandoned or otherwise terminated, in whole or part, except by any instrument in wri ng signed by an officer of the
Company.
10. Governing Law; Forum. The laws of the jurisdic on where the Employee is employed by the Company govern all ma ers arising
out of or rela ng to this Agreement without giving effect to any conflict of law principles. Any dispute or controversy arising out
of or rela ng to this Agreement shall be submi ed either to the court of the domicile or seat of the defendant or as otherwise
allowed under Swiss law. Addi onally, notwithstanding anything in the foregoing to the contrary, a claim for equitable relief
arising out of or related to this Agreement may be brought in any court of competent jurisdic on. For the avoidance of doubt,
the foregoing terms will control over any conflic ng terms in the Employee’s offer le er or employment agreement, as
applicable.
11. No ces. Any no ce required or permi ed by this Agreement shall be in wri ng and shall be delivered as follows, with no ce
deemed given as indicated: (a) by personal delivery, when actually delivered; (b) by overnight courier, upon wri en verifica on
of receipt; (c) by facsimile transmission, upon acknowledgment of receipt of electronic transmission; (d) by email, effec ve (A)
when the sender receives an automated message from the recipient confirming delivery or (B) one hour a er the me sent (as
recorded on the device from which the sender sent the email) unless the sender receives an automated message that the email
has not been delivered, whichever happens first, but if the delivery or receipt is on a day which is not a business day or is a er
5:00 p.m. (addressee’s me) it is deemed to be received at 9:00 a.m. on the following business day; or (e) by cer fied or
registered mail, return receipt requested, upon verifica on of receipt. No ces to the Employee shall be sent to any address in
the Company’s records or any other address the Employee may provide in wri ng. No ces to the Company shall be sent to the
Company’s Legal & Compliance Department, A en on: Intellectual Property, at the address listed below or to another address
the Company may specify in wri ng.
12. En re Agreement. This Agreement represents the Employee’s en re understanding with the Company with respect to the
subject ma er of this Agreement and supersedes all previous understandings, wri en or oral.
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 12
-- 114 of 140 --
The Employee has read this Agreement carefully and agrees to its terms.
On Behalf of Philip Morris Services S.A. (the “Company”):
Avenue de Cour 107, 1001 Lausanne, Switzerland
Dated: June 12, 2023
/s/ CONSTANTIN ROMANOV
(Signature)
/s/ RALF ZYSK
(Signature)
Constan n Romanov
(Printed Name)
Title: Vice President Total Rewards
Ralf Zysk
(Printed Name)
Title: Vice President Labour Rela ons
Employee:
Dated: 22 June 2023
/s/ STACEY KENNEDY
(Employee Signature)
Stacey Kennedy
(Employee Printed Name)
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 13
-- 115 of 140 --
A achment 1
List of Prior Innova ons made by the Employee (if none, write “NONE”):
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
Page | 14
-- 116 of 140 --
Exhibit 10.12
CONFIDENTIAL
Ms. Stacey Kennedy Lausanne, June 12, 2023
Dear Stacey,
We are pleased to confirm your assignment to the PMI Global Services Inc. in Stamford, United States.
Overview of Assignment
You will be assigned from your employer Philip Morris Services S.A. (“Home Company”) to PMI Global Services Inc. (“Host Company”).
During this assignment you will be based in Stamford, United States and will work as President Americas Region and CEO of PMI’s U.S.
Business.
Employment with Home Company
During the assignment you will con nue to be an employee of the Home Company and your employment contract with the Home
Company will remain in effect as amended and supplemented by this le er. The provisions of the PMI Global Long Term Assignment
Guidelines – Strategic (as they may be amended or re-issued from me to me) (“Global Guidelines”) will also apply to your assignment.
Commencement and Dura on of Assignment
The assignment will be effec ve as of July 1 , 2023 or, if later, the date of issue of your work permit, and is expected to con nue for a
period of 36 months, although no commitment can be given as to its exact dura on. The Company may decide at any me to end your
assignment in the host loca on. As the end of the expected 36 months period approaches, and should your assignment not have ended
earlier, your assignment will be reviewed in order for the Company to determine the next steps.
Home Country/Point of Origin
Your Home Country, for the purpose of your remunera on package, shall be deemed to be Switzerland. Your point of origin for the
purposes of Home Leave will be deemed as Geneva, Switzerland.
Direc on and Control
During your assignment, the Home Company will remain your employer, however, you will be subject to the direc on and control of the
Host Company and you must comply with the rules, policies, procedures and working prac ces of the Host Company, as well as all
applicable laws of the Host Country. Your repor ng manager, Chief Execu ve Officer PMI will define your day to day ac vi es and
par cipate in your performance appraisal for the period of this assignment.
Throughout the assignment, you must not represent yourself as conduc ng business on behalf of the Home Company and you are
expressly not authorized to bind the Home Company in any way. Throughout your assignment you must comply with the “Guidelines on
Business Prac ce for Assignees” a ached to this le er at Annex “A”.
st
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 117 of 140 --
Salary, Bonuses and other Allowances
Your annual base salary of CHF 750,000.-- (“Base Salary”) corresponding to your grade, which is 24 will con nue to be administered by
the Home Company.
You will con nue to be en tled to par cipate in the PMI Variable Compensa on Programs, subject to applicable rules.
Your assignment package will be calculated in accordance with the Global Guidelines and is no fied to you separately. The assignment
package is reviewed on an ongoing basis in accordance with the provisions of the Global Guidelines.
Medical Plan
You and any Accompanying Family Members (as defined in the Global Guidelines) will be provided with medical insurance during the
whole period of your assignment.
Vaca on & Holidays
During your assignment you will be en tled to the number of vaca on days in accordance with the Global Guidelines.
You will be en tled to the public holidays as determined by Host Country law and the Host Company’s policy and prac ce.
Working Schedule, Working Hours, etc.
During the assignment, you will be required to follow the working schedule and working hours of the Host Company.
Travel Security
PMI’s goal is to help our employees travel and work safely and securely wherever our business takes us. Please refer to the Travel
Security page on PMI’s intranet site for travel security informa on, including specific informa on about your Host Country. Before
leaving for your assignment or any pre-assignment trip, please ensure that you have completed an appropriate travel security training
program. If you have any ques ons or concerns regarding health, safety or security in connec on with your assignment, please contact
Host Country People & Culture Team.
Privacy Policy and Data Protec on
The Home Company and Host Company will, in the course of their business, process personal data rela ng to you, you give your consent
to the Home and Host Company to: (a) process your personal informa on for their, and their Affiliates’, business purposes; (b) process
your sensi ve personal data where this is necessary for the administra on of the employment rela onship; (c) make your personal
informa on available to their Affiliates or to third par es, where necessary for the purposes of the administra on of your employment,
or where required by law; (d) transfer your personal informa on within or outside your Home or Host Country, including where the
country in ques on may not maintain data protec on standards that are equivalent to those of your Home or Host Country.
Termina on of Assignment
The Home Company may decide to terminate your assignment at any me. Except in the case of localiza on, at the end of your
assignment, you will revert to the terms and condi ons of employment under your
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 118 of 140 --
employment agreement with your Home Company, except that your compensa on, benefits and other terms of employment may be
adjusted to conform to the corresponding terms and condi ons, benefit schemes and other policies and prac ces applicable to your
return posi on with the Home Company or to any further assignment with another PMI affiliate.
The Company may decide at any me that con nua on in an assignment role will require localiza on. Any decision on localiza on is
taken in the light of periodic reviews by the Company of its Long Term Assignees. Localiza on will be in accordance with the provisions of
the Global Guidelines.
Your assignment will terminate automa cally if your employment with the Home Company is terminated (whether by you or by the
Home Company).
Governing Law
Your employment by the Home Company, and the terms of your assignment to the Host Company, shall be governed by the substan ve
and procedural law of Switzerland, without giving effect to any principles rela ng to conflicts of laws.
We wish you every success in your assignment. Please return one copy of this le er duly signed for agreement.
Yours sincerely,
PHILIP MORRIS SERVICES S.A.
/s/ CONSTANTIN ROMANOV
Constan n Romanov
Vice President Total Rewards
/s/ RALF ZYSK
Ralf Zysk
Vice President Labour Rela ons
Acknowledgment
I acknowledge receipt of this le er and I agree with its terms. I have retained a copy of the le er for reference. I confirm that I have read
the PMI Global Long Term Assignment Guidelines – Strategic, provided during the assignment briefing. I also acknowledge receipt of the
Guidelines on Business Prac ce for Assignees, a ached at Annex “A”, which I have read and understood.
Signed /s/ STACEY KENNEDY
Stacey Kennedy
Date of Signature 22 June 2023
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 119 of 140 --
Annex “A” to Assignment Le er
Guidelines on Business Prac ce for Assignees
1. Your assignment is an assignment to the Host affiliate. This means that you will con nue to be an employee of your Home Company,
but you will be temporarily assigned to the Host Company. The purpose of the assignment is so that you can undertake work on behalf
of the Host Company for a temporary period.
2. Although you remain employed by your Home Company, for the period of your assignment you will be under the supervision and
direc on of the Host Company and you must comply with the guidelines, prac ces, rules and regula ons of the Host Company from me
to me in effect, as well as all applicable laws in the Host Country.
3. You also remain subject to many of your Home Company policies, to the extent that they do not conflict with those of the Host
Country whilst you are on assignment. Further details can be found in the Global Guidelines.
4. During your assignment it is important that you do not do anything that may appear to be, or may be construed as, the conduct of
business by or on behalf of the Home Company.
For example:
• You must not distribute business cards naming the Home Company;
• Your e-mail signature and contact details must reference the Host Company only;
• You must not use your Home Company tle, but should use a tle that is legally acceptable to, and approved by, the Host
Company;
• You may send e-mails only from an e-mail address associated with the Host Company;
• You should not transact any business whatsoever on behalf of the Home Company.
5. During your assignment it is also important that you do not do anything that may bind the Home Company to any agreement,
arrangement or business transac on.
For example:
• You may not sign any agreements, reports to third par es or regulatory filings on behalf of the Home Company, or on behalf of
any other Company affiliates except the Host Company;
• You may not sign any document on behalf of the Home Company;
• You are expressly forbidden to bind the Home Company in any way, whether verbally or in wri ng.
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 120 of 140 --
Exhibit 10.13
PERSONAL AND CONFIDENTIAL
To: Stacey Kennedy Lausanne, March 21, 2024
Dear Stacey,
We are pleased to confirm that effective April 1, 2024, your base salary will be increased to
CHF 810'000.- annually, CHF 67'500.-- monthly. This represents a 8.0% increase and the comparatio at your current
grade 24 will be 100%.
All other conditions relating to your employment with Philip Morris Services S.A., remain as stated in your
employment contract and in any subsequent amendments.
Yours sincerely,
PHILIP MORRIS SERVICES S.A.
/s/ CONSTANTIN ROMANOV /s/ RALF ZYSK
Constantin Romanov Ralf Zysk
Vice President Total Rewards Vice President Labor Relations
Philip Morris Services S.A., Avenue de Cour 107, 1001 Lausanne, Switzerland
T:+41 (58) 242 00 00, F: +41 (58) 242 01 01
-- 121 of 140 --
Exhibit 10.14
IDEMNIFICATION AGREEMENT
-- 122 of 140 --
TABLE OF CONTENTS
Page
1. Service by Indemnitee 1
2. Indemnification Against Liability and Advancement of Expenses 2
3. Indemnification 3
4. Partial Indemnification Against Liability and Advancement of Expenses 3
5. Payment of Expenses as a Witness 4
6. Payment of Expenses as a Party 4
7. Determination of Entitlement to Indemnification; Authorization of Payment 4
8. Presumptions and Effect of Certain Proceedings 6
9. Remedies of Indemnitee in Cases of Determination Not to Indemnify Against Liability or to Pay Expenses 7
10. Other Rights to Indemnification and Advancement; No Duplication of Payments; Contribution 7
11. Expenses to Enforce Agreement 8
12. Continuation of Indemnity 8
13. Notification and Defense of Claim 9
14. Severability 10
15. Headings; References; Pronouns 10
16. Definitions and References 10
17. Other Provisions 12
(i)
-- 123 of 140 --
INDEMNIFICATION AGREEMENT
This Indemnification Agreement (this “Agreement”) is made and entered into as of
________ __, 20__, between Philip Morris International Inc., a Virginia corporation (the “Company”), and
_______________________________ (“Indemnitee”).
WHEREAS, the Board of Directors of the Company (the “Board”) has determined in accordance with its good faith business
judgment that the ability to attract and retain qualified persons as directors and executive officers is in the best interests of the
Company and that the Company should act to assure such persons that there shall be adequate certainty of protection against risks
of claims and actions against them arising out of their service to and activities on behalf of the Company and its subsidiaries; and
WHEREAS, the Company has adopted provisions in its Amended and Restated Articles of Incorporation regarding
indemnification against liabilities and advancement and reimbursement of expenses for its directors and executive officers and
the Company wishes to make further provision with respect thereto as permitted by the Amended and Restated Articles of
Incorporation of the Company and Section 13.1-704.B of the Virginia Stock Corporation Act (the “Virginia Act”); and
WHEREAS, in order to induce and encourage highly experienced and capable persons such as Indemnitee to serve and to
continue to serve as directors and/or executive officers of the Company and in any other capacity with respect to the Company or
its subsidiaries with the knowledge that certain costs, judgments, penalties, fines, liabilities and expenses incurred by them in
their defense of litigation are to be borne by the Company and that they shall receive appropriate protection against such risks and
liabilities, the Board has determined that this Agreement is in the best interests of the Company; and
WHEREAS, the Company desires to have Indemnitee become or continue to serve as a director and/or executive officer
of the Company, and in any other capacity with respect to the Company or any of its subsidiaries as the Company may request,
free from undue concern for legal risks and personal liabilities by reason of Indemnitee’s performing his or her duties to the
Company or its subsidiaries; and Indemnitee desires so to serve the Company, provided, and on the express condition, that he or
she is furnished with the indemnity and other protections set forth herein.
Now, therefore, in consideration of Indemnitee’s agreement to provide, or continue to provide, services to the Company,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:
1
-- 124 of 140 --
1. Service by Indemnitee.
2. If Indemnitee is currently or is about to become a director of the Company, Indemnitee shall continue to serve in that
capacity so long as Indemnitee is duly elected or appointed and until such time as Indemnitee’s successor is elected and qualified
or Indemnitee is removed as permitted by law or tenders a resignation in writing.
3. If Indemnitee is currently or is about to become an executive officer of the Company, Indemnitee shall continue to serve
in that capacity at the pleasure of the Board and until such time as Indemnitee’s successor is elected and qualified or Indemnitee
is removed as permitted by law or tenders a resignation in writing.
4. If at any time while Indemnitee is a director or executive officer of the Company, Indemnitee is also acting as a director,
officer, manager, partner, trustee, employee, agent or fiduciary of any subsidiary of the Company or any other entity in which the
Company, directly or indirectly, has an equity or ownership interest or has the right or ability to elect or appoint such person in
such capacity at such other entity, Indemnitee shall be deemed for all purposes of this Agreement to have been serving in such
capacity at the request of the Company. Indemnitee shall be considered to be serving an employee benefit plan at the Company’s
request if Indemnitee’s duties to the Company also impose duties on, or otherwise involve services by, Indemnitee to the plan or
participants in or beneficiaries of the plan.
5. Indemnification Against Liability and Advancement of Expenses. The Company shall indemnify Indemnitee against all
Liability and, subject to Section 6 below, shall pay to Indemnitee in advance of the final disposition of any Proceeding all
Expenses incurred by Indemnitee, to the fullest extent permitted by the Virginia Act in effect on the date of this Agreement or as
such law may from time to time be amended (but, in the case of any such amendment, only to the extent that such amendment
permits the Company to provide broader rights than said law permitted the Company to provide prior to such amendment).
Notwithstanding the foregoing or any other provision of this Agreement to the contrary, but subject to Section 3(b), the Company
shall not be obligated under this Agreement:
6. to indemnify Indemnitee or advance or reimburse Expenses to the extent expressly prohibited by applicable law or the
Amended and Restated Articles of Incorporation of the Company;
7. to indemnify Indemnitee for any payment that has previously been made to Indemnitee under a valid and collectible
insurance policy or under a valid and enforceable indemnity clause, provision of the Amended and Restated Articles of
Incorporation, By-laws, or agreement of the Company or any other company or organization, except in respect of any Expenses
or Liability exceeding the payment under such insurance, indemnity clause, provision of the Amended and Restated Articles of
Incorporation, By-laws or agreement;
8. to indemnify Indemnitee or advance or reimburse Expenses in connection with an action, suit or proceeding, or part
thereof (including claims and counterclaims), initiated by Indemnitee except (i) in a judicial proceeding or arbitration pursuant to
Section 9 below to enforce rights under this Agreement or under any directors’ and officers’ liability insurance policies
maintained
2
-- 125 of 140 --
by the Company or (ii) if such action, suit or proceeding, or part thereof, was authorized by the Board; or
9. to indemnify Indemnitee for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by
Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state
statutory law or common law, or (ii) any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or
equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company, as required in
each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company
or under a clawback policy adopted by the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 or Section 954
of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the payment to the Company of profits arising
from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act of 2002).
10. Indemnification.
11. Except as limited by Section 2 above, the Company shall indemnify Indemnitee against all Liability incurred in any
Proceeding, including a Proceeding brought by or in the right of the Company, by reason of the fact that Indemnitee is or was a
director and/or executive officer of the Company, or while a director and/or executive officer of the Company is or was serving at
the request of the Company as a director, officer, manager, partner, trustee, employee, agent or fiduciary of any other entity,
including, but not limited to, another corporation, limited liability company, partnership, joint venture, trust or employee benefit
plan; or by reason of anything done or not done by Indemnitee in any such capacity; provided, however, that no such
indemnification shall be made against willful misconduct or a knowing violation of the criminal law.
12. Notwithstanding any other provisions of this Agreement to the contrary, the Company shall indemnify Indemnitee if he or
she was wholly successful, on the merits or otherwise, in the defense of any Proceeding, including a Proceeding brought by or in
the right of the Company, to which Indemnitee was a party because Indemnitee is or was a director and/or executive officer of the
Company, or while a director and/or executive officer of the Company is or was serving at the request of the Company as a
director, officer, manager, partner, trustee, employee, agent or fiduciary of any other entity, including, but not limited to, another
corporation, limited liability company, partnership, joint venture, trust or employee benefit plan, against all Expenses in
connection with such Proceeding.
13. Partial Indemnification Against Liability and Advancement of Expenses. If Indemnitee is entitled under any provision of
this Agreement to (a) indemnification for some or a portion of the Liability, and/or (b) advancement or reimbursement of some or
a portion of the Expenses but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee
for the portion of such Liability and advance to or reimburse Indemnitee for the portion of such Expenses to which Indemnitee is
entitled.
14. Payment of Expenses as a Witness. The Company shall pay directly or promptly reimburse Indemnitee all Expenses
incurred or suffered by Indemnitee or on Indemnitee’s behalf
3
-- 126 of 140 --
if Indemnitee receives a subpoena or appears as or is threatened to be made a witness as a result of or related to Indemnitee’s
service as a director and/or executive officer of the Company, or while a director and/or executive officer of the Company,
Indemnitee’s service at the request of the Company as a director, officer, manager, partner, trustee, employee, agent or fiduciary
of any other entity, including, but not limited to, another corporation, limited liability company, partnership, joint venture, trust or
employee benefit plan, in any threatened, pending or completed action, suit or proceeding, whether of a civil, criminal,
administrative, arbitrative, investigative, legislative or other nature, and whether formal or informal, to which Indemnitee neither
is, nor is threatened to be made, a party.
15. Payment of Expenses as a Party. At the Request of Indemnitee, the Company shall pay directly or promptly reimburse
Indemnitee in advance of the final disposition of any Proceeding, including a Proceeding brought by or in the right of the
Company, to which Indemnitee is, or is threatened to be made, a party, all Expenses incurred by Indemnitee in connection with
such Proceeding if Indemnitee furnishes to the Company a written undertaking, executed personally or on Indemnitee’s behalf, to
repay any funds advanced or reimbursed if it is ultimately determined in a final, nonappealable adjudication that Indemnitee is
not entitled to be indemnified. One such written undertaking shall suffice for the duration of such Proceeding. Such undertaking
shall be an unlimited general obligation but need not be secured and shall be accepted without reference to financial ability to
make repayment. To receive an advancement or reimbursement of Expenses under this Agreement, Indemnitee shall from time to
time submit written requests to the Secretary of the Company. Such requests shall reasonably evidence the Expenses incurred by
Indemnitee. Each such advancement or reimbursement of Expenses shall be made within twenty (20) calendar days after the
receipt by the Company of the written request therefor. Indemnitee’s entitlement to advancement or reimbursement of such
Expenses shall include those incurred in connection with any action, suit or proceeding by Indemnitee seeking a judgment in
court or an adjudication or award in arbitration pursuant to Section 9 below (including the enforcement of this provision).
16. Determination of Entitlement to Indemnification; Authorization of Payment.
17. To receive indemnification against Liability under this Agreement, Indemnitee shall submit a written request to the
Secretary of the Company. Such request shall include documentation or information that is both reasonably available to
Indemnitee and necessary to determine whether indemnification is payable under this Agreement.
18. The determination of entitlement to indemnification shall be made not later than thirty (30) calendar days after receipt by
the Company of a written request for indemnification; provided, however, that such period may be extended for a reasonable
time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to
entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or
information relating thereto. Any amounts incurred by Indemnitee in connection with a request for indemnification or
advancement of Expenses hereunder, under any other agreement, any provision of the Company’s Amended and Restated
Articles of Incorporation, By-laws or any directors’ and officers’ liability insurance, shall be borne by the Company. The
Company hereby indemnifies Indemnitee for any such amounts and agrees to hold Indemnitee harmless therefrom irrespective of
the outcome of the determination of
4
-- 127 of 140 --
Indemnitee’s entitlement to indemnification. If the person making such determination shall determine that Indemnitee is entitled
to indemnification as to part (but not all) of the application for indemnification, such person shall reasonably prorate such partial
indemnification among the claims, issues or matters at issue at the time of the determination.
19. Upon written request by Indemnitee for indemnification pursuant to Section 7(a) above, the determination, if required by
applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case:
20. if there are two or more Disinterested Directors, by the Board by a majority vote of all Disinterested Directors, a majority
of whom shall for such purpose constitute a quorum, or by a majority of the members of a committee of two or more
Disinterested Directors appointed by such a vote; or
21. by Special Legal Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, with such
Special Legal Counsel:
22. selected by the Board in the same manner as clause (i) above;
23. if there are fewer than two Disinterested Directors, selected by the Board, in which selection, directors who do not qualify
as Disinterested Directors may participate; or
24. in the event that there has been a Change of Control after the date of the alleged act or omission with respect to which
indemnification is sought by Indemnitee, selected by Indemnitee (unless Indemnitee shall request that such selection be made by
the Board, in which event clauses (ii)(1)-(2) shall apply).
25. If the determination is to be made by Special Legal Counsel, then the party entitled to select Special Legal Counsel
pursuant to clause (c) above shall give written notice to the other party advising it of the identity of the Special Legal Counsel.
Following such selection of Special Legal Counsel, Indemnitee or the Company, as the case may be, may, within ten (10) days
after written notice of selection of such Special Legal Counsel shall have been given, deliver to the Company or to Indemnitee, as
the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground
that the Special Legal Counsel so selected does not meet the requirements of “Special Legal Counsel” as defined in Section 16 of
this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely
objection, the person so selected shall act as Special Legal Counsel. If such written objection is so made and substantiated, the
Special Legal Counsel so selected may not serve as Special Legal Counsel unless and until such objection is withdrawn or a court
has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a
written request for indemnification pursuant to Section 7(a) hereof and the final disposition of the Proceeding, no Special Legal
Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Virginia Court for
resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Special Legal
Counsel and/or for the appointment as Special Legal Counsel of a person selected by the court or by such other person as the
court shall designate, and the person with respect to whom all objections are so
5
-- 128 of 140 --
resolved or the person so appointed shall act as Special Legal Counsel under Section 7(c) hereof. Upon the due commencement
of any judicial proceeding or arbitration pursuant to Section 9 below, Special Legal Counsel shall be discharged and relieved of
any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).
26. Each of the Company and Indemnitee shall cooperate with the person, persons or entity making such determination with
respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable
advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is
reasonably available to such party and reasonably necessary to such determination. Any costs or expenses (including reasonable
attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such
determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to
indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.
27. If it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within
thirty (30) days after such determination.
28. Presumptions and Effect of Certain Proceedings. The Secretary of the Company shall, promptly upon receipt of
Indemnitee’s written request for indemnification, advise in writing the Board or such other person or persons empowered to make
the determination of entitlement to indemnification as provided in Section 7 above that Indemnitee has made such request for
indemnification. Upon making such request for indemnification, Indemnitee shall be presumed to be entitled to indemnification
hereunder and the Company shall have the burden of proof in making any determination contrary to such presumption. If the
person or persons so empowered to make such determination shall have failed to make the requested determination within the
thirty (30)-day period prescribed in Section 7 above, a requisite determination of entitlement to indemnification shall be deemed
to have been made and Indemnitee shall be absolutely entitled to such indemnification, absent a misstatement by Indemnitee of a
material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection
with the request for indemnification. The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea
of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee is not entitled to indemnification
under this Agreement.
29. Remedies of Indemnitee in Cases of Determination Not to Indemnify Against Liability or to Pay Expenses. In the event
that a determination is made that Indemnitee is not entitled to indemnification hereunder or if payment has not been timely made
following a determination of entitlement to indemnification pursuant to Sections 7 and 8 above, or if payment of Expenses is not
made pursuant to Sections 5 or 6 above, Indemnitee shall be entitled to final adjudication in a Virginia Court of entitlement to
such indemnification against Liability or payment of Expenses. Alternatively, Indemnitee at Indemnitee’s option may seek an
award in an arbitration to be conducted by a single arbitrator pursuant to the rules of the American Arbitration Association, such
award to be made within sixty (60) calendar days following the filing of the demand for arbitration. The Company shall not
oppose Indemnitee’s right to seek any such adjudication or award in arbitration. The determination in any such judicial
proceeding or arbitration shall be
6
-- 129 of 140 --
made de novo and Indemnitee shall not be prejudiced by reason of a determination (if so made) pursuant to Sections 7 or 8 above
that Indemnitee is not entitled to indemnification. If a determination is made or deemed to have been made pursuant to the terms
of Sections 7 or 8 above that Indemnitee is entitled to indemnification, the Company shall be bound by such determination and is
precluded from asserting that such determination has not been made or that the procedure by which such determination was made
is not valid, binding and enforceable, absent a misstatement by Indemnitee of a material fact, or an omission of a material fact
necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification. The
Company is precluded from asserting in any such proceeding or arbitration commenced pursuant to this Section 9 that the
procedures and presumptions of this Agreement are not valid, binding or enforceable and will stipulate in any the Virginia Court
or before any such arbitrator that the Company is bound by all the provisions of this Agreement. If the court or arbitrator shall
determine that Indemnitee is entitled to any indemnification against Liability or payment of Expenses hereunder, the Company
shall pay all Expenses incurred by Indemnitee with respect to such adjudication or award in arbitration (including, but not limited
to, any appellate proceedings).
30. Other Rights to Indemnification and Advancement; No Duplication of Payments; Contribution.
31. The indemnification against Liability and advancement of Expenses provided by this Agreement shall not be exclusive of
any other rights to which Indemnitee may now or in the future be entitled under any provision of the Amended and Restated
Articles of Incorporation or Amended and Restated By-laws of the Company, vote of shareholders or Disinterested Directors,
provision of law, agreement, policies of insurance or otherwise (including with respect to claims, issues or matters in relation to
which the Company would not have the power to indemnify or advance Expenses to Indemnitee under the provisions of this
Agreement or otherwise).
32. The Company shall not be required under this Agreement to make any payment to Indemnitee to the extent the underlying
Liability or Expense has previously been paid or reimbursed, whether under a source identified in Section 10(a) above or
otherwise (the “Other Payment”). To the extent Indemnitee receives the Other Payment for the underlying Liability or Expense
after payment has been made by the Company under this Agreement, Indemnitee shall promptly reimburse the Company for such
payment after receipt by Indemnitee of such Other Payment.
33. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is
unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by
Indemnitee, whether for Expenses or Liability, in connection with any claim relating to an indemnifiable event under this
Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to
reflect (i) the relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to
such Proceeding and (ii) the relative fault
7
-- 130 of 140 --
of Indemnitee and the Company (and its other directors, officers, employees and agents) in connection with such events and
transactions.
34. Expenses to Enforce Agreement. In the event that Indemnitee is subject to or intervenes in any action, suit or proceeding
in which the validity or enforceability of this Agreement is at issue or seeks an adjudication or award in arbitration to enforce
Indemnitee’s rights under, or to recover damages for breach of, this Agreement, Indemnitee, if Indemnitee prevails in whole or in
part in such action, suit or proceeding, shall be entitled to recover from the Company and shall be indemnified by the Company
against any Expenses incurred by Indemnitee. If the person making such determination shall determine that Indemnitee is entitled
to indemnification as to part (but not all) of the application for indemnification, such person shall reasonably prorate such partial
indemnification among the claims, issues or matters at issue at the time of the determination.
35. Continuation of Indemnity. All agreements and obligations of the Company contained herein shall continue during the
period Indemnitee is a director and/or an executive officer of the Company and shall continue thereafter with respect to any
possible claims based on the fact that Indemnitee was a director and/or an executive officer of the Company or while a director
and/or an executive officer of the Company was serving at the request of the Company as a director, officer, manager, partner,
trustee, employee, agent or fiduciary of any other entity including, but not limited to, another corporation, limited liability
company, partnership, joint venture, trust or employee benefit plan. This Agreement shall be binding upon all successors and
assigns of the Company (including any transferee of all or substantially all of its assets and any successor by merger or operation
of law) and shall inure to the benefit of the heirs, executors and administrators of Indemnitee.
36. Notification and Defense of Claim.
37. Promptly after receipt by Indemnitee of notice of any Proceeding, Indemnitee shall, if a claim in respect thereof is to be
made against the Company under this Agreement, notify the Company in writing of the commencement thereof, but the omission
so to notify the Company shall not relieve it from any liability that it may have to Indemnitee.
38. In the event the Company may be obligated to make any indemnity or is obligated to pay or reimburse Expenses in
connection with a Proceeding (other than a Proceeding brought by or in the right of the Company) pursuant to this Agreement:
39. The Company shall be entitled to participate therein at its own expense.
40. Except as otherwise provided in this Section 13(b), to the extent that it may wish, the Company, jointly with any other
indemnifying party similarly notified, shall be entitled to assume the defense thereof, with counsel reasonably satisfactory to
Indemnitee. Indemnitee shall have the right to employ Indemnitee’s own counsel in such Proceeding and the fees and expenses of
Indemnitee’s counsel shall be at the expense of Indemnitee, provided that if (A) the employment of separate counsel by
Indemnitee at the Company’s expense is authorized by the Company, (B) Indemnitee shall have reasonably concluded that there
may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or (C) the
8
-- 131 of 140 --
Company shall not continue to retain such counsel or has failed to defend such Proceeding, then the expenses of Indemnitee’s
separate counsel shall be considered an Expense subject to payment or reimbursement under Section 6.
41. If the Company has assumed the defense of a Proceeding, the Company shall not be liable to indemnify Indemnitee under
this Agreement for any amounts paid in settlement of any Proceeding effected by or on behalf of Indemnitee without the
Company’s written consent (not to be unreasonably withheld, conditioned or delayed). The Company shall not, without
Indemnitee’s written consent (which may be provided or withheld in Indemnitee’s sole discretion), consent to the entry of any
judgement against Indemnitee or enter into any settlement or compromise unless such settlement solely involves the payment of
money by persons other than Indemnitee and includes an unconditional release of Indemnitee from all liability on any matters
that are the subject of such Proceeding and an acknowledgement that Indemnitee denies all wrongdoing in connection with such
matters.
42. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any
reason whatsoever, (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, but not
limited to, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that are not by themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby,
and (b) to the fullest extent possible, the provisions of this Agreement (including, but not limited to, all portions of any paragraph
of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid,
illegal or unenforceable) shall be construed so as to give effect to the intent of the parties that the Company provide protection to
Indemnitee as set forth in this Agreement to the fullest enforceable extent.
43. Headings; References; Pronouns. The headings of the sections of this Agreement are inserted for convenience only and
shall not be deemed to constitute part of this Agreement or to affect the construction thereof. References herein to section
numbers are to sections of this Agreement. All pronouns and any variations thereof shall be deemed to refer to the masculine,
feminine, neuter, singular or plural as appropriate.
44. Definitions and References. For purposes of this Agreement:
45. “Disinterested Director” shall have the meaning given in the Virginia Act from time to time.
46. “Change of Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the
following events:
47. Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined
below), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting
power of the Company’s then outstanding securities;
48. Change in Board of Directors. During any period of two (2) consecutive years, individuals who at the beginning of such
period constitute the Board, and any new director
9
-- 132 of 140 --
whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least a
majority of the directors then still in office who either were directors at the beginning of the period or whose election or
nomination for election was previously so approved, cease for any reason to constitute a majority of the members of the Board;
49. Corporate Transactions. The effective date of a merger, share exchange or consolidation of the Company with any other
entity, other than a merger, share exchange or consolidation which would result in the voting securities of the Company
outstanding immediately prior to such merger, share exchange or consolidation continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of
the voting securities of the surviving entity outstanding immediately after such merger, share exchange or consolidation and with
the power to elect a majority of the Board or other governing body of such surviving entity;
50. Dissolution or Disposition of Assets. The approval by the shareholders of the Company of the dissolution of the Company
or of an agreement for the sale or disposition by the Company of the Company’s assets that requires shareholder approval
pursuant to Section 13.1-724 of the Virginia Act (or any successor provision); or
51. Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of
Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the
Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.
52. “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.
53. “Person” or “person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange
Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an
employee benefit plan of the Company and (iii) any entity owned, directly or indirectly, by the shareholders of the Company in
substantially the same proportions as their ownership of stock of the Company.
54. “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however,
that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the shareholders of the
Company approving a merger of the Company with another entity, and further provided, that any calculation of securities
beneficially owned by a Beneficial Owner shall include securities that are the subject of a derivative that creates for the
Beneficial Owner the economic equivalent of ownership in such securities for the Beneficial Owner by tying the value of the
derivative to the price or value of such securities.
55. “Expenses” includes, without limitation, all reasonable fees, costs and expenses incurred in connection with the defense
or settlement of any action, suit or proceeding, including all investigations, and all judicial, arbitrative, administrative or
legislative proceedings, whether formal or informal, and appeals, attorneys’ fees and expenses, witness fees and expenses, fees
and expenses of accountants and other advisors, retainers and disbursements and advances
10
-- 133 of 140 --
thereon, expenses related to photocopying, transcripts, computer research and travel, the premium, security for, and other costs
relating to any bond (including cost bonds, appraisal bonds or their equivalents), and any expenses of establishing a right to
indemnification against any Liability or advancement of Expenses hereunder, but (i) shall not include the amount of any Liability
and (ii) shall not include attorneys’ fees and expenses that are payable by Indemnitee under Section 13(b) above. Any evaluation
as to reasonableness of Expenses for which Indemnitee seeks advancement or reimbursement pursuant to this Agreement shall be
made in the same manner as an authorization of indemnification as described in Section 7 above.
56. “Liability” means, with respect to any Proceeding, the obligation to pay a judgment, settlement, penalty or fine, including
any excise tax assessed with respect to an employee benefit plan. .
57. “Proceeding” includes any threatened, pending or completed action, suit or proceeding, whether brought by or in the right
of the Company or otherwise, against Indemnitee, whether of a civil, criminal, administrative, arbitrative, investigative,
legislative or other nature, and whether formal or informal, by reason of the fact that Indemnitee is or was a director and/or an
executive officer of the Company, or while a director and/or an executive officer of the Company is or was serving at the request
of the Company as a director, officer, manager, partner, trustee, employee, agent or fiduciary of any other entity, including, but
not limited to, another corporation, limited liability company, partnership, joint venture, trust or employee benefit plan, or by
reason of anything done or not done by Indemnitee in such capacity, whether or not Indemnitee is serving in such capacity at the
time any Liability or Expense is incurred for which indemnification or advancement can be provided under this Agreement.
58. “Special Legal Counsel” means a law firm or a member of a law firm that neither is presently nor in the past five years
has been retained to represent: (i) the Company or Indemnitee in any matter material to either such party, or (ii) any other party to
the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Special Legal
Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a
conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s right to
indemnification or advancement under this Agreement.
59. “Virginia Court” shall mean a state or federal court in the Commonwealth of Virginia.
60. Other Provisions.
61. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance
with, the laws of the Commonwealth of Virginia, without regard to its conflict of laws rules. Except with respect to any
arbitration commenced by Indemnitee pursuant to Section 9 above, the Company and Indemnitee hereby irrevocably and
unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only
in a Virginia Court, and not in any other court, (ii) consent to submit to the exclusive jurisdiction of the Virginia Court for
purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying
of venue of any such action or proceeding in the Virginia Court and (iv) waive, and agree
11
-- 134 of 140 --
not to plead or to make, any claim that any such action or proceeding brought in the Virginia Court has been brought in an
improper or inconvenient forum.
62. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an
original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party
against whom enforceability is sought needs to be produced as evidence of the existence of this Agreement.
63. This Agreement shall not be deemed an employment contract between the Company and any Indemnitee who is an
executive officer of the Company, and, if Indemnitee is an executive officer of the Company, Indemnitee specifically
acknowledges that Indemnitee may be discharged at any time for any reason, with or without cause, and with or without
severance compensation, except as may be otherwise provided in a separate written contract between Indemnitee and the
Company.
64. Upon a payment to Indemnitee under this Agreement, the Company shall be subrogated to the extent of such payment to
all of the rights of Indemnitee to recover against any person (other than another past, present or future director and/or executive
officer of the Company, in such capacity) for such liability, and Indemnitee shall execute all documents and instruments required
and shall take such other actions as may be necessary to secure such rights, including the execution of such documents as may be
necessary for the Company to bring suit to enforce such rights.
65. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both parties
hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions
hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.
(Signature Page Follows.)
12
-- 135 of 140 --
IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the day and year first above
written.
PHILIP MORRIS INTERNATIONAL INC.
By:
Title:
INDEMNITEE
-- 136 of 140 --
Exhibit 31.1
Certifications
I, Jacek Olczak, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: April 26, 2024
/s/ JACEK OLCZAK
Jacek Olczak
Chief Executive Officer
-1-
-- 137 of 140 --
Exhibit 31.2
Certifications
I, Emmanuel Babeau, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Philip Morris International Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially
affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control
over financial reporting.
Date: April 26, 2024
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
- 1 -
-- 138 of 140 --
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Philip Morris International Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jacek Olczak, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ JACEK OLCZAK
Jacek Olczak
Chief Executive Officer
April 26, 2024
-1-
-- 139 of 140 --
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Philip Morris International Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Emmanuel Babeau, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ EMMANUEL BABEAU
Emmanuel Babeau
Chief Financial Officer
April 26, 2024
-1-
-- 140 of 140 --